var title_f5_63_6128="Initial evaluation of hyperandrogenism";
var content_f5_63_6128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Initial evaluation of hyperandrogenism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 445px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Initial work-up for causes of hyperandrogenism. This algorithm identifies the common causes of hyperandrogenism, which is most often due to polycystic ovary syndrome (PCOS).",
"    <div class=\"footnotes\">",
"     * Ultrasonography is the initial study that detects polycystic ovaries and excludes ovarian pathology other than polycystic ovaries. The abdominal ultrasound that is indicated for pelvic ultrasonographic imaging in virginal adolescents can be used to screen for adrenal enlargement/mass. A polycystic ovary has been defined by international consensus in adults as an ovary with a volume &gt;10 cc and/or containing &ge;12 follicles 2 to 9 mm diameter, in the absence of a dominant follicle (&ge;10 mm diameter) or corpus luteum. In adolescents these parameters seem equivalent to a volume of &gt;10.8 cc and &ge;10 follicles in the maximum plane.&nbsp;Unless the ultrasound reveals an abnormality other than a&nbsp;polycystic ovary, further work-up for PCOS&nbsp;is indicated.",
"     <br>",
"      &Delta; Ovotesticular disorder of sex development (DSD) was formerly termed true hermaphroditism.",
"      <br>",
"       <font class=\"lozenge\">",
"        &loz;",
"       </font>",
"       Virilization during pregnancy may be due to androgen hypersecretion by a luteoma or hyper-reactio luteinalis.",
"       <br>",
"        &sect; The presence of a polycystic ovary supports the diagnosis of PCOS in hyperandrogenic adolescents. However, the presence of a polycystic ovary is not necessary - nor does it suffice -&nbsp;for the diagnosis of PCOS in a patient with hyperandrogenic anovulation.",
"        <br>",
"         &yen; In a eumenorrheic symptomatically hyperandrogenic adolescent with normal menses, the presence of a polycystic ovary (which meets Rotterdam-AES diagnostic criteria in adults) is provisional evidence for the diagnosis of PCOS.",
"         <br>",
"          &Dagger; A polycystic ovary is not specific for PCOS; it has been reported in several specific endocrinopathies (eg, hypothyroidism and Cushing's disease) and is also common in asymptomatic individuals.",
"          <br>",
"           &dagger; Further evaluation should include levels of serum prolactin, thyroid stimulating hormone (TSH), insulin-like growth factor I (IGF-I), cortisol, 17-hydroxyprogesterone and dehydroepiandrosterone sulfate (DHEAS). An abnormality of any of these endocrine tests is suggestive of one of the disorders that most commonly mimic PCOS.",
"           <br>",
"            ** Plasma cortisol &lt;10 mcg/dL essentially rules out endogenous Cushing&rsquo;s syndrome, unless the clinical index of suspicion is high.",
"            <br>",
"             &Delta;&Delta; 8AM 17-hydroxyprogesterone &gt;170 to 200 ng/dL is approximately 95 percent sensitive and 90 percent specific for detecting common type (21-hydroxylase deficient) nonclassic congenital adrenal hyperplasia (CAH) in anovulatory or follicular phase women; it is often found in virilizing neoplasms. DHEAS &gt;700 mcg/dL suggests adrenal virilizing tumor or a rare type of CAH (3&beta;-hydroxysteroid dehydrogenase deficiency).",
"             <br>",
"              <font class=\"double_lozenge\">",
"               &loz;&loz;",
"              </font>",
"              Computed tomographic scanning of the adrenal gland is a more definitive study for identifying adrenal tumor than is ultrasound.",
"              <br>",
"               &sect;&sect; Exclusion of the preceding disorders in a hyperandrogenic patient with menstrual dysfunction meets standard diagnostic criteria for PCOS with approximately 95 percent reliability. However, this work-up does not identify rare adrenal disorders (eg, some types of CAH and related types of congenital adrenal steroid metabolic disorders), the rare testosterone-secreting adrenal tumor, or, most commonly, idiopathic hyperandrogenism (hyperandrogenism of unknown origin, which can arise from obesity or possibly metabolic abnormalities).",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin North Am 2005; 34:677. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6128=[""].join("\n");
var outline_f5_63_6128=null;
var title_f5_63_6129="Nephroscope";
var content_f5_63_6129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephroscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 253px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD9AX4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6gcYcSMT0wVHrSyKGUpIQEboAaZwku5cuJOuDwKYwY7lchn+8g6ZpASrkr3QJ+opFbcwaL7hOG7HNNLOyCSQYZOqLQM7yZNot2HQ8daAHpsQhF3AnkFucUpO1OMPKopjK5jZF/dgH5W60Alk3xbdwOGLDGaAHlxF8zliGwOmQKUru+WQg5OR2qOMbJCoywfnd1ApFK4AZhJKvT60ATMSyhiSgXqDQT/dx5ZHJzzTJcArI+cgYIpCuUKSY2MOB0oAeCB+6QnIGQTTWcBgyYeQcNj0pqlyuPubTxjuKVW3MHjACHO89DQA9gkZLMSQx784pRnOHOSDkYqMr/BHnJBIf0pAOOoedPWgCQMWw5G0Dt60eYGIPAiPfpUeBG/mkOxbAIHOKVlViyzHIJyozQBJnJKKGBXuaasgKloyGIPOKTl0Bb5NppUxt3rgRnqMYNADg6oQC5bceKbu+bDkGQZKgDtSKoUeXGMDGQ3WgnAAUb5RwTjFACvLiPzHyAOq0H0+VYmHbg5pNyoSxBO7ggdBSYVW2SsCWPyD0oAcCwBRPkCjAY80GRiu6NVzn5tx7U0gvtaQkMnO0HrQzEhXb5IiPmUjmgB3mAMoUFg5PzelG5S2xiGlAyOKapAzHjCYyrZpqHdnysB0OGLDqKBkjPgB2OSOCoNOZ9uCzAIwwB71GGRZN8a7i5wxHalwqHY7byxyM0ASqxO4MNo7HPWmxyiT5lGMcHNNUkoC/Mi84BpDINokbIU8EUAP3YcbB8p5JpwyF2qfmxwah44U7REw45xUoyyY5XHegBQx2nHzOOCKC2375+8cAUiMGAaPG3PJPWk3BWCddwyDSAUns5x6YOM0jZZEckrt5I9aGYbsEBpAMjih2wAxBJ6baAEyxYYwIsHJ6GmlnDGNARxkOeeadwG+dhtfopqNnLORJ8u1sqP71AD2kZlIiGWUgHNPDYYYywb05AqJpdyrJnbGM7tw609GC52ACMjOaABNysyu+5jyO1ObdwxY5Xqq01G+8in5170F8fMi72ztOKAFdijBmYhTxtxQhZgQ52jPykHk0hYqejNu5yOgpiMW+Wba0o+YKKAHlnZd24oFPOe9JvdtrJjy2GcmmO7BFkk3DHDIvOaJiPuyHEbjCqOpoAXdIQ0SltwXPmHFNWVygRH8yROG7UHe8RX5k2njnkioTJNKgktFRSTht9AyYP821BiJhkP6Ui7gjIjbpVH3m704orfu3wq5wvNISzIpjOwKfmJ7imQND4xIoLuflbaeKXeFl2yuCHOVAFAI6RgeW+dzZ6UwbU/cqd8irldw/rQMdKx25lPzLyFXvQ8v7tZc4iIwVxyDTHdQfMwHmUAEA44p7EI4MjcOfu46GgBImYq0QBVQMhs0iys4xEDvXglh29aUqWyHG3acrtPJAoMhYCT7iDqCOooEOkk2upjUvv+8c8Co3fGUkKu45XNM3jcFRQsLDO/NM27lKRfNKgyGI680ASJMx2u4zIoyQtL5p3bpGHlED5SO9QbsYlVQ7n5GAPA96bJIqvskO8yH5eMBfx9aALatuVo9xjUdD6ihZN6B4MDB2uW6mqmTtDTZDoMhVPaj7QXjWXG2Fh8y4/WgZcRgku1FYq/JbPSgnAMeQ8o5Xd+lUEkZswKCkIX5WpGvSxaK3+WWPG4t3FAGm77VV3BLqMEDmjGMmVv3b4wDWfLfCBhIiZBO1zu6e/pWfP4m0iwkdL3VrFASW3S3KfJ6ZJNAHQEO+Ub5FB4IPWmyM8hVojtVWIfI5rhrr4neFLRFe98SaZ5oGVWKbfu/75zWJc/G/wSJxjWXlAHzRx2znP44AP50rjsz1VSBhIgTG/O4dqZFhS0SkvMgyGPYfWvD7z9obwr5cqJbarJEPuIsSqT9SW9ax739o2xSONbDRb4txzJOgJ9uAaLhY+ijxIJRl5QNpVTmlfCuTK2UfouK+af8AhoHU5vM/s3wwwkbkh5nctn2C8VDB8Z/HDwssHhF3yxI3RTsR9OMUXCx9N7SyFJcKQflAPJFLv/diZgY0X727vXzZZ/Fbx/Pqlut54aNvAD805sZ5WQdclFIJqfXfi54k0wtPHpsV9zsZJLC6tlA2n5vmyOvGM570BY+ilkjA3KVWBxndnuaSNvkaGIncvR2r5nufj5dJF5Uug2l3Hwd0M0sag9wAy5yKvW/7Rdi8Kx3egXcBBA3RXStt+uQKYH0YkmV3RjzJl+Vh/WjKxzbhufecHHIFeP6b8fvBlxKEuPt9g7ffaaHcv4FCf5V3vhzxb4c1txHouqW135g3fLKNwPoVOCD+FDEdLIFIEcpDNnKj0p53FEeXIK9VB61RkliDeUGL3CfNzTvtlvgXCku33GC56+4oGXgO4wIyOVxTdrMxTG1BjaagF1Gkm2RyVkOEUL0p7Sb1G4spU5AA5OKQEuSzAR8FThiepFIWSNgUUtvbB284qNrhTGJeY0B+YFeTUaydVjjIhccP70AWAFVxHu3OQSpPOKbwPnf5plHp/SqaTOwkihVvOjHEjimC6PmeZDF5kuQrn+dAF5mUfvJSdjADZjoakCq8ZWQDZnjtmqLXGyUIyPJ5uSCFyBTmuG2bJk3XCDcB2PtQMuL+8OVJTaeeODSk5UeXjyz1qk88ixrcyI67eCg70jzS5/eALA4+XJGc/SgC4+QPKTcMjh/SmGTCMYkEk6jBxxVOV7qUtGyeUsbAqwb74pn2u4lCyQRRqgbDlj1FAGgGSNt45LnBAOcU12VXCSsGYnKDuKpieZJRHDGvlSAnzd3Q1B5l6XeKMxmWMcOc/lQBps2QJXGDGM7B3FMDuxWRGEaMOjDn8qoG5mQGeJI5pSQrhW4qJrqezZmmxKrnhRztoCxYaSQxK0yo0qncoDYzQ9xOUSZgqRgfOh6VE56eUVkuY/lOeTiiUBXEr/OHG0oecGmQH2md5DHtRYHHyEHnNBnunLRw4Vkxhj3Fc74l8V6L4ceOHxJqMds0p3W6bGYsM46KD3rlbz42+ELeUBbu+llTI2Q2j8j6nA/Ogdj05bmTeGiEZ+bDkH86cspjPl797SZZe+K8Su/2hNAQTCx0rUJYsfMjNHHuPr1JrEm/aAvpoPL0fwwucfKZJnkb6DYuKQWPocSzbd8jIZ4+oXr7U2WSQDzpZCqMMFcZr5tPxS+J2pyyvpOgRx8clLB3IHbJY0n9o/GjUo1/ey2YJ3bgkMZ59epFMLH0jmVx5UshWI4KkDrUV7fpBCXlv47Xy2wzTOsYwPqa+dH8EfE/V5tuq+JZUBHKm9duPYKAKkg+A9xOqzaprshHfbESzE+7E0Aewan488LadIUuPElhHnl9s6s35DNc3ffGnwTYRkLqlzevyV8i2YgfnisKx+Anh62Obue+uExwTIEJ/ACulsfg/wCEbcN5ekozrj5rgtICO2MmgRyV9+0Lo2UNlpOqXM4GN0kqRqfwGTWHN8bvFuos40jw2DGw2BWEkoH0AA5/GvbLDwnolj5R0/SLBFA2lliUbSPqM1t21lbQMIVTlvmV8cL7UwPnaTxP8YtbCrDZtaKfmAW3SLA7feOaY3h34u6uHe81u4jQnDI12UAH+6gxX0iLZBhnZXnjzkD3p8kSqBNIGwRgooyAaAPmyP4KeI74rLqfiR2hOSGTe4/JmFadp+z7aSSyifU7yWYDI+RUVs+/Jr6CKIQ0M4VY2OEA69KcqGSIgZh8rj1JHakO54b/AMKM0K3tZebu4kQ4wZ8Afkta1r8F/DFksbzWQkaQDaGZ2568/N6161iJhvhVVjlGWPfNEUSxg26B2LDIkb5sUBc84tfhN4ag3CXS7LzeoUR53AfU1oWngHRIoIp0soLVYgQ0cUSjPv0612744xskuY1wT06+nalcxxP5z5cvgFQcgUAc/F4fSNvkmmSzdO0hHJ/zxUq6F+7aGKe6i2Y2uJW5/Wt1oULbLgo0bHdEAeKRg8iBpgUaM5AHcCgDBOjwttlt/MkkBCu3mHJH50f2Rb2zbRLcSrN1O7cFxW4DuCyRIFtmJ8wEYOaeqJv+zxhliYErIOef8aAOdTR7cEw3McM9wMtGGj6g9qZc6DpkyCa90nT3KKd0X2ZCD9eK6MKrIYoSHuIhtLH0pGCCTzkQyS/cfbzRcDidU+HPg/Udst74dsIYXGAYFMLhieuVxXEa18A9EuLmSTQ9QvdLcAGIzHzVJ+vDCvcFRYpdlwxbzT8gZc4P9O1MaASgC4KidDlAvpRcD53gn+K3w63SFm1/R4iQS2Z1UfU/vFH6V6H4A+M3hrxFMlneRjRtTlOGjuXHlu3+y/58HBrvZYQVS4JdEHLqx6ivP/iF8KtH8TxPdW9vDp18Y90V7boFLNnpIvAYe/BFIZ6zF8kjQg73HzKxGaY8uMt/rblPlIWvmvwl488SfDHV08OeNDJPpPAguAPMMS54ZD1ZPVTyO1fRdrew3ltFe6a8dxDLgmVWwrDHWgC1PMI8STbirjaYx0B96RhuRo58LGWzGFOKZvWOUp80nmnO7GVFBYE+XK3mXKAsuKBjg0kkW85iERyR3IpoYnEkARYG5fOc5pry8rMzfMOGjU5ApJmCSBbgqIJOFWgB6FlDW0JZcLkSHkU5CSv7rD3EeFZiO1REySIY5Mx7PuhTkkCnLL5iefEDGmf3m4c+1AEjkJOrqWk3/KwDcA0MAJDFIfMcndGG7U2Paj/uYwInH3++aRMjfFESZUHyyPzQAkvmGMPOuZY8kKD1FIGIKTykLC64Ke9IX+fzoVEk4+Rznp+FI7ok+1t0glb7p5CmgBNnmF4pNkduf9WehodnmiBiJj8s4YkdQKYw3kR3DLJcLllXGP8APFRzylYkuJQwwMNEvv60ASllODBtEEnLtnHNRw4hHkL5jDG8Sdc+1EqZOJmRYHGETpyaYgkmQxTBoVjOFIOM4pASJIXQTQqAuf3jEYJoxsYpErFZMtv64NKcAF5MR28gwVIzzS7MxmDASEfdYGqIOL8ceBNO8Xvbf2pJdtcWQPlqkxRTuPcDqRgdDWNafB3whaxeZLpn2ht3zLLI7kZ9ya9LJLR74QFdDhy45IojUCQeWCVcYdie/r7UAcjZfD/w3YP+70nT4w3CYhUEfjity20a0SP93apAiHO1FC5/CtAoit5RIkl++hbkCncKFkfLTKNpRe30oArpBG214Y41hOd/y49s09YETFvFGVTYQsmO9S4Vmy74R+iEcA0KHK+VIDHtPyhTyaAGbAI/3SK10mM5FAVIpN2C7v1A5FP8xmAkVwq5IcsCP/101R1jQDY4J3g9/WgBpVWcrclT3Qdx7UuW2CRvkKfw5ySKccAugYNMgyGJ7HtSFtgMmN74Cnb2oAVhmQNgR27DnjHNEUZdXiRWQr0ZufwoIUPi5ZWRvuKTSsHkx5o8sxHdtXuPwoAjzht0QVnQ4ZjxTkyjBsmTzc7j1Cn1p5kC4mUCOI53bhShQmYI18uAjIbPQmgBoVtoikIaVcsgpH4jWeQlXTJKKck9qertykABkjOCz8Z9cGo2nCXMDwIJvNbbIy/wgAn/AAoGO8vBAdlW2kG0Kowc0FJWhMK/utn3G65ApzbBL5ErGRm+ZAecf/WokUqBLLnzYiSETuKBCozyIssIICn52dcEjvxQqhX/AHal45fvOTkLStKzKs8hKwsMNHt70kb5LRECGAqNrDvQMZgbjAG8y4QblLDFOlLAicjzJkHKg5GD7U8+YysIxsaMgF2/iFM4V/MtVD7uHJOSKABsJLmZ8wy8BMcLTSsjgxyFUUNuj2nqKcCsZ8obnaQ7kZuQD2pjBgSXIlu4+cD0oAXc8wSdT5QjJ3jGM06ILk+TjyJR87Hjk02WTYi3EpbkYMfUZ+lKVwCkxVYJMbB0/WgB1uNitbozGTblXY0pZmbfGqyXMWF5NJbmSaExgNGUbg56ilMpbY1so2E7ZOOaAElCI3msGkLnaVHIFeMePPjRBpF/c6bpNpb6gbeUxvczORGrjqFC/ewR1ziu/wDEviOfSbieyt9PhMUiZS6mv44EJYcnB+YYPtzXyDePc6dql4kbRMW328hGJFZTwSpxyD60h3O/8efEWw8b+GUgv9OFvrFvOkkTRndGV/iIz0OMcHrn2rrP2f8AxtGLhvDt3O/2eVWeIPyFP93Pv6V4Xb2wjuYIkeN15c4OdoIxtb3/AMRW58OJmi8Q6ZdwIUaOUK2RweenvTA+1NrMjW4Xy48DbIp5qRXLg+RgSoQpZ/6VDseVf367TG25drckVIGLbJzmOIZ3gjqKQx0ZRJd0C7xIxDtngfhTAAsxikcSysd0e4ZCmiNSQwiAS3kH3jxz7UyNWMTQQkrLFwrsOTSAfxkPJiS5iGCqVKSUPmyn922F8sDOKjR+VkgUSSgBX4wPenxBYZCu5pFlOc9l9BTAVkDl4rhwID9wDgmkBMsAYFoghyR1yKRk/wCWUjiSYZZV6UjAqkVzLuDKMNGpz+dADVZWCtFtW3kH7zPXNIDkm3j3bcZWQ88mnSIF4lZVtnwqqODmo/Kmkj8jaYVRvkI7j60ADscAQYe5jwMsOSPWkdo4XEihpBN8r4OQpoSQyhZYSI41JEhPU01dgkMNuCqSqW3g/wAqAEKIriN2ErsdyA9BUM8AvEC3eTKpPyo46etSBQMwRszXCD5XbnP+c0bAzeZFtkmxtfk4oETMEik2uCxlG4ZGQtKyM0eyZlMycooO2hQQrW8SMPl4kboKcrBsvEqyXKfKxORTJEcviOaQ7FPBjApDG25kHlpbuBg9KRtqTbnBcScFRyBTwpLmOdgxPzRgdsUAM+aVWiQmMxn7x54p5wZBJEqtuO13zSyOzQrNKJI2j6ovOajU4yy7I7eT73GCc0AEcSwytCrFix3qx6D8aHiZgJH/AHlxGD8oxgCljUskkCKU2Yw55+oo5Pz2yqzE/MTQAxwFAmkPyOANuOhpoj3K0cxCxDlMHGfWp3xE+1vnE+cegNR+Wdg+0YkmXJX0xQAwszJmPKFGIIxnP+RRkDCwjMTcMaHBwk75QAENGBxSSRZIUtshdRg55BoAcgIUQp80uCQzD9M04ZUmdlL3CnDBe1IhaSNoow0flkZ75H9aQOpYNbqNrHDk9RQA6UotwDcHckmAqeppJYzNmOQ7UBBQZwTTCixsYdzFm5BJ7+xpQhIztR54x370APVi/lzbRFGpwynPK4pibTc/uUCwMnL9MEnH9KnJ8vbcyFtpAVk7Z+lCQmQus2wwvyhHB9qBkajbugiyZkUnew4+lGQx86MeZMMK4Bx+NP8AKklAK7otjc570sQBUPbAFGJWRumaAAbY5P3heVZSPlx9yo8bnEdwyhlYlAOuKcqLDm2Qu+4bgx7U3ARMlvNuolzjrmgBS5aJbiQtEqDJUc5HuKcpVUDLsS1kGSQMHJoYKhE8pb5wFZAM9aSSIEvHcMvkvwg7igBI42ETW0IaMqPlkZt2aGlyPMtQHnTCux6kU7bJNEc7ovLOcg53LSKd+2SLZ5WcSFvlpDCR4reTKhpBMepOQp9qayRqRFcuJJiS6cYp/Cf6NGrBXGRJ2oKZUxqRJcxfMGIpiEYBkWaXcJIuWRW+99acZOkjsFtmHKkYoGIx55BeX7rKOg/ClZUWVjM5aN/ur70gOZ8XWMAtZ72PSbW6u4ohHCZY9+cEkAfiT+deAfGxtbvtJs9R1DRILO3tnFuJIrcJ8pBwCe3PTtmvqJlaUbbj5dhypU8EVxvxe0qXxH8N9ZtbZSJvJLpGTjLIQw9v4aBnxnp1xBDJullbaDxCASWOODu6Yz+Nd58J/s96lwblhHJBeRTKx42q5AbA9wK80kQ28zrKoLqcfSu4+GUE8WsxxBiY76SO3ZQPut5ikH36H86APtVFKQedIA9wi/dU5zSiUZ+0SsQGABQ9qaJNih4lDTA7XI9PWpQEgOXJbzT0PIBpDEdTIZIrgqsTY2c4zTS0ksJZGMawt+YFIygjbcbWlUlkB60r/OEuZztKjLIB1oAkEmQrwqjQNnfzjFOibYpt0DdCVc9KiYqP7iWzLwelPzvjaBNyFeA3YimA4SAFljG+4jHUikkxAfO2ljIQCB2NYfiXxfonhm2W51bUbWzwduJTh3/3VGSfw4rxrxT+0ZYQGaHwnpUlwxOPPvfkTPqEHPr1IosB720YMrJPIHDklF9DWRrHiHS9Gg87XtUs9PMZJCSTKrMPpnJr5FvviD8QPGNyLa3u9QlBPy2+nxlAM46lefzNWNL+DXi/WGMt7FHaDcNzXUu6Xr3UZP5+tAHu2rfHHwVZzjydQuL0KpBitbcnP0JwP1rktR/aO0wQtFp3h69ePOEMk6xkflms7S/2f7SARf2xrNzLv/htogufbJya6ux+CHhe0YmexnkkByqy3DMXXjqBgflSA4S9/aN1vdttNCsIOPvNK7Njnr0H6Vln4++KzK7xw6NBu5IEDMCfxY17TbfDPwxbwLNHoNjDGAdweHzGPpyxOK1IPBmkWqgwaTpiQOARm3TIP5UxXO7IaYFeYvLI2sMcinKwfbJb4Izh2YYpVzKiSSqY2izx6igP5ih12i2YfMGGOtMkbEI42McYysozkdAaSMqjBCwmuVXI7cU6JcBoIMomMq46ClV2wPJVXmQBST3oAhkdkXz23DjBUYO2pAu8ES7fJbBQe9OISJ8qGfzDggcgGkRVYGOchpBllA4OKBjU3SI2cx7G9PvYo3/KHhVRC2dxIORTmJZfOckFOGQc5pzlWYbyqQsowD1JoEIBsJhiBy3Ic9BTMZT5cS3SDBxxxT9rlTCAYwvCsec//WpqsrkPAAvaRm4/GgBrqsbrI7Ft4C4PIFJJHkvHOysMgxgdaflFnCrllk+YN2FMX5srvEkycg4wBQAxyX2yEmPbkFQOopEG5x5aAQuvJAww+tSu+wLNIckjBQHhc96GAb5ZSAjH5AOBigBipyYYwwKcq3X/ACKV1CgtAivcD5WGcZFSIGkQg5j2cDnkgetAcMfNg2hDy+RQAiqISxky/mYHsDTljBYi4ZWIOY8HrTowFUxIDhgSHPPNAK7igAa5j5JIoGMkywWZg0e3gr680rYbO0qIHXnHGKdIUjbzeWJAVl6gUSbVBW4YFJGBRfSgCNVxFJAgfI+65FRszGPMKB5VO18nBxUo3Sx7pcoYySMN1A7UySR2AlTKQZO8dCTQAxgIpQyq7CU5O0ZA9+KQoAwjlbfKPmjXNOC/I0CKyROMh+nNAwwZYjmVOGYjr+NADirkRzzEq8YIdE54+lLKCrZlCR2sgHyEc5pqMqkSxp5jE7Xwc4qRMJcNHK5k8zlQRwKAGmN3V4NpiHRH67qcheSPfEMPGdrOeMimlgwVrkfvozuCKckjNOaYlUnZykZ4aLHNAxkJCTebCu5JCckNwvvSEAExEvIzfOrNwFqQKNrJsVLd16k4OTTdsmxoo/l2DAkfnIpCI5CWyX+eeP8AhU4rkPij4isfD/hW8e/uFjuLu3eO3tgctI5XHA9BnrXXSOcmW2A38B2bjpXyr8dtUW/8cXkcb74rYeUoyT064H1oGeS3LpPdq6K+5QAxLZJx3r074NRpL4p0mE7X3Xauc9QFVnz+gry2A/vS5+VCcGvV/grNHY+J7G8aMOsc4jQZwRuUg4+mR+dAH1jGw+WS3QCBslyafAAuYI0baVJWVucUwDBxK48lsBUp6q8kRjkBiwfkC88UhiNtJAjAkuohgk9cf40spSJ1m27i+FbuB+FI8uU84MkUUYJlMny8DufavC/iZ8dbLS2udP8ABQjurnJV72Rcxqc87f7316fWmB6x4u8U6J4SsHn8SahFChy8UR5d8Doqjk9RXz147+P+rarK1v4Ytxp0Cg4uXG6Vu2QOi/qa43wx4P8AFfxN1pr1vNkR2PnX9052DnoCeT9BX0F4C+Eeh+F4kuI4V1TU1Ybp5wCIz1JROg57nJp2Fc8G8PfDnxh43mOpX5lhgc5N/qbtlwT/AAjkt+AxXsXhT4EaBpkiyasZdTmAB8yX5IifZB1/E17Mlslu2WLP5ny4PIFSC3/d7bkK0iksgz/SkBiWGjW1jb+TplrDYpDhSscYQEDHpWjBDEmJLVFKvw75q43zxrcTZUxjBSo9uSxbato6c8Y+lAxiQxxZgQM5ILBz0H401uQGAEt3GMHHFSskkkZhjJiCEYf19qjkkZwHt8AK+JM8fnSASYKj+axaTfhSi8gVn6pd2enpu1W6gigZsRiR9gBx61j/ABA8baT4B0Y3V3mWWbcYIEYbpmHp6Dpk9K+Q/GvjTVfGWp/a9UnIiXIgtlf5Il9vU+ppgfdbEKROAZJPulQf6U5kCrtnIZJDhVY1HCwXa8ABSQfOx45py4TMQLM5+YMeaZAMkki7ZSU2HK7e4oBZtkoISI8NuGKd8u4uFV5h8rAdQO9Ok2RbXlY7JPlCHpmgBoDDMcSEQsCd49fahcCLYjgyxj7zcGldN2Ul24B+QL3pEJmVZBmML94EdRQAgCCTemZCx2tg8ZpzINxRzvZ+VB7U6MAyLsQCEgkkcYNDKxzDF99RlWP8s0ANdXdQ0n+tiOdiZ5FOOUIkc+XEwwVxyKQEIXZVDynhsU4BYyxlO4SHIQ84oAiSLfvRcInVWHBNJt3AGM/MnyksOtOeNmDCUKWVspj0pZPMMaSFtig/OMce1AAqBZN0a7lk6tj7tMRPm8tz5smN4J471KOFMe3bCwyGDVGpbGyHJkXjc3egBzKuBKfmkQcqp/pSSAADzGIicY29gaVcLIrxKHZjh8HpTzGokKOdxYllB7UAKse+Mxt8iD7u3PI+tOTLnfGojIPzk9cUz5iN0+DJGcgL3pV3bxNIxVMfNH6GgYoVFciIKUkzlxzTQo3LCGZpgN4dhT/LV2aP7sDAbWWmplleOMlJIz98jqKAIidpEhAknXqB0pJlC/PO25JTgAngU/oWktxuLcOfSmFBDJs+d953LnBANIBiq8gMcu1dp+QBu30pyv52JF3RhGO4HjcKYYyBmUb7hORipG24NzMSoA+ZCMimA6PaT+4CCB15I45pUGxWt4i28DKORx+dMWEFWSRlFu/3B0p+2SUFVDRmJup6HFIBocIGkUK9yMK+Kcyxw/vX3EyYGM5pFbhXgClST5h6Y+tIgSFkijy4mJw/UA0DFxlmS4KE7sx9jTZCXAaYGNl5Cg5NIqDARmV7hASpP1omUKyzspMoXDBTnrQBFf3Aht3uG2x26xlpARznFfEXim9a61K+uZeXkkckdcAk/wCNfVvxf1YaX4MvmRyr3SC3jTPO48k/lXx/qsh2uzZDMOcgjH40AjJjVcZz8rdOf516L4Fk+yy2b7BnerjnnHmLj/0GvOlwNuWwCfoK734flLrVdMt5JFZnmhQADlP3wJ/qaYM+zYgqtslJkZjvTPQVQ1rVrTRdMl1LXLlLaK3yzOWx9B7n2qW9vrXSbC7mvLiOGG0iaV7iThVUck18efFPx9qPxF8Qrb2aSppyuEtrZRln7B2H9456Dp096QzR+K/xU1Px1etp2kia10bcFjt1yHuPRnx19l6Cuv8AhT8EQ62+qeMonAkG+Kxzj6eZ/PH511nwd+FVr4Tt7XVdeiSbWpV4UruFtntju/v2r15IONtxtYhi0YGRnFAivpljFHaLBZwpbJbnYiqMAKOwA6VehAG02ygoxIkYilTMiLO5MYX7y9cj/IqSIFgAgUWzryR1oGMXEcnkxbiXG4SHkA05srEcBZbmMfjUgXrBECmFyHNDMuN0ChpAQrk9SKAIJMRn7Q+dzqFZOwNIwO5lumUxkgouORUjBIJF2DcZjz3ANMztcRyMkk6gshNICJ2kkCmUmMxHIAOcj6Vznj3xlp/hHQH1fUGBhKlYrYcPcSdkA/mew5rc1O/g0+yl1PUSIo7aMtMQeAo7818T/FDxte+PvFcl2wlFpGxisbXrsQnjj+8eppgZmralrXj3xWrukl3qd5J5cFtEMhB2RfQD1+pNfT/wo+F2n+EtNkN5DBfa7KoFxM8YeOMdfLjBB4B6nvj0qH4IfDSLwlo8l/rEYXXblQWc8m3TGfKB6ZPc/h2rT8ZfEe00mVILSXMufnIxQI9LkUE7SEW2YZyDg5p6hnjaJQU2Dh+5FEqI2Y5sEEZUDI6U/DOMyAxlD90HqKZJGD+83wgMRw5HYdzSttjk2cv5pyGIzT0G6TMe1YXHJHHNIEIP2dCynqrnvQBEEbjzcPcICwx1xTy4AWdwRxhkxUhOxQyYadeCfWkURxne+8iQ9OwNADMF2aN+Im+7zj8KVQW3FAyFCOSMZFSeSCMXB3MGytL99VkYshX7y+ooAYdu0GNQUP3jnFClYwYUBLNyCe1SYBXaoUW7L196RQNpijJUgcHt+FAEBbauWAe4Ucj8adJhSJZSQDgbSOAf8mnuw3bolDOCA2OtNO2MgFmJc9Dzg0AMEYkzHKwC9ExQJDIhbJi2nkMucgetPZT5i+ZgupLAE8gUKTu81iUXoV65oAZ8qMCikRPncfSjBGYlJ81V+92pZQHURtjymGQQcHNAXcmyM7SpHJ6H3oAaqt/rRh514IB4qUvslV5WLCTjAHSmxkKC8IDEna+MdaRGVW2bgwf5lOOBQMc4MgZZiBzlAOM0okZ4hJ80YXkgc5FNX5kAkbdOnII4zTnIVEnkJVcYZByKAGRNypiVRbsMkg8nNMUMoa3iUqwXIY1MFBUodqwt90A4Ipql3yqZQxnqeSwoAryMQvmRKGnXCkdM05tsLF2JYOQOeQKf5g+V4UBDffJPSmqFRwiBsPkg9gfWgAWJ2BjuGVmzlM/n0pW8yRVncsnlnO31oxuOzIe4i5BPFPmITEzkk/dZBz+NADWLMVZSotyDk9KYgDKbdQwVRkOOR1pZMAFJSPIfG0LxSANMCuWi2Nxt7ikAjNhTtIeaPgkrk1y/jnxnpfg6we+v5VkmYHbaxyDe5xxx26dTXSpLuKvCdqqcOSDnFfBnjjU5tR8UazPLIXDXkxXnqu9sfhigZv8Ajz4paz4ruszyrDZoxMVtHwqZ9+pPTmuEurySUtvcsp681AxY4JI+h5oYc47EZoGWYruWLhXBI555rtfhprEI8VaVFLAqKbtJXdDjoCPw6/pXnxPO3GD34qa1cxzI6SPESQDIM5UevFAHvv7Snj6W4v18JadIwtrbm9f/AJ6yYBVM+ijn3J9q3v2dfh/9lsYPE2qW6y3Erf6Gj8+UuMGT684H0z6V458OdM/4S7xha6NfXBkWVjILh2YkhSCx5PXaGr7Y0+CK3toYLOERWYTYqjgKAMAUbCHwxJATGCZC5JUnkCnsmVTztrzR/MAppcFVNtGG3KMq/b86M/LuiAe4XCtQMkI27ZpWYK3ymNegJqQRnPlTFFjb7gWmoFinyTuEpxt6hTTlVw5SZleQEsi+lAD3DtlTlNhyMHkgUwgSbXhwIWyJC3WlcsxjlkypQnKj07Ur4+YsQtuwxgjnJoAhRArNDEPlYFhITmoiD/CQ9wmBuapBFIyvEoMca9GJzmsPxZ4ig8PeGNS1l9gWyiJYuOXPRVx7sQMUgPBv2nfG4luU8LadMfl2zX7g8Fs/LH+GNx98elZ37OHgeG/vG8V64kZsrVmjs436PMMZcjuFzx7n2ryfT7a/8Z+Lo7dWD6lql0SWJ4Bc5Zj7AZP4V9BfEHxNaeGdHtPCuguRHZxiHeONq/4nJpiLfxN+I+VGnaa+Z1JVpEPAJrO8DfDO91+1kv8AWG8kS8x7gSx+tO+FHgZr5hrerxEhWDwxuMlvc/rXuqxJa7WWQpHtChAM7aPIDQOSCsoWSZeVHTihmbAuJN2FBDIOnXvTA7IjBQJZ4x24zzSrLtImYNl+CoOcUyReS7KzIsDAFQOD78U4xu0TRq3l7DgEjqKj3Ydo5mTnlABzSl2dRIxaPYeVHPFADwSx3QjdnhyeKWMLETGpYiTJDnkA0F8KrjAgbls9abHJuLwxhlOMK55/CkMCvC7SHmTpk1LKoVllkJ5GGXPGah3AHMa75V4bP86klcROD8zCTg+in1pgP8ssjI5Gw8rg0i7nA4KbD9MimgMRslw0gO5AD1pNzttkk+Qp1T1oAUlml3xYCHO/jFDx7Mwxkhtu5WpSCXAyq27DoOOaRA5VooyyhB9885H1oAYymNMkBpVH40xf3TtK7M2cDaexqZTk74drP0Y01SI5ig3HzDyccCgQ1oRIxW4xjOUGeaVlLYYAqF7YpWXA+cb5FBIBolJ8sSuSoxgoTQAihA48tQITnJz0NAjVA0MYY8bgx6GkGQGRyqxsOMcEUAO4KAbFQ8HsaADKhcjEk6jBA7U4hI2yxz5nG08gGhnL7WhAGOGxxSBdreWmWDgnPagYKvmEx3G3JbKgGl2vKFkfMezllx1qMRmNMM6yToMjilPyus7Fi2NpjHvQA4lGwEGLdxyTximpGMPbqGUDG1z0NOlVWyshAibhRnr7VXuJVSBjPIlrHEQd7uFBH1NIB6KAT5AVrhQAzFjTmCxyq+3fvODjtXIax8SfCOlHfda9YK3IaKN/NkPthc1werftCeGNPSVNLs9Rvm6ZKiLn2JzQB7SQocpOysScrxjFIXLxCSUFXj52L3/Cvl3Vv2j9WkG3TtHsrc44knYyuPfsK4fVfjB421KZy+tXFtvzgWyiPj04oGeo/tWa1qNn/YNvYXV1b2N1FK0scblBKwZR82OuAa+bGbIVzyxyOtams6rquqkS6tdXly8Y+U3Ds23P16ZrPs0BcNyU43ce4FAyzb6bcz23nhdsZGVLEDf2wo7/AEFac/h25g3LHewOOBnZIAcjkcp17Yp82l6mfCp1qSIrpvmC1SYyKCzjOAq53HAGMgYFc+0shlz5rbw3BB5H40xEtzZXEEbyyJuiU7S8ZBX25HT8avaT/ZZ0XWxfbxemGM2JHTzBIN2722k1Ui1C4C7ZJZJEdDGQTyQeoz+fBzUNxEpRJk/1THaR0wf/AK9IZu6HLc6NrWjXVjfQ/aJQCDav+8iBJUq3HDY5/HNfaPw3vZtU8HadPfzmbzoFO/dyW96+JNKtQLid/mMlvF50Z+jKOfoGr68+AMM6+AbaS8dj5ztJAjnhRnAx+VAj0k75FCYaHZj8cdqcXB/eW4URk/vT0pCc7JpMhkBylBKPh32i2dcbWGKQx8G1GMUWdrfMHJ6UsL8sinzJ0GORSKnmRvFjYi4KsDjIqVSZCfKIVgfmPTNMBjybW8zaXkOFZF5ANObYku2Zsq/3RTlAUkxgsJCSWHakULGhh+/LywJ9/egRWkBkRfNDK0ZyFB5IFfP/AO1h4hdNH0rQ4W2tdubqZAcfKnC5+pJP4V9AvhR5uBJcqMFQa+Lf2hdXbV/ilqoVz5dkEtVGQcbVBOP+BE0ARfCKeLRrfW/EDjNzFF9jteOruPnIz6Lx/wACrsPhn4WuvGHiVry9UvbRv5sjNyCc52/zrz3RUml03TtPtVf5mLHHd3I/pivsD4f+HIvDnhyzhjXy2RczkjlyetAHQWcccCKLCFShO1jjGPpTZ5BayEKskwfnHUCrIbIBTaLWRTkng5oVhExjjidkAzuJ6mgBxfdF5kQGQ2GPSlGxNqxqSknJYDIFMdtypOXEcJX5lPHP0pAvymBE2RYyr5pkg5HCHbLcLkge1KSDmVsl1GGQc0xiXO2DDSIcF+hxS4CuJIwxYt8xU8D8KAJZdqf61l8p8BVxTQzlCo+UJ0I701fllEbsXkOWXPrShNo8yVyJVGNoPWgCWKbIWRFCqeHJ4zSqQMRxbtrDcHzn8KhZcjzJWHlOoAHTmkEZKeTzGq9D1zQBZRhz5fzzIMc8U7cqnecuzfKQDwDVRXYxq0Y2nOGyDnA606ABDmJdyyHl+gFAFl2jD7JyCGOVFPJ3RliWXYTwD2qmrq58tyWkXkEjipC2Asud0ijDIp4zQMmRwy+YpVYedw6GmxthjGq7BjIOc1E7lThyBCxxgjGKUrIUKsTGAeNvcUgJGYBf3QBlXhvWmzFEwxG/ccHPOKjEjsFkXaAOH7HFc14l8c+GvDCFNX1WC2YruCb98hPsq5NMDp1w2VkIbJymfSnB2ZN8uUKk5X1r558RftGWUBMfh/RZrlxkLcXbbFx67V5/UV5tr3xp8bavI5XUF0+NxjbZII+P945P5GgLH2Vd3UUMYlnlihtsZJlYJ/OuT1f4j+DtNDQ3XiPT49v/ADyk8w/TC5r44jsvFXiibekOrai7872EkgJ9ieK6jSfgn45veTpaWakZzdSqh/Lk0Ae9T/HLwx9rjtNEh1TVrxzhEtLUkyAemef0rnvF3xh8T6c6/wBneDp9MEoyj6t8rOehKrkAAe5rlfDvwD8S2x+1nxBa6bInSSBpCwHcZGP8K2rj9n2fUTC9z4pkuZMEGSWFpAPpls0WC557rXxf8eXqeXNrltZxnJK2vlqf++lBP61wOraxfanOW1HV7q7YnkyO8mPzIr3+H9nC33sH8QyMU6qtrgH8d1XF/Z40UQoRrGoSlTghIU4P50cqC58xN5I4USFgevAGKYoK4ZIwxxzu5r6rj/Z+8ORyKs2p3shbhdqICTn8asQ/AHwxGWE93fF/vCMeXzj/AIDRYLnySoYScKmW4x6Glfzc53AOMEYPavro/AnwqtuJRc6iiD5mz5ZI+ny9qVvgb4ZLqxutSWJgP3hePOff5aAufJF5Lc3Cq08pkb7pGck46CrK2V1DbxNPE1tDMu9JHXAZeeRnr0r6r/4UZ4bE7k3OrEouR+8RA3HT7tfN2vTWVjAqBrt9QW4l8q3nYMlvDkbMnu57/QUDJE0OXVtP06HTdLjt5YUZZJ5Z/muWLEhtp+7gYXjr1qbxP4N8Q6Vo9il9pEcUMJdxNEys7lsH5u5HGB6c1zMGr38crNHezRHOf3blR+lauqeMNdvLaCGe/Z41TjDMcj3BJH5UAc4QFxxl+4YYq3DHG2m3BJYOrqVHbHQ/zqIzGd/3qg56NiplBGmylQCwYKdx6HORgd84P5UhnQeArtE1+yWaPzTJFNC6YyCCucn2GP0r7k0m2ittOgt7SKON4owEAXaoHsBXwj4D0m91nxLZW2mxPNcPMq7E6lT1OPQAEk196W7FoUMK+V5ZCncOSAMUCJflEomX945wrY6D8KeyImVnbcHOVB4ApiuRJm3XMcmdzk9KQYQGBQTKBuVyM4NAEsaOUVpf9YmcAdxUis3yzMxjhI5Q1GG/diTIe4QYPNPJEU2ZXLLLwExkA0DHSIzxtGnywuOGHGKJFZ4fLTKsmBk9xSSjLeXNyOqgHHTtTXdniWZw0ezqp5yKAIgVEiPCA298SkV+ffjG8bUvFerXTDDXF5MxGfVz/wDWr761ck6bdSRYjRoJOemG2nFfnqGL3Ubycuz5fPqTz+tAHtfwD0Q6p4vFwqkwWSeaV9W6D+tfVBZVYXEoPzKFMY/hrxn9m3THg8OX2owKPNmuNuSP4FGK9pjIicCMFhIeSOcUMSGuq7is7KY2+560yaISpslXylVvl57U6JfmMUpEk/LqD0H40ySFLgKLqTbIOqhhxQA9ykchMhaRZG+6RwppilyjLOAWU7kCnk/Slj2pI0MYbB5V92QKRMMpKYe4jOM9OKZIvmO5Wcny41zuX1FL22rtWB14IPrTgI0YSzZJcbWUcgGmyxx7vLmfhj8gHGKAGr86tFGxDxjILU6OUoS6jezfKxHp60Mu6IFi0ew5wOc/hTUcYVo8CJwdwPTNAEgCq5GSwkORxwKTDlQZeZE5CiiQDZ5aKVIGQ56fjSsowHhw84wDQASsVVZXzt7p1596URtzG+FiblSSOPSpAY4Tll3+Z1x0BqNslxHJtdxyqryaAIyJHBWE7GU4Yt+vNSAKvzRLuLH5iO/vTZCxVJJiyY4KD/61VtUv7XTraS6v7qC20+NNzyyNgKP85oAsxr5Z8st5jH5lJGQDXCePfih4d8Grsv7r7VqseQLK2ILA/wC2eij68+1eM/FH46X+ohtN8HvLZacDtN2DieYe39wd/X6dK4bwB8OPEPju5ae0i8uxDgS30+dg7nHdj7CgdjW8cfGvxT4lklitJf7JsTlRDaEhmX0Zup/DFYvhT4beK/FkyXNnpsqRSHJvLwmKNvU7m5b8M19L+BvhH4b8JvDKbY6rqWP+Pq5QMqt6qnIHb3r0NIy0f70+bKn3RnpQFzwTwt+z1Yx7ZvEeqzXD/wAUFsmxfpuPP6CvUNA+HvhbRVhbTdCs2IG0zXC+a/5tmuv2BUWZ/lIXDIvenGM/dJWOGQYVehBoAprAQpgUjcvKkD5R7U6NW/1h/eTKAMCrbozW21N0RQ4yByRTUwiK8QCo2d7HrxQIiddmTIfkl4244Ge1IsReIxzsEx9zacE/5xUkaAOYl3MW+YMeQKGRgArfvbhOQT3oAQsXTzCPK2n5gw5NNixhSgAhfO4jipJU8vFwwYsBgovSk8sH5bhlET42KRjBoAhG3JgTIO3Kv1/WnoRt3xASXCY3H155pRC8g2k+WsbcEdxSgmVUmtyFiziTI5NAxzlYpBI25g/ylRyFpm2MN5NwdxY5jApUj8tjFAp8pxu8zOcUyNQiNCmXmj6O1AEGpM4sbiZvleGN2VFPXA9K+AZbwPc6g01vFcPcKyI0uSYmLA71ORyACMnPBPFfoBKqEmQp5suNrqp7ehr4g+J3hZ/C/jjUNJZvKt2m8y3kYHBhc5U/gDg+4NA0cY3D/Lz+NKScA5yMdDRIgRnVZFcKxG9fun3H1pGGMED5c569KQxWLiNELNsXJVT0qdELWzSEkZbaPc0kTW6QzrNAXlZQIiHwEbIOcd+MjHvT03hYU2gs3z7R2J4H40AbngXXbnwj4u0/U1Vla1l/eI2VyvRl/EGvurTdRttR0211Wzm82ynjEi7ecg18wfEv4eXd54I0zxZa2zrqFvboup2yj5toGFkHrgYB9ue1R/Aj4q/8IreDR9eIbRJmwJMc2zE/e919R26igD6vlABKOUjt3+6B1zQ2Xj8ld8YjYYfrkCmRvFOq/vo7gPiSEoflKkcEHuDTmBbEkoPmR8lEPJoAkhkD7HtQuCSHZhgkU+B0SbyowfnAYN2H0qMEJhmYJC/8G3nNPiiyWi2iJc/Iynk0CHFsSBSBLNHyGI9aJWC/vsM8hG1lB4p6lmXeo2bOGLDkgUi7UYtGoMb8sxNAyreRrJBPFK4K3CFURv4SR/jX53TAQ3hQ/wDLOUg59m/+tX6LKFU+UpLOvzqzdBXwD8QLJtK8ca9ZsB+6vZQoAxxvJGPzoA+ufgXD9n+Gmmy+YqRMZGfI6ksa9FXBGwYWEjIcHnmvOPgHPG/wu0qQs0kbF02nkAhq9HCgr5U+0ktlAOMjtQAiMWRoYciVD94+n1qKSSNizxKJJAQrEVw/j34reHPCSGK8umuNTQ8WVoQzf8DPRfx/Kvn/AMXfHnxXqtzu0MxaNbhsiOAb3I/2mPX8KBH15FaloSj4jUEbCD1pcsRugxHjhiw54pzBioLnMyc7VNNfcoEkh2xEYZAMmmSIAiSbY1+V+d+c4P0pTGFPlfflUZVj60hjcbotwSNh8uOtOAZ4yqFo2Q8seuKAGSbUxI+XlxtKg8AfSnKEXKyNmMnCrjvSBQX3RAFG+8x6U6KNUYxEliTvBbtQA3cZVzIGXaeMHBI9qcX3KrLgR/xe9PkUB1kIWSdOCBxj3qV0RcmXLBxgLQBBEuT5cYIQ5O/PenLhWYR/POi8kjtThHlAkhCY5XbxxVa/vIbKxmvrudba1tkLyySdAo6nNAFDxV4h03wro9xq+qzbbeIfNg5Z27Ko7sfSvjf4l/EXV/iBqjLIXg0uNj9msUbIXPdsfeb/ACKl+LXjy68d+Iy1uHi0q3crZ24PJH99h/eP6V7J8DfhIukxQ654jj3as6iS2t5F+W3B6M3+36Dt9aNx7GF8J/gakkEOr+M1OColj0wfK5HrJ3H+71r6Kt4reC2jhtoobeyVNqwooVV9gB0qYKkRMqjzJuhApzRqJB5rblfoM8igQwxrjyF/dpjAfI5pyOGQ+WA0g+8SMU5otyr5iqHU5UL/ABU/OQsi7VToy460DIkMYYSLlixwcdBTTtB8pyGc/Mgx0qcIpyiYWFh1HrSKrKPLi/1gA+ZhmgRFIW8ve64dRkolQXDFpgCFSMgHGORngH6nmrpGCJI0DseG9qjK+XOQx3iQfkQaBoiO5kkiAMarwjZ5NODbsSREB0O1mYdQKk2BjvkH71MkKpxkUrsCokY7UwQUPegRGRsYtCu5ZTlm3cCkjj4aL7z4yrFcgfSpVVSm3IWEjjmnICyNGgMbJgBjzmgZVYdJHO+aPsO34Us4Ebb5RmJsARgAgH1qcOu7dAAWzhz3o2JE3lqCfNOQT0WgCLy2KNFLhUz+7CnB+lRqZpItwQxbDyT/ABYqy0a7VWXDzJ8yk01shVnfO8DDKDxQBTL5YSQoghcnzGPFeNftDeA5dd0eLU9Hgee9sgWdEOTJF3A9x1x9a9vlVQ2JGVbZxgLjBye9Nkg8xWix5arjYy9xQB+dDwhGBI+TPK9DT7lI/MkSAFVX+KRsEivs3xj8H/Cvi6V7r7M+nXu7Elxa/Jvx3K9D+WeK8+n/AGa0aWP7J4oZoSfvyWeSAD3w2KB3Pm9IQYt4Yls/dx+teifBjwNd+LfE8UxRzptofOuZj3x0QHuT/SvZtD/Z20Cwuh/bGo3upyhd3loohjb64yf1r2LStMstG06KDTbGG3EC7Fgt12qPy6mgAaNTbozIEttpWSNhncDxjHevmD41fCGTQp59c8OwS3GkO294VGTAe/8AwGvqxtqZluG+STACn+E+lJ5JlEkNxtWPPyDoSPTHelcD4x+F3xa1bwS32K4JvdFHHkOctCfWMnp/u9PpX1Z4P8XaP4sskv8Aw/dJcuQPtERO2SL/AHlPT69PevJPij8Dk1EXOreEoxBISXfT2bCk5yTH6A/3T+HpXz7BJrXhHWzJby3WnalbNsLRkqw5+6fb2NDA+/kxHKUkZnMhypx0p6JuUCVt80ZyFVsV84+Af2hQkMdh4wtsfwrf2q5I9S6Z/Vfyr33QNd03XbFb7Qr2DUEGAZIm6deo6joetAzWm4CTOWAAwU7H6011PllJtqxMMKAOc0SMqOrAO/mnBGeFp5Bz5cpBfO5B6UAQbWeEqN0W09e5Ar4+/ae0hdO+IbahCv7jU4FuAW671+Rx+gP419iMzlVeTh0OfLU5yO3FfM/7VXiHQdVXTdOsrhJ9YspC7eUAVhQj5kZvUkA49qBEnwB+Imj+Gvh9qcOu3qW4trgmJesj7gMBF6nmuS+I3xz1rxAWsdEDaXpvKmRD/pEo6csPu59B+deQ2kEt1cw29uhknlcIiL1ZicAfma+lPhZ8AY4PK1LxgwlmU7hp4+6vf943f6CgZ414M8CeIfGdwTplpI0AI8y6kGI1yfXufYZNfQPh34F6Bo9kv9vSvqdw46rmJFPsByfxr2KxsobOOGHTreOK1C7QqABUHoAOgp/y2zFGUyqeQxoEWMgqXiCSSj5XPSlX93MTkuHHI6hafkHDRBBEfvE8YpIwN3lxZ2MCQ3oaZJGQTIVmO6ZTuQA06Q5VJWygAwyDqacDjgfPMgxyKHdQwkIZiflKgZwaAGgZ5yFicfjzSp+83RY27TgMedwpxVQ2yZgytyi+lL8zJuYeXs/hX+IUAIGGQ8Kgno5zS5WMlNzsXOc9QKV2C/NwkTdSaQIpyiAjAwHPegCNQ2EBAedORz2r54/ah8ayoIvCmnzsm+NZ74K3bPyxn+ZH0r6CuLiO1gnuWbKQIXkZhjAAya+EdZubnxj45u7k7jPqV6Sob0ZvlUfQYo8hrueo/s2+AE1i7fxDq1u32S0bZbBukkvXP0H88V9Qr5jrs5TYc5NZXhTQ7bw74f0/R4gCLaLAwMZbq365rZPMZkkDKy8sF70xCQ4MpMQUhjhiOo46U5FEbbMHPUE9aZ8rEBcLGw6ZxmnqXy8SIU24ww5pAI+9QDtVpkHQdaceHEkrAKeCPT2pWZsF4VBbOGNClQwGSQ/tQA1Iy7MrsApOUAOKVleUKwJjCnBB9KIyMbX+aVTuUUO+FEzkjsVFADs4AMePKYctnpSRKVVolzkDIY0rDKlXwImGBTAzvGy7WTYePegAYBSZEG+ZBg4NRlAXDuCQ/VRyAacHYhXiVdpOGY8U5EEX7uMEh84bqBQMQpvTZOQB/AF4qXDmMM2UCnlfUCmYJTBKvOoyKNzAiZj8wGCo5oAdjJDKFWFhk8YNHljyzDHuUAcP1pHP70rKw8t8BVx0pXQyIynMe05G3uBQA0DecRHM0fBLDFACxyl0y7NwwzwDTyxZQ6Eqo+9kcmkhXaxEQxG/O7PT6UAMkjUPslKuHOVBHQ0rx79pmC+YhyApxxSqvLRqNzqMhmHGaGw/7xQrzJwcUAIuHImztjPBjwOfrSpEGV412rC44K9aB8ku9yWVyBt7LTvLLLskKg5ygFIYwIzDy0JR0OA3cilcBX3woG3cORwfzpWEhRZHLIU5ZV6N7UuCVB4SJgcg9eaAGosUS7FOS5JGeQKjCDA34e4QEipI48K0KqVAGQxppUMwaHaZFO1mPpQBC5AQXMmVwuGQen0rlvG3gfQ/GEAXW7dVbGILmEBJUz2z0I9jkV1skapLmNS3mcMRzimNGqgQzEPJ95MjOKLgfIXxA+B+u6AZLnS421KwUnLwL8yj1KcnH0yK8z0zVNX8L3outJvLmxu05EsL7c+x7Eexr9Cgrb1mmLebGPuL3/CuL8cfDLw14r8y41K1W0uZQALm2AR89twxhvxFG4Hi3gj9oy9tYUtPFWnrdRng3Vp8kv1Kn5SfpivdfDPxF8LeIdPafS9ZtWlhi3utwwidABkkqcHsemRxXy98Wfg/e+BLY6gl7bXOnu+xJC4SQ56DYefyzXk6BjgjJI545xRYe59AfF/453GofaNL8HyyW1sy+XNfj5ZJeeRH3Ve2ev0ryrwH4G1nxzqXkabHsi3gzXcwPlx57k9z14FcuCfOyw8zBBKnPI9K+mfht8avD2keHbfTdR8O3OjWsIC/abRDLCW7s3G7J/E0AfP3izQdQ8F+LbzSr1it5ZTDZMmVDDqsi9+eDX2l8JfGcXjPwVZaoZk+2QgW99EOSJQPvewYfMPrXknx2j8MfEDwzH4g8NazZ3etaan72FZAkksHUjY2CWXr+deW/BXx/J4G8VpNMzNo13iG9ixnKdnA9V6+4yO9AH3F93CEKsDD5fWkV2j/AHew7F4DMRzTLWeC8topknjnt5lEkEiHKup5BB96klAmQLcERMp4HXIoEPUDcd5AjYfdNIFbDI+I4wflI7+1O2qpK5LbzkHrimBWEYEjb5kyRjvTJFH7zEigoVOG3DrTlwAPKXMb5y3TFJICpSd2KqRgrjvSsu/dG+BEfu4PegBUVQNgbdIASDScK3mDdJIOCqnpQMtHgbk2YGT396VcCTdEBtflmoAWQAZEpG1vurjoacy7lCsCpXkAHk0jA8xry33lYjgUAE4ZsNKnUUDOM+Md41j8MPEV1bny2+ysmOMndhf5Gvl34A6amp/FDS0lAIh3S88j5QSMV9MfHeJn+FHiM4YkwKwQdsOpr50/ZvliHxUsY3ypkikAPPXaSBQHQ+xY9zEqvLIMbmHvUmB5hcKXJ4ODwKjIYsH3GPHUHuKemEzgARsMls0CETG8h2DFvmAHQfSlILAGUjenOxT1FJEoUCIbi45Bb/GkZVDhwN0g4Jz/AEoAcxwu8kJGeo7mkXJ3Io2Jj5T60sgAZg53K3QdhSiMlMS4JByqjigBi4GRHgOnykkdaHKKwMali/BpTkkOQVXqwxQVyCqgLGwzkUABwuEc73+8M9qYxJAdh+8XqB3qTacBI2/eKPvEU1E2HdF85Y/Nz0oGNYgY83akTDG0+tPI3ZjPyJ/CQetNURpKQzF97cAjgU4gEjzceYpJVQeSKYCht65j2jb94njNJG6lgY13K3VumKcT8vmuSqY+ZcUqqAu35RCRx65pARBxHN5XLP8AeUkZxSsw++w3SIMbVzSZdgVjyhU43EdafuUgvHgn+I0ALuBG98hWXlCKayltySbVib7uODSIEjIQ5YPyD2oUg/K5DTrkgHigBS0hQ8FNh+uRSq/yBkChGPzE8UrkZ8xj86j7oNEhCjdIdsRH3cdDQAR/KxVAxV+Q3alQ5yud8qDr0oA3fKw2L/CR1NPUhzkfKR1J7ikMbMxTa20sT8pUUrcHEnIboMUucuCgyrdWzQDhigyxHIJHFAEeC4IkUrsOVGeoppJYq4wkY4dSOtOyOWwGmTjiiR40bfIxw5A2kUARBSGKQhUhYZ3A96jBd1eNCRJGfvkfyqaVUIMc7DBPyAHH0FRSyDyDM7GFIss3PUD1oGNjcKwkQea2drke3euH+KXxL0j4f2ji4cX2qzjdBZIwyP8Aaf8Aur+prgPi18drfSlutL8FtHNfHKSXm3KRN0Oz+8ffp9a+ctO07WvF+vBLVLjUdUun6cszE9yewHPPamIveOPF2s+ONb+2atcNKz/LFAmfLhGfuqv+c16/8KPgH9tsf7V8cJNDbvjybGM7JGB/iYjlfYdfpXe/B/4NWXhKNdR1hYr7XlIKKRujtuf4fVvft29a9kK+Ud6bnLnnnNAHzp4n/ZtgZml8N6uYVI+SLURu/Deoz+YNcbbeH/iX8NIry3sbS9/s+4yJRFGLu2Y4xu24ODjvgdK+vdpEm2Vg7HlBjpQ/zYZwd6DO0HtQB+bl3aSrcv8AdaQMSVXgjuRjtVZw6kO5Kt0Ir9DvEHg/w3ryb9Z0WxuAw5ZoQJAc/wB4YYfnXnWsfs9+FNQmmaxfUdNJ+7tlEqH8HBP60Bc8A+H/AMZfEXg/SlsLVLS7sY2LRRXSsxiz1CkMMAnnHqa78ftK3MyK154at5JAMZju2UH8CprhPix8KdV8Cz/aYQ19oznaLpYtuxvRlycc9D0Neb7HC5C5bPSkPc/SVFBjMURKhej0AjrFhpAcMT6VIAGUFxtZOQAaQHc25cBOQ1MghkKRyjhnMhxxyBTiPmCyfM/VQKUqFzGikRkfeH1pxBxtTJdf4iOtADAzEK8mFK9VzQNxkG7AiboD606PCEuBuLdcc04KobDtkk5UelADMOQY0GwJjDHvTgSV3xgH+9Tjgje/3l9PShm+UEkCIjBGOaBmP4l01NZ8ParpLbj9ttpIwT0BKkDH44r4c8D6pJ4W8c6ZfzDy/sV0olVuDgNhgfwzX3yDn90nyjHDDv8ASvjf9orwl/wjvjye/gBGn6qTcKwHAl/jX8zn8aAR9hLIs0Md0rGSKQKyheQQRnI/OpdmQUb5UP3dteL/ALNvjyPV/DqeHr2TOp2C4iDNzJD2/FemPTFe1rwdpYO45FAEaiQrkrsKnBPqKcch1ZAqo33jTgRu3OBuHUDmhz8wDkeWfXrQAgjKgopJyMhj2NNCtgdHlXgmpcEqVXKgYwaQMSCyjp94kYoAjf5JVZskH5cDoKR49wZHPGcqB2qQEBsAMQwzmmMcBgRvkXkUCExvQNypTrjvSp94lAvlt1PvSP8AKvmlSTjlR0FKRkFZMbG6YoAYEKho1zleQx5pG6BowrTLgE4pRvkjKONmw/mKVmI2vGAqZ+fIxQMd8qdSWLnnvTVVhlJ2DHOVFKPk/dx/dbnd6UzJGY1YtKnIJFACujvtlfKspyVFEoyoIIETA5B46013KyK7Asx+UgcgGnuFBPmHKv0U+tAhI1HlmHawULw3vShBv/d4Mqfxe1OVWdSJBt2nIA7iokLsyOG2AZ3DHWgZIcK4dF3E8HAzg0/IVhG53FjkCmqCZAYgPLYZJ96DuwYlJ3Dnd60APRSSvm43ryMGlK5kEm7AxgqajhPAyN0o+VjUmAshJJO7jHpQMUrkEEgRkcYpACyFRlSOMmiVAVKsf93mk+YxhmyuOwpACYyXQfeOGNNIQAgcl+h64qO8u4bG3kuryaK2s41LySysFCj1JPSvnf4p/tALbifTPA4SQAFW1FxkA9/LX/2Y0Aey+NvGGheC9Ka6169RZV/1UI5lkPYKvevlL4ofGHWfGjyWdqW07ScnEETHdJ/vt3+nT6159eXeqeJdYee5ludRvLhgSXYs5J/z0r3P4XfAaW8W11TxiHhtXOVskbEjjsXP8I9uv0pgeY/Dj4ca143vVSyh8ixVgsl5KCI19vc+wr68+Hnw70fwTpzW+lxMLxh+9vZADJL7ey/7IrptK0610u2i0+1hiigiH7mKNAqoPw/nV5kD7TIcyKOi0AOB3KHB2r/FkURKq4EYyhGc5pzYxufhMYINAQFdpAC9gKQDf4tg++P4jzSswUlguX6HFChjwONpxz3FKCCcoBg9TQA0lVb5sneeBjOKQIGOJMFlPFPQbV2Akn1PNMYAfMoDSKMUAVr+0g1C0livY0ltZFKSwyLlXU8YIr5k+IvwD1C21UXng1ftemXGT9mkkVZID6ZY4ZfTvX1KUVWMrZyRgjPFNddhLSMuwngEdKAFIwA7klwMEChgFfdI52NwFNSqgViRnJ60giUZyS2Tnk1QiN4iyFSSAPu4OKVSXjBHy+tPMQbbuZiR3zTtvzZyfpSAiiCjPlgbW5LZo2DARSN46E81IYwUKDgEYpSgOOSCO4pgRsozu6sBg01gFI8x8qx4U1NsAJx360KuFwSSfU0ARhckbux4wa5P4meDrXx14Yn0y4cRMD5kEpHMcoBwfpzg+xrrxGNwJJJA60jRBnJYkqRgr2oA/Pr/AInXgbxY4Jey1XT5cfL1z7eoI/Q19f8Awi+JVj450iNPkt9aiXE1uzAb8dWT1H8qtfEn4VaF49e3mv2ns72H5Rc223eyf3WyCCK4jSv2dLLSNRivdL8V6xbXMTBo5EjjDKc+uKLA2e3jYJCyjcWODjnFOwoO18HJyM1BpVpPZ2aRXV215MBhpmjVC59SF4H4VZEWFxnJHQkUgEPTcTyvPFCMTluNh7Y5pwQZyetIIzk5bKntjpQAi9CgGF7GjfkHbyw6kinMm4DJPBzxSuu7HP6daAIcBBmMFg/JI6CmdwkhDP8AeWpxEAhReAaYkGxBltzr0YigCNzgCR/voM7RTnZSuXOI2GNpHelMIEvmE5J4IxxTjCGLbzuXsMdKAI8b1aLlFH3WB60zeZDiFtpUgMSMkip3hDgZOCDnimlT9oUKQFI5GOtAELsqyfIhKucFgehxT0IQ+Xks5GQWpwgC7lQ7RjsOacqkIoDc9MkUxDEyQHcKZlB700gbvNckKRgoRxmpSgjbeMbzwTTljCliSW3c4NIZBt52tgR/wjpinq5kR1GVKd/WnNGGQ+Z8xU8Y4pMF1jfJGD0HQ0ACPnaYwuM4Y08bVbYo68g9qapPmlRgIR0xVHxHqJ0jRbu8SPzDChYLu25wPWhgi85Kx44aUDgGvL/H/wAafDnhSMwwzJqmrA7WtbZ8oh/23wQPoMmvBPiN8XPFPiTzbeO6GmWByvkWmVZgODuf7xz6cD2ry2K2abOZPu4xx6/jRysLo674g/EfxB46uCNSuStqCTHaQfLEn4dT9TnpSeBvht4h8YyxnSrFhasTvupfkiTHqx6/QZNeu/A74P6FrGkx67rkkt6CfktcbEBBx8xByw46cde9fR1lbwQW8UVtDHBDECqRxqFVR6ADgUbDvc81+Fvwn0nwNHHfLKL7VRnfcyJhY8jkIvb6nn6dK9MQAMBHzG4yWz3p75M6rn5SMEdjTSAztB0TGRjrQA2Ld80QOZE6MRTycESBS0g+U4o3ENtXghsE9c8U92EZXA+8eaQBwCdxzu7elCqTnfjI6AdhTgNuepye9NHEe88tjNACLvwHY7fVaGyc5IEbfnTo8sA5PUdKC2WZT0FADAp8kxqSuBjNC/wtGASTgt7U5f3iKR8vNBOGRQMBs5oAaVCSDaCwc85NAAiP7xi2e5FBbEvlKMA96VsE7WG7HrTA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6129=[""].join("\n");
var outline_f5_63_6129=null;
var title_f5_63_6130="Chondromalacia patella PI";
var content_f5_63_6130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Chondromalacia patella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In people with chondromalacia patella, the cartilage (rubbery material) behind the knee cap gets too soft or wears away.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6130=[""].join("\n");
var outline_f5_63_6130=null;
var title_f5_63_6131="Truview detail photo";
var content_f5_63_6131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Truview detail photo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 533px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Truview EVO video-laryngoscope in adult, pediatric and infant sizes for indirect laryngoscopy in routine and difficult airways, manufactured by Truphatek International Ltd., Israel. www.truphatek.com.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6131=[""].join("\n");
var outline_f5_63_6131=null;
var title_f5_63_6132="Mupirocin: Patient drug information";
var content_f5_63_6132=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mupirocin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     see \"Mupirocin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"     see \"Mupirocin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bactroban Cream&reg;;",
"     </li>",
"     <li>",
"      Bactroban Nasal&reg;;",
"     </li>",
"     <li>",
"      Bactroban&reg;;",
"     </li>",
"     <li>",
"      Centany&reg;;",
"     </li>",
"     <li>",
"      Centany&reg; AT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bactroban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a bacteria found in nose passages and stop its spread to others.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid or treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mupirocin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The treated part may be covered with a dressing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For single use nose ointment, place",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       the ointment from the tube into one nostril and the other",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       into the other nostril. Press the nostrils at the same time and let go many times (for about a minute) to spread the ointment into the nose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10881 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6132=[""].join("\n");
var outline_f5_63_6132=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198518\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198519\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017304\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017303\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017308\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017309\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017311\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017306\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017307\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017312\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017313\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=related_link\">",
"      Mupirocin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=related_link\">",
"      Mupirocin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_63_6133="Nabilone: Drug information";
var content_f5_63_6133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nabilone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/8/29828?source=see_link\">",
"    see \"Nabilone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/35/30260?source=see_link\">",
"    see \"Nabilone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2980459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cesamet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F554086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cesamet&reg;;",
"     </li>",
"     <li>",
"      PMS-Nabilone;",
"     </li>",
"     <li>",
"      RAN&trade;-Nabilone;",
"     </li>",
"     <li>",
"      Teva-Nabilone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F553979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nausea and vomiting associated with cancer chemotherapy:",
"     </b>",
"     Oral: 1-2 mg twice daily (maximum: 6 mg divided in 3 doses daily); begin with the lower dose in the range and increase if needed. May administer 2 or 3 times per day during the entire chemotherapy course; continue for up to 48 hours after the last chemotherapy dose. A dose of 1-2 mg the night before chemotherapy may also be of benefit.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F198760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/35/30260?source=see_link\">",
"      see \"Nabilone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nausea and vomiting associated with cancer chemotherapy (unlabeled use; Dupuis, 2003):",
"     </b>",
"     Oral: Children &gt;4 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;18 kg: 0.5 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     18-30 kg: 1 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;30 kg: 1 mg every 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2983126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing. Use the lower end of the dosing range (to minimize adverse events).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2983127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15068804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cesamet&reg;: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F198766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F198737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dose should be given 1-3 hours before chemotherapy.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory nausea and vomiting associated with cancer chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (52% to 66%), dizziness (59%), vertigo (52% to 59%), euphoria (11% to 38%), ataxia (13% to 14%), depression (14%), concentration decreased (12%), sleep disturbance (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (22% to 36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbance (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dysphoria (9%), headache (6% to 7%), sedation (3%), depersonalization (2%), disorientation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (8%), nausea (4%), appetite increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening) and frequency not reported: Abdominal pain, abnormal dreams, akathisia, allergic reaction, amblyopia, anemia, anhydrosis, anxiety, apathy, aphthous ulcer, arrhythmia, back pain, cerebral vascular accident, chest pain, chills, constipation, cough, diaphoresis, diarrhea, dyspepsia, dyspnea, dystonia, emotional disorder, emotional lability, epistaxis, equilibrium dysfunction, eye irritation, fatigue, fever, flushing, gastritis, hallucinations, hot flashes, hyperactivity, hypertension, infection, insomnia, joint pain, leukopenia, lightheadedness, malaise, memory disturbance, mood swings, mouth irritation, muscle pain, nasal congestion, neck pain, nervousness, neurosis (phobic), numbness, orthostatic hypotension, pain, palpitation, panic disorder, paranoia, paresthesia, perception disturbance, pharyngitis, photophobia, photosensitivity, polyuria, pruritus, psychosis (including toxic), pupil dilation, rash, seizure, sinus headache, speech disorder, stupor, syncope, tachycardia, taste perversion, thirst, thought disorder, tinnitus, tremor, urination decreased/increased, urinary retention, visual field defect, voice change, vomiting, wheezing, withdrawal, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nabilone, other cannabinoids, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: May cause tachycardia and/or orthostatic hypotension; use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dizziness, drowsiness, ataxia, depression, hallucinations, and psychosis have been reported.  Use with caution in patients with mania, depression, or schizophrenia; cannabinoid use may reveal symptoms of psychiatric disorders. Careful psychiatric monitoring is recommended; psychiatric adverse reactions may persist for up to 3 days after discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Substance abuse: Use with caution in patients with a history of substance abuse; potential for dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Effects may be potentiated when used with other psychoactive drugs, sedatives and/or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may cause postural hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cocaine: May enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: Cannabinoids may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2983124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2980460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2983122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Because some cannabinoids are excreted in breast milk, use in breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Cesamet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (50): $1595.86",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2983128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Blood pressure, heart rate; signs and symptoms of excessive use, abuse, or misuse",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiemetic activity may be due to effect on cannabinoid receptors (CB1) within the central nervous system.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~12.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively metabolized to several active metabolites by oxidation and stereospecific enzyme reduction; CYP450 enzymes may also be involved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent compound: ~2 hours; Metabolites: ~35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~60%); renal (~24%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dupuis LL and  Nathan PC, &ldquo;Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children,&rdquo;",
"      <i>",
"       Pediatr Drug",
"      </i>",
"      , 2003, 5(9):597-613.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tramer MR, Carroll D, Campbell FA, et al, &rdquo;Cannabinoids for Control of Chemotherapy Induced Nausea and Vomiting: Quantitative Systematic Review,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2001, 323(7303):16-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6133/abstract-text/11440936/pubmed\" id=\"11440936\" target=\"_blank\">",
"        11440936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ward A and Holmes B, &ldquo;Nabilone: A Preliminary Review of Its Pharmacological Properties and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1985, 30(2):127-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6133/abstract-text/2863127/pubmed\" id=\"2863127\" target=\"_blank\">",
"        2863127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9995 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6133=[""].join("\n");
var outline_f5_63_6133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980459\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554086\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F553979\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198753\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198760\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983126\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983127\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15068804\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198735\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198722\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198766\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198737\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198736\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198763\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198740\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198726\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299732\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198730\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983124\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198732\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980460\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198757\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983122\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323442\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983128\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198725\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198739\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/8/29828?source=related_link\">",
"      Nabilone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/35/30260?source=related_link\">",
"      Nabilone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_63_6134="Energy metabolism in muscle";
var content_f5_63_6134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Energy metabolism in muscle",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6134/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6134/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6134/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6134/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6134/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6134/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/63/6134/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metabolic myopathies have underlying defects of energy production in muscle. Most affected patients have dynamic symptoms, such as exercise intolerance, muscle pain, and cramps upon exercise, rather than static symptoms, such as a fixed weakness of a specific muscle group.",
"   </p>",
"   <p>",
"    To better understand these disorders, this topic review provides an overview of energy metabolism in muscle. The classification, diagnosis, and treatment of the metabolic myopathies are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to a review of the pathways of energy metabolism, it is helpful to first briefly review the sources of energy in muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENERGY SUBSTRATES IN EXERCISING MUSCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main types of \"fuel\" used by muscle for energy metabolism are glycogen, glucose, and free fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The particular energy sources used by working muscle for aerobic metabolism depend upon a number of factors including the intensity, type, and duration of exercise, physical conditioning, and diet [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At rest, muscle predominantly uses fatty acids [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During high-intensity, isometric exercise, anaerobic glycolysis, and the creatine kinase reaction, in which phosphocreatine is converted to adenosine triphosphate (ATP), are the primary sources of energy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With submaximal exercise, the type of substrate used by muscle is heavily dependent upon the relative intensity of exercise. During low-intensity submaximal exercise, the main sources of energy are blood glucose and free fatty acids. With high-intensity submaximal exercise, the proportion of energy derived from glycogen and glucose is increased, and glycogen becomes the main source. Fatigue is experienced when glucose and glycogen stores are depleted (as when a marathon runner hits the \"wall\").",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sources of muscle energy also vary with the duration of exercise. During the first hour of mild, low-intensity exercise (such as jogging), glucose, glucagon, and free fatty acids are the major sources of energy. The uptake of free fatty acids by muscle increases substantially during one to four hours of mild to moderate prolonged exercise; after four hours, lipid oxidation becomes the major source of energy (",
"    <a class=\"graphic graphic_table graphicRef55245 \" href=\"UTD.htm?11/61/12251\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ENERGY METABOLISM IN MUSCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle contraction and relaxation depend primarily upon energy derived from hydrolysis of adenosine triphosphate (ATP). A number of biochemical processes in muscle fibers are responsible for maintaining a constant supply of ATP. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glycogen or glucose metabolism",
"     </li>",
"     <li>",
"      Oxidative phosphorylation",
"     </li>",
"     <li>",
"      Creatine kinase (CK) reaction by which phosphocreatine is converted to ATP",
"     </li>",
"     <li>",
"      Purine nucleotide cycle",
"     </li>",
"     <li>",
"      Lipid metabolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glycogen or glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Energy generation via the metabolism of glycogen or glucose in muscle occurs either anaerobically or aerobically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anaerobic glycolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic glycolysis supplies energy in relatively rare circumstances. This pathway is primarily used during conditions of high-intensity, sustained, isometric muscular activity (eg, lifting heavy objects), particularly in the setting of limited blood flow and oxygen supply to exercising muscle fibers.",
"   </p>",
"   <p>",
"    Phosphorylase, phosphorylase b kinase, and the debranching enzymes are responsible for the production of glucose-1-phosphate from glycogen (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/8\">",
"     8",
"    </a>",
"    ]. The rate-limiting step in glycolysis, however, is the conversion of fructose-6-phosphate to fructose-1,6-diphosphate by the enzyme phosphofructokinase (PFK). The last step in glycolysis is the conversion of pyruvate to lactate by lactate dehydrogenase.",
"   </p>",
"   <p>",
"    The development of fatigue is related to the increased concentration of lactate within muscle fibers, thereby resulting in acidification of the muscle cell. The accumulation of inorganic phosphate (Pi), adenosine diphosphate (ADP), and the monovalent form of organic phosphate are also important in fatigue generation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As an example, maximal acute exercise to exhaustion is associated with a systemic pH as low as 6.80 and serum lactate concentrations as high as 20 to 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Aerobic glycolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;During dynamic forms of exercise (isotonic), such as walking or running, aerobic glycolysis appears to play an important role in energy production. With aerobic glycolysis, pyruvate is formed through the same steps described in anaerobic glycolysis, but oxidative decarboxylation of pyruvate takes place through the pyruvate dehydrogenase complex, generating acetyl coenzyme A (acetyl-CoA). The latter compound enters the tricarboxylic acid (TCA) cycle, also known as the citric acid cycle or Krebs cycle, where it is converted into carbon dioxide and water (",
"    <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Oxidative phosphorylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxidative phosphorylation system, localized in the inner mitochondrial membrane, is the main source of energy in muscle and other cells (",
"    <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"     figure 2",
"    </a>",
"    ). Compared to glycolysis, this system produces 17 to 18 times as much adenosine triphosphate (ATP) from the same amount of glucose.",
"   </p>",
"   <p>",
"    The respiratory chain is composed of four multi-subunit complexes (I, II, III, and IV) linked by the mobile electron carriers coenzyme Q and cytochrome c. The reduced forms of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) are formed from the citric acid cycle and the beta-oxidation of fatty acids in the mitochondrial matrix. The respiratory chain transfers electrons from NADH (via complex I) and from reduced flavoproteins (via complex II and electron transfer flavoprotein-coenzyme Q oxidoreductase [ETF-Qo]) to coenzyme Q, then complex III, cytochrome c and finally complex IV. At the same time, complexes I, III and IV pump electrons across the inner mitochondrial membrane from the matrix to the intermembrane space. The influx of these electrons (protons) back into the mitochondrial matrix releases energy that is used in the phosphorylation of ADP to ATP by complex V (ATP synthetase), which is also embedded in the inner mitochondrial membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Phosphocreatine pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;During very high intensity exercise, rapid formation of ATP can be accomplished through the reaction of phosphocreatine with ADP catalyzed by creatine kinase. Because the amount of phosphocreatine in muscle is small, the duration of this reaction is very brief. When oxygenation of muscle again becomes adequate, stores of phosphocreatine are replenished [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Purine nucleotide cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensely exercising muscle can generate ATP over a short period of time using the adenylate kinase reaction; this reaction catalyzes the conversion of two ADP molecules into one molecule of ATP and one molecule of adenosine monophosphate (AMP). The AMP may then be deaminated to inosine monophosphate (IMP) by myoadenylate deaminase, with concurrent production of ammonia (",
"    <a class=\"graphic graphic_figure graphicRef58885 \" href=\"UTD.htm?23/6/23661\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Myoadenylate deaminase activity seems to be higher in type 2, fast muscle fibers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lipid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of lipids in muscle occurs via beta- and omega-oxidation of fatty acids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Beta-oxidation of fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;At rest, fatty acids are the major energy substrate for muscle. Long-chain fatty acids constitute a major source of energy for prolonged, low-intensity exercise, lasting for more than 40 to 50 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/18\">",
"     18",
"    </a>",
"    ]. Fatty acids are derived from circulating, very low-density lipoproteins in the bloodstream or from triglycerides stored in adipocytes.",
"   </p>",
"   <p>",
"    Once in the cytoplasm, short- and medium-chain fatty acids of less than 10 carbon atoms can cross both the outer and inner mitochondrial membranes; these compounds subsequently enter the mitochondrial matrix where they undergo beta-oxidation after activation into their CoA esters (",
"    <a class=\"graphic graphic_figure graphicRef59178 \" href=\"UTD.htm?10/16/10504\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, the mitochondrial membrane is not permeable to long-chain fatty acids; a multi-step process is therefore required for these compounds to be used by mitochondria. In the muscle cytoplasm, long-chain fatty acids are first activated by long-chain acyl-CoA synthetase to their CoA thioesters. The CoA thioesters are subsequently linked with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    by the enzyme carnitine palmitoyltransferase I (CPT I), which is located on the inner side of the outer mitochondrial membrane. The acylcarnitine form of the long-chain fatty acid, palmitoylcarnitine, is then transferred across the inner mitochondrial membrane by carnitine:acylcarnitine translocase [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/19\">",
"     19",
"    </a>",
"    ]; once in the mitochondrial matrix, it is converted back to free acyl-CoA derivative and carnitine by CPT II, which is localized on the inner side of the inner mitochondrial membrane (",
"    <a class=\"graphic graphic_figure graphicRef59178 \" href=\"UTD.htm?10/16/10504\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    is released, the long-chain acyl-CoA derivative enters the beta-oxidation pathway. With every complete cycle, a two-carbon fragment is cleaved and an acetyl-CoA molecule is released. The acetyl-CoA is then oxidized via the citric acid cycle for energy production in muscle, heart, and other tissues (",
"    <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ninety percent of the hepatic acetyl-CoA, however, is converted into ketones, which are an important source of energy for all tissues, particularly the brain. During prolonged fasting, ketones provide an important source of energy in brain tissue because the blood-brain barrier is impermeable to long-chain fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/20\">",
"     20",
"    </a>",
"    ]. The intramitochondrial beta-oxidation of fatty acids requires the existence of chain-length specific enzymes. The complete oxidation of fatty acids is mediated by at least 11 enzymes (",
"    <a class=\"graphic graphic_table graphicRef55245 \" href=\"UTD.htm?11/61/12251\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peroxisomal fatty acid oxidation enzymes are genetically distinct from the mitochondrial enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/18\">",
"     18",
"    </a>",
"    ]. In mitochondria, the first step of beta-oxidation occurs via a flavin adenine dinucleotide (FAD)-containing enzyme coupled to oxidative phosphorylation that generates adenosine triphosphate (ATP). In peroxisomes, however, beta-oxidation occurs via a flavin-containing oxidase that generates H",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    and then, through peroxisomal catalase, H",
"    <sub>",
"     2",
"    </sub>",
"    O and O",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/23\">",
"     23",
"    </a>",
"    ]. Therefore, some energy is wasted. In mitochondria, the next steps in beta-oxidation are managed by two separate enzymes, while in peroxisomes they are managed by a single multifunctional enzyme protein.",
"   </p>",
"   <p>",
"    It is believed that fatty acid oxidation in peroxisomes handles very-long-chain fatty acids (&gt;C22), because these accumulate, particularly in neural tissues, in genetically linked peroxisomal disorders such as Zellweger syndrome and adrenoleukodystrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Omega-oxidation of fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;During prolonged fasting, as much as 20 percent of total cellular oxidation of fatty acids is accomplished in liver microsomes (endoplasmic reticulum) through omega-oxidation, thereby resulting in the formation of dicarboxylic acids (DCAs) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/24\">",
"     24",
"    </a>",
"    ]. DCAs are further metabolized through beta-oxidation in peroxisomes and mitochondria.",
"   </p>",
"   <p>",
"    In metabolic defects of intramitochondrial fatty acid oxidation, mitochondrial beta-oxidation of DCAs is impaired at a time when the production of DCAs is increased due to the recruitment of microsomal omega-oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/25\">",
"     25",
"    </a>",
"    ], which explains the appearance of DCAs in the urine. However, DCAs are also produced in other settings, including normal fasting, diabetic ketoacidosis, and diets containing medium-chain triglycerides. In addition, thioesterases catalyze the deacylation of coenzyme A and the conjugation of the acyl groups to glycine and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Thus, the detection of acylcarnitine derivatives in serum, and the detection of DCAs and acylglycines in urine, has proven valuable for the diagnosis of inborn errors of fatty acid oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6134/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impairments at any of the important regulatory steps of lipid metabolism can lead to a myopathy and, in some cases, involvement of other organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H400796899\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main types of fuel used by muscle for energy metabolism are glycogen, glucose, and free fatty acids. The particular energy sources used by working muscle for aerobic metabolism depend upon a number of factors including the intensity, type, and duration of exercise, physical conditioning, and diet. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Energy substrates in exercising muscle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muscle contraction and relaxation depend primarily upon energy derived from hydrolysis of adenosine triphosphate (ATP). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Energy metabolism in muscle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Energy generation via the metabolism of glycogen or glucose in muscle occurs either anaerobically or aerobically. During dynamic forms of exercise (isotonic), such as walking or running, aerobic glycolysis appears to play an important role in energy production. Anaerobic glycolysis supplies energy in relatively rare circumstances. This pathway is primarily used during conditions of high-intensity, sustained, isometric muscular activity (eg, lifting heavy objects), particularly in the setting of limited blood flow and oxygen supply to exercising muscle fibers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Glycogen or glucose metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The oxidative phosphorylation system, localized in the inner mitochondrial membrane, is the main source of energy in muscle and other cells (",
"      <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Oxidative phosphorylation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During very high intensity exercise, rapid formation of ATP can be accomplished through the reaction of phosphocreatine with ADP catalyzed by creatine kinase. In addition, intensely exercising muscle can generate ATP over a short period of time using the adenylate kinase reaction (",
"      <a class=\"graphic graphic_figure graphicRef58885 \" href=\"UTD.htm?23/6/23661\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Phosphocreatine pathway'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Purine nucleotide cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The metabolism of lipids in muscle occurs via beta- and omega-oxidation of fatty acids. Short- and medium-chain fatty acids of less than 10 carbon atoms can cross both the outer and inner mitochondrial membranes; these compounds subsequently enter the mitochondrial matrix where they undergo beta-oxidation after activation into their CoA esters (",
"      <a class=\"graphic graphic_figure graphicRef59178 \" href=\"UTD.htm?10/16/10504\">",
"       figure 4",
"      </a>",
"      ). Long-chain fatty acids constitute a major source of energy for prolonged, low-intensity exercise, lasting for more than 40 to 50 minutes. However, the mitochondrial membrane is not permeable to long-chain fatty acids; a multi-step process is therefore required for these compounds to be used by mitochondria. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Lipid metabolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Beta-oxidation of fatty acids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During prolonged fasting, as much as 20 percent of total cellular oxidation of fatty acids is accomplished in liver microsomes through omega-oxidation, thereby resulting in the formation of dicarboxylic acids (DCAs). DCAs are further metabolized through peroxisomal and mitochondrial beta-oxidation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Omega-oxidation of fatty acids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/1\">",
"      Felig P, Wahren J. Fuel homeostasis in exercise. N Engl J Med 1975; 293:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/2\">",
"      Wahren J. Glucose turnover during exercise in man. Ann N Y Acad Sci 1977; 301:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/3\">",
"      Ess&eacute;n B. Intramuscular substrate utilization during prolonged exercise. Ann N Y Acad Sci 1977; 301:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/4\">",
"      Gollnick PD, Piehl K, Saltin B. Selective glycogen depletion pattern in human muscle fibres after exercise of varying intensity and at varying pedalling rates. J Physiol 1974; 241:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/5\">",
"      Ess&eacute;n B. Glycogen depletion of different fibre types in human skeletal muscle during intermittent and continuous exercise. Acta Physiol Scand 1978; 103:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/6\">",
"      Das AM, Steuerwald U, Illsinger S. Inborn errors of energy metabolism associated with myopathies. J Biomed Biotechnol 2010; 2010:340849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/7\">",
"      Lithell H, Orlander J, Sch&eacute;le R, et al. Changes in lipoprotein-lipase activity and lipid stores in human skeletal muscle with prolonged heavy exercise. Acta Physiol Scand 1979; 107:257.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro, S, Tsujino, S. Nonlysosomal glycogenoses. In: Myology, Engel, A, Banker, B (Eds), McGraw-Hill, New York, 1994, p.1554.",
"    </li>",
"    <li>",
"     DiMauro, S, Tonin, P, Servidei, S. Metabolic myopathies. In: Handbook of Clinical Neurology, Rowland, L, DiMauro, S (Eds), Elsevier, Amsterdam, 1992, p. 479.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/10\">",
"      DiMauro S, Miranda AF, Sakoda S, et al. Metabolic myopathies. Am J Med Genet 1986; 25:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/11\">",
"      Lindinger MI, Heigenhauser GJ, McKelvie RS, Jones NL. Blood ion regulation during repeated maximal exercise and recovery in humans. Am J Physiol 1992; 262:R126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/12\">",
"      Lewis SF, Haller RG. The pathophysiology of McArdle's disease: clues to regulation in exercise and fatigue. J Appl Physiol 1986; 61:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/13\">",
"      Lewis SF, Vora S, Haller RG. Abnormal oxidative metabolism and O2 transport in muscle phosphofructokinase deficiency. J Appl Physiol 1991; 70:391.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro S, De Vivo D. Diseases of carbohydrate, fatty acid, and mitochondrial metabolism. In: Basic neurochemistry: Molecular, cellular, and medical aspects, 7th ed, Seigel G, Albers RW, Brady S, Price D.  (Eds), Elsevier Academic Press, 2006. p.695.",
"    </li>",
"    <li>",
"     Taanman JW, Williams S. Structure and function of the mitochondrial oxidative phosphorylation system. In: Mitochondrial Disorders in Neurology 2, Schapira AHV, DiMauro S (Eds), Butterworth-Heinemann, Boston 2002. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/16\">",
"      van Adel BA, Tarnopolsky MA. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis 2009; 10:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/17\">",
"      Fishbein WN. Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 1985; 33:158.",
"     </a>",
"    </li>",
"    <li>",
"     Tein I. Lipid storage muscular disorders. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Jones HR Jr, De Vivo DC, Darras BT (Eds), Butterworth Heinemann, Philadelphia 2003. p.833.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/19\">",
"      Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med 2004; 25:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/20\">",
"      Tein I. Metabolic myopathies. Semin Pediatr Neurol 1996; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     Hashimoto, T. Peroxisomal and mitochondrial enzymes. In: Progress in Clinical and Biological Research, Coates, P, Tanaka, K (Eds), Wiley, New York, NY 1992. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/22\">",
"      Luo MJ, He XY, Sprecher H, Schulz H. Purification and characterization of the trifunctional beta-oxidation complex from pig heart mitochondria. Arch Biochem Biophys 1993; 304:266.",
"     </a>",
"    </li>",
"    <li>",
"     Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 7th, Brady S, Siegel G, Albers RW, Price DL (Eds), Elsevier Academic Press, Boston 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/24\">",
"      Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000; 22:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/25\">",
"      Krahling JB, Gee R, Murphy PA, et al. Comparison of fatty acid oxidation in mitochondria and peroxisomes from rat liver. Biochem Biophys Res Commun 1978; 82:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/26\">",
"      K&oslash;lvraa S, Gregersen N. Acyl-CoA:glycine N-acyltransferase: organelle localization and affinity toward straight- and branched-chained acyl-CoA esters in rat liver. Biochem Med Metab Biol 1986; 36:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/27\">",
"      Roe CR, Millington DS, Maltby DA, et al. Diagnostic and therapeutic implications of medium-chain acylcarnitines in the medium-chain acyl-coA dehydrogenase deficiency. Pediatr Res 1985; 19:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6134/abstract/28\">",
"      Baretz BH, Ramsdell HS, Tanaka K. Identification of n-hexanoylglycine in urines from two patients with Jamaican vomiting sickness. Clin Chim Acta 1976; 73:199.",
"     </a>",
"    </li>",
"    <li>",
"     Millington D. New methods for the analysis of acylcarnitines and acyl-coenzyme A compounds. In: Mass Spectrometry in Biomedical Research, Gaskell S (Ed), John Wiley, New York 1986. p.97.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6212 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6134=[""].join("\n");
var outline_f5_63_6134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H400796899\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENERGY SUBSTRATES IN EXERCISING MUSCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ENERGY METABOLISM IN MUSCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glycogen or glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anaerobic glycolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Aerobic glycolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Oxidative phosphorylation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Phosphocreatine pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Purine nucleotide cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lipid metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Beta-oxidation of fatty acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Omega-oxidation of fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H400796899\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6212\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6212|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/55/12148\" title=\"figure 2\">",
"      Mitochondrial pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/6/23661\" title=\"figure 3\">",
"      Purine nucleotide cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/16/10504\" title=\"figure 4\">",
"      Carnitine cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6212|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/61/12251\" title=\"table 1\">",
"      Fatty acid oxidation enzymes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_63_6135="Olmesartan and hydrochlorothiazide: Drug information";
var content_f5_63_6135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olmesartan and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/8/31877?source=see_link\">",
"    see \"Olmesartan and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benicar HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6860153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Olmetec Plus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F203655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dosage must be individualized; may be titrated at 2- to 4-week intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Replacement therapy:",
"     </i>",
"     May be substituted for previously titrated dosages of the individual components.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients not controlled with single-agent therapy:",
"     </i>",
"     Initiate by adding the lowest available dose of the alternative component (hydrochlorothiazide 12.5 mg or olmesartan 20 mg). Titrate to effect (maximum hydrochlorothiazide dose: 25 mg, maximum olmesartan dose: 40 mg).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F203645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13931267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     20/12.5: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     40/12.5: Olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     40/25: Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13931268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food. Take early in day to avoid nocturia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (not recommended for initial treatment)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F203653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequencies reported with combination product. See individual monographs for additional adverse effects reported with each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness (9%), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia (4%), hyperglycemia, hyperlipidemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%), abdominal pain, dyspepsia, gastroenteritis, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, arthritis, arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (7%), cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: CPK increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, alopecia, angioedema, anaphylactic reactions, BUN increased, creatinine increased, diarrhea, facial edema, hyperkalemia, pruritus, rhabdomyolysis, urticaria, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to olmesartan, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with olmesartan/hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use olmesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use olmesartan with caution with pre-existing renal insufficiency and severe renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective); may precipitate azotemia; discontinue or consider withholding if renal impairment occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Olmesartan. Management: Administer olmesartan at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13931258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F203636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benicar HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (30): $119.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-12.5 mg (30): $167.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-25 mg (30): $167.04",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F203629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Assess weight, I &amp; O reports daily to determine fluid loss; blood pressure, serum electrolytes, BUN, creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alteisduo (FR);",
"     </li>",
"     <li>",
"      Alzor HCT (PH);",
"     </li>",
"     <li>",
"      Benicar HCT (CR, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      CoOLMETEC (FR);",
"     </li>",
"     <li>",
"      Fu An Tan (CL);",
"     </li>",
"     <li>",
"      Iltux HCT (EC);",
"     </li>",
"     <li>",
"      Olmegan (IT);",
"     </li>",
"     <li>",
"      Olmetec Comp (NO);",
"     </li>",
"     <li>",
"      Olmetec D (AR);",
"     </li>",
"     <li>",
"      Olmetec HCT (BR, CO, EC);",
"     </li>",
"     <li>",
"      Olmetec HCTZ (NL);",
"     </li>",
"     <li>",
"      Olmetec Plus (AT, AU, BE, CH, CN, DE, DK, DO, EE, FI, GB, GR, GT, HK, HN, ID, KP, MY, NI, PE, PH, PT, SG, SV, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Olmetec Plus H (CZ);",
"     </li>",
"     <li>",
"      Omesar Plus (IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K and Kjekshus J, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/63/6135/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10250 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6135=[""].join("\n");
var outline_f5_63_6135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709180\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203642\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860153\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203655\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203643\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203644\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203645\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13931267\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203631\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203620\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13931268\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203632\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203653\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203635\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203622\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837692\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203625\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203627\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203637\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203647\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13931258\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203636\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203629\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539906\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203621\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203634\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10250|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/8/31877?source=related_link\">",
"      Olmesartan and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_63_6136="Placement and maintenance of the peritoneal dialysis catheter";
var content_f5_63_6136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placement and maintenance of the peritoneal dialysis catheter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6136/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6136/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6136/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6136/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6136/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6136/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/63/6136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main function of a peritoneal dialysis catheter is to permit consistent bidirectional flow of dialysate without extraordinary effort or undue discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/1\">",
"     1",
"    </a>",
"    ]. The catheter's function depends upon its design, implantation site, and the configuration of the system used to perform dialysis exchanges.",
"   </p>",
"   <p>",
"    Most catheters are flexible tubes with multiple ports in the distal (intraabdominal) segment which is ideally positioned freely in the intraabdominal pelvic area. The catheter's midportion is normally implanted within the wall of the abdomen via one to two Dacron velour cuffs. With double-cuffed catheters, the deep cuff is imbedded in the abdominal rectus muscle; the superficial cuff in both double cuff and single cuff catheters is placed subcutaneously approximately 2 cm from the catheter exit site on the abdominal wall.",
"   </p>",
"   <p>",
"    A review of the placement and maintenance of the peritoneal dialysis catheter is presented here. Prior to a discussion of these issues, it is helpful to briefly review the different types of catheters that are currently available. Complications associated with these catheters are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF CATHETERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many types of catheters are available for chronic peritoneal dialysis (",
"    <a class=\"graphic graphic_figure graphicRef50191 \" href=\"UTD.htm?20/40/21121\">",
"     figure 1",
"    </a>",
"    ). The double cuff straight Tenckhoff catheter, a silicone catheter with a straight (as opposed to coiled) intraabdominal portion is a commonly used catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The Missouri Swan Neck catheter and the Toronto Western catheter have also been used extensively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/4\">",
"     4",
"    </a>",
"    ]. Regardless of type, overall catheter survival is approximately 88 percent at one year with removal rates of 15 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of one catheter over another has not been conclusively demonstrated by prospective, randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/3,5-9\">",
"     3,5-9",
"    </a>",
"    ]. A systematic review published in 2004, for example, found no difference related to prevention of peritonitis with respect to straight versus coiled or single versus doubled cuffed catheters, although all cause mortality may be lower with straight catheters (RR of 0.26, 95% CI of 0.07 to 0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized prospective study of 132 patients found no difference in time to catheter malposition, catheter-associated infections, or overall catheter survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/10\">",
"     10",
"    </a>",
"    ]. However, an unexplained finding on secondary outcome analysis in this study was that a significantly decreased time to technique failure was observed with the coiled catheter (1.4 versus 2.1 years). This was principally due to inadequate small-solute clearance. However, the authors report no difference in dialysis adequacy measures between the two groups, suggesting that study bias is responsible for the observed difference.",
"   </p>",
"   <p>",
"    A randomized controlled trial that compared swan neck catheters with a coiled versus a straight end showed no significant difference in overall catheter failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/11\">",
"     11",
"    </a>",
"    ]. However, late (&gt;8 weeks) catheter tip migration was more common with the coiled end catheters, which was also observed in a meta-analysis that included four additional trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/11\">",
"     11",
"    </a>",
"    ]. Additional study is needed before one catheter can be recommended over another.",
"   </p>",
"   <p>",
"    A catheter design in which the \"tip\" is weighted (ie, self-locating catheter) may reduce the incidence of catheter migration and other complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In a study of 15 and 13 patients with weighted and conventional catheters, respectively, the number of migrating catheters was significantly higher among the conventional group (four versus zero), suggesting that weighted tip catheters may possibly lower the frequency of dialysate flow problems [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/12\">",
"     12",
"    </a>",
"    ]. In a second study, this design was associated with decreased transfers to hemodialysis, and rates of peritonitis, exit site infections, cuff extrusions, obstruction, migration, and leak [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal catheter type may differ in men and women. In a study of 200 patients, anthropometric analysis to help maximize the position of the catheter tip to a deep pelvic location and ideal exit site location found that the optimal catheter type varied by gender [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/14\">",
"     14",
"    </a>",
"    ]. Swan neck catheters with a downwardly-directed external limb and exit site were better suited to females, while Tenckhoff catheters with straight intercuff segments and a laterally-directed tunnel and exit site were better suited to males [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The gender differences primarily resulted from the location of the belt line combined with the desire to produce a downwardly-directed exit site; women favored the belt line above the umbilicus position and men favored it below the umbilicus position. Obesity, the presence of stomas, floppy abdominal skin folds, or incontinence of urine or feces are all indications to use an extended catheter system providing a remote exit site location to the upper abdomen or chest, such as the presternal catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/15\">",
"     15",
"    </a>",
"    ]. However, neither catheter was suitable for 25 percent of patients, a finding that emphasizes the benefits of extended catheter systems, such as presternally-located catheters to achieve ideal pelvic positioning of the catheter tip in some patients. Thus, using a single, preferred catheter for all patients may not be the optimal strategy; preoperative evaluation of patients may include assessment of body habitus and consideration of the most appropriate catheter.",
"   </p>",
"   <p>",
"    Most available catheters are made of silicone. Although polyurethane catheters are also available (eg, the Cruz catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]), there is limited long-term experience with these catheters for PD. Thus far, no available catheter material resists biofilm formation, an important factor in the development of PD catheter infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Summary and recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catheter used by a peritoneal dialysis (PD) program primarily depends upon the preferences and experience of the clinician inserting the catheters, with 2005 guidelines stating that no particular catheter is definitively better than the standard silicone Teckhoff catheter for the prevention of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/16\">",
"     16",
"    </a>",
"    ]. However, we and some international guidelines prefer double cuff catheters over single cuff catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/3,7,17\">",
"     3,7,17",
"    </a>",
"    ]. Double cuff catheters have the advantages of fewer complications, a longer time to first peritonitis episode, and longer survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Programs may also consider body habitus assessment when evaluating patients for catheter placement and catheter type [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/14\">",
"     14",
"    </a>",
"    ]. Following Crabtree's guidelines, the patient's belt line location should be marked (with the patient clothed) followed by determination of the catheter insertion site, which will suggest the appropriate catheter type [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/15\">",
"     15",
"    </a>",
"    ]. With the patient in the supine position, the position of the deep cuff location, which corresponds to the insertion site, is established by aligning the upper border of the catheter coil with the upper border of the symphysis pubis (a reliable landmark for the ideal position of the catheter tip in the true pelvis). Once the insertion site and deep cuff location are determined, the appropriate catheter can be selected to produce a downwardly-directed tunnel and acceptable exit site location for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONSIDERATIONS IN CATHETER PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various factors require consideration when inserting a peritoneal dialysis catheter. These include the location of the exit site, use of prophylactic antibiotics, implantation technique, pre- and postoperative care of the catheter, and temporal needs for dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Exit site location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most PD catheters are placed in a paramedian or lateral abdominal location rather than in the midline. This location allows for positioning of the catheter's deep cuff in or below the rectus muscle, thereby permitting better tissue ingrowth around the cuff due to the richer vascularization of muscle tissue. A paramedian location also provides better structural support for and a strong seal around the catheter, thereby minimizing the risk of peritoneal leak [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The incidence of peritonitis or",
"    <span class=\"nowrap\">",
"     exit-site/tunnel",
"    </span>",
"    infections appears to be similar with midline or lateral insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PD catheters can also be placed in a presternal location (",
"    <a class=\"graphic graphic_figure graphicRef58863 \" href=\"UTD.htm?12/2/12335\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This location may be desirable in obese patients, very young children (whose need for diapers may contribute to high infection rates with abdominally located PD catheters), patients with ureterocutaneostomies, and those with recurrent exit site infections with abdominal PD catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one review of the experience at the University of Missouri, a nonsignificant trend for improved survival and lower peritonitis rates was observed with presternal compared with abdominal catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/22\">",
"     22",
"    </a>",
"    ]. Exit site location of a presternal catheter should be at least 3 cm off the midline, and the catheter tubing should not cross the midline of the chest in case cardiac surgery is required [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient comfort and accessibility to the catheter are also concerns when considering the exit site location. It is therefore best to avoid exit sites over scars, belt lines, and skin folds. To determine the best location, it is often necessary to mark the desired location for the catheter's exit site with the patient in a sitting position (rather than when the patient is lying on the procedure table awaiting catheter insertion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that PD catheters be placed in a paramedian or lateral abdominal location rather than in the midline [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exit site size",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonrandomized prospective study comparing the procedure used to exit the newly-placed catheter from the skin found that the risks of first exit site and tunnel infections, catheter-related peritonitis, and catheter removal were associated with large exit site wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/23\">",
"     23",
"    </a>",
"    ]. Gentle dissection and careful exit-site construction resulting in the smallest possible hole for the exiting catheter is therefore desirable.",
"   </p>",
"   <p>",
"    Sutures should never be placed at the catheter exit site. Suture material may act as a nidus for bacterial growth and increase the risk of catheter-related infection. Fibroblast ingrowth of the Dacron cuff is sufficient to anchor the catheter, obviating the need for suture material at the exit site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data relating to the efficacy of prophylactic antibiotics before PD catheter implantation. The administration of an antibiotic just prior to peritoneal catheter placement may decrease the incidence of wound infection and peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest prospective study, 221 patients undergoing PD catheter placement were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (1 gm given intravenously 12 hours prior to the procedure),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (1 gm given intravenously 3 hours prior to placement), or no antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/28\">",
"       28",
"      </a>",
"      ]. At two weeks, the incidence of peritonitis was significantly lower in those given antibiotics, particularly vancomycin (1, 7, and 12 percent for the vancomycin, cefazolin, and no treatment groups, respectively).",
"     </li>",
"     <li>",
"      In a systematic review published in 2004, an analysis of four randomized prospective studies consisting of 335 patients (including the study just mentioned) found that the use of perioperative intravenous antibiotics, compared with no treatment, significantly reduced the risk of peritonitis within one month of surgery (RR of 0.35, 95% CI 0.15 to 0.80) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are reports of a rise in the incidence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistant Enterococcus sp. As a result, the routine use of vancomycin for prophylaxis prior to catheter insertion is not recommended. Other antibiotics, such as a cephalosporin, should therefore be the first choice [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Summary and recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics appear to help prevent early catheter infections. Given the emergence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant organisms, the optimal choice of antibiotic is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2002 review written in collaboration with major national societies suggests administration of a first generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 g), given intravenously one hour before the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/32\">",
"     32",
"    </a>",
"    ]. This recommendation was made even though",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    may be more effective.",
"   </p>",
"   <p>",
"    The 2005 International Society Guidelines state that each program should consider giving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , with a view of the",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    ratio with this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/16\">",
"     16",
"    </a>",
"    ]; by comparison, another 2005 updated Guideline suggested that a single dose of a first or second generation cephalosporin should be given intravenously, with vancomycin not to be routinely used [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/17\">",
"     17",
"    </a>",
"    ]. We prefer to administer a cephalosporin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Implantation technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with an upwardly or horizontally-directed PD catheter tunnel, a downwardly-directed tunnel is preferred and recommended by International Guidelines since it may be associated with fewer catheter infections and fewer peritonitis episodes resulting from catheter or tunnel infections [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/17,18,33\">",
"     17,18,33",
"    </a>",
"    ]. Catheters with a permanent bend (eg, Swan Neck catheter) naturally have a downwardly-directed tunnel because of the catheter's configuration (",
"    <a class=\"graphic graphic_figure graphicRef50191 \" href=\"UTD.htm?20/40/21121\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are several basic methods of PD catheter insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/1-3,20,34-38\">",
"     1-3,20,34-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At the bedside, using a trocar and guidewire technique (generally reserved for temporary acute PD)",
"     </li>",
"     <li>",
"      Via laparoscopy",
"     </li>",
"     <li>",
"      Via fluoroscopy",
"     </li>",
"     <li>",
"      Via surgery, either by a standard dissection or by a modification, such as the buried technique (Moncrief-Popovich) or using a presternally-located catheter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bedside catheter placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of bedside catheter placement are that the technique requires a small incision, is quick and inexpensive, and permits immediate use. The shortcomings are primarily technical: it is a blind procedure, thereby resulting in a greater risk of inadvertent organ",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vessel perforation; leaks and poor catheter flow are also common.",
"   </p>",
"   <p>",
"    The problems with this type of catheter placement generally",
"    <strong>",
"     outweigh",
"    </strong>",
"    the advantages in most patients; exceptions include some cases of acute renal failure expected to reverse quickly, and some individuals unable to tolerate the anesthesia required for catheter placement in the operating room. This method is not used for chronic catheter placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Peritoneoscopy/laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneoscopic catheter placement permits immediate use and, in experienced hands, is a relatively simple and quick procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/3,34,37,39,40\">",
"     3,34,37,39,40",
"    </a>",
"    ]. At one center, a significantly lower incidence of flow dysfunction was observed with such placement (particularly advanced laparoscopic techniques) compared with an open surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fluoroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous fluoroscopy-guided placement provides accurate placement with little waiting time and a relatively small incision [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/38\">",
"     38",
"    </a>",
"    ]. Limited data suggest that this approach provides similar outcomes compared with more invasive techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/38\">",
"     38",
"    </a>",
"    ]; however, the incidence of late leakage appears to be increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical placement of catheters has the advantage of precise catheter placement with little risk of viscus perforation. Disadvantages are the longer time involved (including operating room scheduling), greater cost, and larger incision required.",
"   </p>",
"   <p>",
"    The buried catheter technique differs from the standard surgical technique in that the entire catheter remains buried subcutaneously until it is ready to be used, usually four to six weeks after catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/35\">",
"     35",
"    </a>",
"    ]. At that time, the catheter is exteriorized. This method was developed to possibly reduce peritonitis and catheter infections by allowing complete sinus tract healing and fibroblast ingrowth into the cuff before local trauma to the exit site could occur.",
"   </p>",
"   <p>",
"    Few randomized prospective trials comparing this method with the standard surgical technique are available, with some conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/7,41,42\">",
"     7,41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective randomized study, the buried technique, compared with the standard technique, was not associated with a reduced risk of peritonitis or exit-site infection [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of 214 new catheters (59 implanted using the buried technique and 155 via the conventional method) also showed no difference in peritonitis rates [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study of 349 buried catheters found that prolonged catheter embedding (131 to 2041 days) prior to exteriorization and use may be associated with primary catheter failure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most programs continue to use the standard technique unless early infection rates are high. The principal disadvantages of the buried technique are the need for two procedures and the longer waiting time for catheter use.",
"   </p>",
"   <p>",
"    Catheter patency should always be assured before leaving the operating room by infusing one liter of peritoneal dialysate over five minutes and allowing an additional five minutes for drainage, or by instilling and aspirating saline [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the choice of catheter, the technique used by a PD program depends upon the preferences and expertise of the surgeon or nephrologist inserting the catheter. Each method of insertion has its benefits and proponents, but no technique has been shown to be preferable overall [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/7\">",
"     7",
"    </a>",
"    ]. A survey of surgical residency program directors showed that, although most programs included peritoneal dialysis catheter placement as a procedure taught to their trainees, most surgeons placed two or fewer than five catheters during their training [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, experience in individual programs will dictate the technique and operators placing PD catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Postoperative catheter care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newly placed catheters are usually flushed with small volumes of dialysate (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be added as 500 to 1000",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    dialysate if fibrin or clots are evident) until the effluent is clear. The catheter is then capped and a dressing applied to the site.",
"   </p>",
"   <p>",
"    There are few controlled trials of optimal catheter care post-placement, but most suggest that the catheter site be covered with gauze dressing and remain undisturbed for several days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/3\">",
"     3",
"    </a>",
"    ]. The catheter should be immobilized with a dressing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tape to minimize trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/3\">",
"     3",
"    </a>",
"    ]. Infrequent dressing changes (eg,",
"    <span class=\"nowrap\">",
"     once/week)",
"    </span>",
"    are probably sufficient for the first one to two weeks after implantation.",
"   </p>",
"   <p>",
"    It is important to minimize catheter movement and handling, since local trauma can increase the risk of bacterial colonization with subsequent infection. However, limited data suggest that if necessary, the catheter may be used immediately after placement without increasing the risk of infection. This was shown in a single center study in which 18 patients were started on in-center three times weekly peritoneal dialysis immediately after catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/45\">",
"     45",
"    </a>",
"    ]. Compared with 9 patients who waited two weeks prior to starting dialysis, urgent initiation was associated with no greater risk of peritonitis or exit site infection at three months.",
"   </p>",
"   <p>",
"    To minimize the risk of fluid leak, it is preferable to wait at least 10 to 14 days after catheter insertion before beginning peritoneal dialysis. If PD is required less than 10 days following catheter placement, small volume exchanges (ie, less than 1500 mL) performed in the recumbent position only (eg, with a cycler or chronic ambulatory peritoneal dialysis with supine dwells only) can be performed with little risk of a significant leak [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/4,29\">",
"     4,29",
"    </a>",
"    ]. In the study cited above, immediate use of the catheter was associated with a higher incidence of pericatheter leak (22 versus 11 in patients who waited two weeks prior to using catheter); however in most cases, the leaks were minor and easily managed with temporary cessation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6136/abstract/45\">",
"     45",
"    </a>",
"    ]. In two instances catheter replacement was necessary.",
"   </p>",
"   <p>",
"    Some may choose to \"lock\" the PD catheter during temporary cessation of PD in an attempt to avoid clotting of the PD catheter.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    can be used for this purpose in the same dosages used to lock hemodialysis catheters, as the heparin is not peritoneally absorbed. Others may elect not to lock the PD catheter as the risk of catheter occlusion during non-use is probably low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Exit site care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal care and cleaning of the exit site is unknown. There are few prospective, controlled trials comparing agents to clean PD catheter exit sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link&amp;anchor=H2#H2\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\", section on 'Prevention of catheter infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9894345\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main function of a peritoneal dialysis (PD) catheter is to permit consistent bidirectional flow of dialysate without extraordinary effort or undue discomfort. The catheter's function depends upon its design, implantation site, and the configuration of the system used to perform dialysis exchanges. Most catheters are flexible tubes with multiple ports in the distal (intraabdominal) segment which is ideally positioned freely in the intraabdominal pelvic area. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many types of catheters are available for chronic peritoneal dialysis. The catheter used by a PD program primarily depends upon the preferences and experience of the clinician inserting the catheters, with some guidelines stating that no particular catheter is definitively better. However, we prefer double cuff catheters over single cuff catheters since double cuff catheters have the advantages of fewer complications, a longer time to first peritonitis episode, and longer survival. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of catheters'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Summary and recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that PD catheters be placed in a paramedian or lateral abdominal location rather than in the midline. For certain patients, presternal catheters may be preferred. A downwardly-directed tunnel is preferred and prophylactic antibiotics should be given at the time of catheter placement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Exit site location'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Recommendation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with the choice of catheter, the technique used by a PD program depends upon the preferences and expertise of the surgeon or nephrologist inserting the catheter. Each method of insertion has its benefits and proponents, but no technique has been shown to be preferable overall. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Implantation technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/1\">",
"      Cruz, C. The peritoneal dialysis catheter. Semin Dial 1995; 8:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/2\">",
"      Lee HB, Park MS, Cha MK, et al. The peritoneal access. Perit Dial Int 1996; 16 Suppl 1:S322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/3\">",
"      Gokal R, Alexander S, Ash S, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. (Official report from the International Society for Peritoneal Dialysis). Perit Dial Int 1998; 18:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/4\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/5\">",
"      Piraino B. Which catheter is the best buy? Perit Dial Int 1995; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/6\">",
"      Eklund BH, Honkanen EO, Kala AR, Kyll&ouml;nen LE. Peritoneal dialysis access: prospective randomized comparison of the Swan neck and Tenckhoff catheters. Perit Dial Int 1995; 15:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/7\">",
"      Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: a systematic review of randomized, controlled trials. J Am Soc Nephrol 2004; 15:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/8\">",
"      Stegmayr BG, Wikdahl AM, Bergstr&ouml;m M, et al. A randomized clinical trial comparing the function of straight and coiled Tenckhoff catheters for peritoneal dialysis. Perit Dial Int 2005; 25:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/9\">",
"      Crabtree JH, Burchette RJ. Prospective comparison of downward and lateral peritoneal dialysis catheter tunnel-tract and exit-site directions. Perit Dial Int 2006; 26:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/10\">",
"      Johnson DW, Wong J, Wiggins KJ, et al. A randomized controlled trial of coiled versus straight swan-neck Tenckhoff catheters in peritoneal dialysis patients. Am J Kidney Dis 2006; 48:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/11\">",
"      Xie J, Kiryluk K, Ren H, et al. Coiled versus straight peritoneal dialysis catheters: a randomized controlled trial and meta-analysis. Am J Kidney Dis 2011; 58:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/12\">",
"      Cavagna R, Tessarin C, Tarroni G, et al. The self-locating catheter: clinical evaluation and comparison with the Tenckhoff catheter. Perit Dial Int 1999; 19:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/13\">",
"      Di Paolo N, Capotondo L, Sansoni E, et al. The self-locating catheter: clinical experience and follow-up. Perit Dial Int 2004; 24:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/14\">",
"      Crabtree JH, Burchette RJ, Siddiqi NA. Optimal peritoneal dialysis catheter type and exit site location: an anthropometric analysis. ASAIO J 2005; 51:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/15\">",
"      Crabtree, JH. Selected best demonstrated practices in peritoneal dialysis access. Kidney Int 2006; 70:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/16\">",
"      Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/17\">",
"      Flanigan M, Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments. Perit Dial Int 2005; 25:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/18\">",
"      Warady BA, Sullivan EK, Alexander SR. Lessons from the peritoneal dialysis patient database: a report of the North American Pediatric Renal Transplant Cooperative Study. Kidney Int Suppl 1996; 53:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/19\">",
"      Ash SR. Chronic peritoneal dialysis catheters: overview of design, placement, and removal procedures. Semin Dial 2003; 16:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/20\">",
"      Twardowski ZJ, Prowant BF, Pickett B, et al. Four-year experience with swan neck presternal peritoneal dialysis catheter. Am J Kidney Dis 1996; 27:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/21\">",
"      Warchol S, Roszkowska-Blaim M, Sieniawska M. Swan neck presternal peritoneal dialysis catheter: five-year experience in children. Perit Dial Int 1998; 18:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/22\">",
"      Twardowski ZJ, Prowant BF, Nichols WK, et al. Six-year experience with Swan neck presternal peritoneal dialysis catheter. Perit Dial Int 1998; 18:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/23\">",
"      Crabtree JH, Fishman A, Siddiqi RA, Hadnott LL. The risk of infection and peritoneal catheter loss from implant procedure exit-site trauma. Perit Dial Int 1999; 19:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/24\">",
"      Keane WF, Alexander SR, Bailie GR, et al. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 1996; 16:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/25\">",
"      Wikdahl AM, Engman U, Stegmayr BG, S&ouml;renssen JG. One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. Nephrol Dial Transplant 1997; 12:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/26\">",
"      Strippoli GF, Tong A, Johnson D, et al. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am J Kidney Dis 2004; 44:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/27\">",
"      Bennett-Jones, DN, Martin, J, Barratt, AJ, et al. Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. Adv Perit Dial 1988; 4:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/28\">",
"      Gadallah MF, Ramdeen G, Mignone J, et al. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. Am J Kidney Dis 2000; 36:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/29\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/30\">",
"      Keane WF, Bailie GR, Boeschoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/31\">",
"      Vas S. Changing picture of peritonitis in peritoneal dialysis. Am J Kidney Dis 2000; 36:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/32\">",
"      Berns JS, Tokars JI. Preventing bacterial infections and antimicrobial resistance in dialysis patients. Am J Kidney Dis 2002; 40:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/33\">",
"      Golper TA, Brier ME, Bunke M, et al. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Am J Kidney Dis 1996; 28:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/34\">",
"      Copley JB, Lindberg JS, Back SN, Tapia NP. Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Perit Dial Int 1996; 16 Suppl 1:S330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/35\">",
"      Moncrief JW, Popovich RP, Seare W, et al. Peritoneal dialysis access technology: the Austin Diagnostic Clinic experience. Perit Dial Int 1996; 16 Suppl 1:S327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/36\">",
"      Veys N, Biesen WV, Vanholder R, Lameire N. Peritoneal dialysis catheters: the beauty of simplicity or the glamour of technicality? Percutaneous vs surgical placement. Nephrol Dial Transplant 2002; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/37\">",
"      Crabtree JH, Fishman A. A laparoscopic method for optimal peritoneal dialysis access. Am Surg 2005; 71:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/38\">",
"      Moon JY, Song S, Jung KH, et al. Fluoroscopically guided peritoneal dialysis catheter placement: long-term results from a single center. Perit Dial Int 2008; 28:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/39\">",
"      Wright MJ, Bel'eed K, Johnson BF, et al. Randomized prospective comparison of laparoscopic and open peritoneal dialysis catheter insertion. Perit Dial Int 1999; 19:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/40\">",
"      Crabtree JH, Fishman A. A laparoscopic approach under local anesthesia for peritoneal dialysis access. Perit Dial Int 2000; 20:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/41\">",
"      Danielsson A, Blohm&eacute; L, Tranaeus A, Hylander B. A prospective randomized study of the effect of a subcutaneously \"buried\" peritoneal dialysis catheter technique versus standard technique on the incidence of peritonitis and exit-site infection. Perit Dial Int 2002; 22:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/42\">",
"      Wu CC, Su PF, Chiang SS. A prospective study to compare subcutaneously buried peritoneal dialysis catheter technique with conventional technique. Blood Purif 2007; 25:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/43\">",
"      Brown PA, McCormick BB, Knoll G, et al. Complications and catheter survival with prolonged embedding of peritoneal dialysis catheters. Nephrol Dial Transplant 2008; 23:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/44\">",
"      Wong LP, Liebman SE, Wakefield KA, Messing S. Training of surgeons in peritoneal dialysis catheter placement in the United States: a national survey. Clin J Am Soc Nephrol 2010; 5:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6136/abstract/45\">",
"      Ghaffari A. Urgent-start peritoneal dialysis: a quality improvement report. Am J Kidney Dis 2012; 59:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1885 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6136=[""].join("\n");
var outline_f5_63_6136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9894345\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF CATHETERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Summary and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONSIDERATIONS IN CATHETER PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Exit site location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exit site size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Summary and recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Implantation technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bedside catheter placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Peritoneoscopy/laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Postoperative catheter care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Exit site care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9894345\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1885|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/40/21121\" title=\"figure 1\">",
"      Types of PD catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/2/12335\" title=\"figure 2\">",
"      Presternal PD catheter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=related_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=related_link\">",
"      Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_63_6137="Assessment and management of auricle (ear) lacerations";
var content_f5_63_6137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment and management of auricle (ear) lacerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6137/contributors\">",
"     Kelly Michele Malloy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6137/contributors\">",
"     Judd E Hollander, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6137/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6137/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6137/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6137/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/63/6137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28089213\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This chapter will cover assessment and management of simple and complex auricle (ear) lacerations. Once serious head or middle ear injury is excluded, careful closure of ear lacerations after copious but gentle irrigation and minimal debridement should ensure coverage of any exposed cartilage to preserve cosmetic appearance.",
"   </p>",
"   <p>",
"    Minor wound management, methods of suture placement, repair of adjacent anatomic sites, and evaluation of middle ear trauma are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link\">",
"       \"Minor wound preparation and irrigation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link\">",
"       \"Closure of skin wounds with sutures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link\">",
"       \"Assessment and management of facial lacerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30872?source=see_link\">",
"       \"Assessment and management of scalp lacerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link\">",
"       \"Evaluation and management of middle ear trauma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089220\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external ear is composed of the auricle, or pinna, and the external auditory canal. Because of the protuberant nature of the ear, most traumatic lacerations involve the auricle; a laceration may, however, extend into the external auditory canal. The cartilaginous subunits of the auricle include: the helix, antihelix, concha, tragus, and antitragus (",
"    <a class=\"graphic graphic_figure graphicRef57847 \" href=\"UTD.htm?7/57/8081\">",
"     figure 1",
"    </a>",
"    ). These structures are composed of elastic cartilage that is continuous with the cartilaginous external auditory canal and is avascular. The cartilage receives its nutrients from the adherent perichondrium. The skin of the auricle is very thin and is densely attached to this underlying perichondrium. The earlobe is composed of fibrous adipose tissue and lacks cartilage. The function of the auricle is to amplify and direct sound to the external auditory canal, and ultimately to the tympanic membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cartilage exposure after auricular laceration can cause infection, erosive chondritis, and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/2\">",
"     2",
"    </a>",
"    ]. Loss of auricular cartilage (notching) or replacement of healthy cartilage with fibrocartilage (&ldquo;cauliflower ear&rdquo;) is disfiguring and not easily reversed. Thus, ensuring tissue coverage of exposed cartilage is of paramount importance during auricular laceration repair.",
"   </p>",
"   <p>",
"    In cases of auricular avulsion, knowledge of the blood supply is essential. The anterior blood supply comes from the superficial temporal artery (STA), while the posterior auricle is fed by the posterior auricular artery (PAA) (",
"    <a class=\"graphic graphic_figure graphicRef68609 \" href=\"UTD.htm?32/51/33587\">",
"     figure 2",
"    </a>",
"    ). There is a supplemental vascular supply from branches of the occipital artery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/1\">",
"     1",
"    </a>",
"    ]. The STA and PAA appear to communicate via the helical arcade that runs along the helix; this arcade is the basis for single pedicle reimplantation of a total avulsion of the auricle [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The auricle is innervated by the auriculotemporal nerve superiorly and medially, the greater auricular nerve and lesser occipital nerve laterally and inferiorly, and the vagus nerve (concha and external auditory meatus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089227\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, ear lacerations result from isolated trauma. However, as for all trauma patients, the initial clinical assessment should focus on rapid identification of potentially fatal conditions. For victims of major trauma, evaluation for airway compromise (while maintaining cervical spine immobilization), impaired breathing, hemorrhagic shock, and altered level of consciousness should be performed immediately upon the patient&rsquo;s arrival at the emergency department. Systematic evaluation helps ensure detection of potentially life-threatening injuries.",
"   </p>",
"   <p>",
"    The approach to the injured child or adult is discussed in detail separately (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Auricular lacerations should be assessed during a careful and organized secondary survey. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H27#H27\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Secondary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089235\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should identify the following aspects of the injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traumatic force (eg, a physical assault with significant likelihood of associated injuries versus an isolated injury with no other symptoms)",
"     </li>",
"     <li>",
"      Associated symptoms of middle and inner ear injury (eg, tinnitus, hearing loss, vertigo, vomiting, otorrhea) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation and management of middle ear trauma\", section on 'History'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Associated symptoms of head injury (eg, altered mental status, vomiting, headache) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=see_link&amp;anchor=H18#H18\">",
"       \"Minor head trauma in infants and children\", section on 'History'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Age of wound (duration of time since the injury occurred)",
"     </li>",
"     <li>",
"      Likelihood of wound contamination (eg, clean laceration from table edge with low risk of contamination versus human bite wound with high risk of bacterial contamination and need for special prophylaxis) (see",
"      <a class=\"local\" href=\"#H3628648\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H3628655\">",
"       'Bite wounds'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Potential presence of foreign body (eg, fall onto glass or gravel)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history should also include a comprehensive review of underlying medical history (eg, diabetes mellitus in adults, cancer, prior keloid formation), medication use (eg, immunosuppressive agents), and social habits (eg, tobacco use) that may negatively affect healing and increase the risk for a poor outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H8#H8\">",
"     \"Minor wound preparation and irrigation\", section on 'Risks for poor outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the clinician should inquire about allergies to any medications, especially local anesthetics, and the patient&rsquo;s tetanus immunization status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=see_link&amp;anchor=H19#H19\">",
"     \"Allergic reactions to local anesthetics\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H22537779#H22537779\">",
"     \"Assessment and management of facial lacerations\", section on 'Tetanus prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089250\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltration of local anesthetics facilitates a comprehensive evaluation of the wound with minimal discomfort to the patient. In young children and other uncooperative patients, sedation may be necessary to perform optimal wound assessment and repair. (See",
"    <a class=\"local\" href=\"#H28089301\">",
"     'Anesthesia and analgesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Wound assessment should identify the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location of the injury (eg, helix, antihelix, tragus, antitragus, concha, or earlobe (",
"      <a class=\"graphic graphic_figure graphicRef57847 \" href=\"UTD.htm?7/57/8081\">",
"       figure 1",
"      </a>",
"      ))",
"     </li>",
"     <li>",
"      Depth of the injury (eg, superficial, through the perichondrium, or completely through the ear [&ldquo;through and through&rdquo;])",
"     </li>",
"     <li>",
"      Degree of cartilage involvement",
"     </li>",
"     <li>",
"      Extension of the laceration into the auditory canal",
"     </li>",
"     <li>",
"      Presence of tissue avulsion",
"     </li>",
"     <li>",
"      Auricular hematoma (collection of blood between the perichondrium and the cartilage) (see",
"      <a class=\"local\" href=\"#H5326055\">",
"       'Auricular hematoma'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should also evaluate for the following associated injuries:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Middle ear trauma",
"      </strong>",
"      &ndash; Middle ear trauma should be suspected in patients with the following findings (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation and management of middle ear trauma\", section on 'Findings of middle ear injury'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemotympanum (",
"      <a class=\"graphic graphic_picture graphicRef62387 \" href=\"UTD.htm?31/17/32031\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amber or clear middle ear effusion",
"     </li>",
"     <li>",
"      Otorrhea (clear or bloody ear canal drainage)",
"     </li>",
"     <li>",
"      Hearing deficit by Weber and Rinne tuning fork tests (",
"      <a class=\"graphic graphic_table graphicRef74212 \" href=\"UTD.htm?13/29/13787\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef58032 \" href=\"UTD.htm?40/5/41043\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nystagmus",
"     </li>",
"     <li>",
"      Ataxia",
"     </li>",
"     <li>",
"      Retroauricular hematoma (Battle sign) (",
"      <a class=\"graphic graphic_picture graphicRef69660 \" href=\"UTD.htm?39/39/40561\">",
"       picture 2",
"      </a>",
"      ). Battle sign typically appears two days after injury, but may appear within 6 to 12 hours",
"     </li>",
"     <li>",
"      Facial nerve (cranial nerve VII) dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Basilar skull fracture",
"      </strong>",
"      &ndash; Hemotympanum, Battle sign, otorrhea, and facial nerve deficits are also findings of a basilar skull fracture. Affected patients may also have deficits of cranial nerves VI (abducens), and VIII (vestibulocochlear). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H12#H12\">",
"       \"Skull fractures in children\", section on 'Basilar skull fracture'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=see_link&amp;anchor=H10#H10\">",
"       \"Skull fractures in adults\", section on 'Basilar skull fracture'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Facial nerve or parotid gland injury",
"      </strong>",
"      &ndash; Lacerations that extend anterior to the ear may disrupt the facial nerve and parotid gland. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=see_link&amp;anchor=H15489009#H15489009\">",
"       \"Assessment and management of facial lacerations\", section on 'Cheek'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19950078\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical features suggestive of middle ear trauma or basilar skull fracture warrant the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of any ear or nose drainage for the presence of cerebrospinal fluid (CSF) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H13#H13\">",
"       \"Evaluation and management of middle ear trauma\", section on 'Evaluation of ear or nose drainage'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tests of hearing (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and management of middle ear trauma\", section on 'Tests of hearing'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Temporal bone computed tomography without contrast including fine axial and coronal cuts, for patients with head trauma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who may require operative intervention,",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1222218\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SUBSPECIALTY CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a surgical subspecialist (eg, plastic or maxillofacial surgeon, otolaryngologist, or, in patients with signs of basilar skull fracture, neurosurgeon), if available, is suggested in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Auricular avulsion",
"     </li>",
"     <li>",
"      Auricular lacerations that extend into the external auditory canal, with risk of cicatrix formation and canal stenosis",
"     </li>",
"     <li>",
"      Auricular laceration with evidence of serious middle or inner ear injury such as hearing loss or vestibular symptoms (eg, nausea, vomiting, nystagmus, ataxia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link&amp;anchor=H16#H16\">",
"       \"Evaluation and management of middle ear trauma\", section on 'Indications for otolaryngology consultation or referral'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Auricular laceration with evidence of basilar skull fracture (eg, hemotympanum, cerebrospinal fluid otorrhea, Battle sign, facial nerve weakness (",
"      <a class=\"graphic graphic_picture graphicRef69660 \" href=\"UTD.htm?39/39/40561\">",
"       picture 2",
"      </a>",
"      )) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=see_link&amp;anchor=H12#H12\">",
"       \"Skull fractures in children\", section on 'Basilar skull fracture'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronically split earlobe or cleft caused by wearing heavy earrings or allergy to the ear ring metal [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Through and through lacerations of the auricle may also be an indication for subspecialty consultation, depending upon the capability of the clinician. (See",
"    <a class=\"local\" href=\"#H3628394\">",
"     'Complex lacerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089264\">",
"    <span class=\"h1\">",
"     WOUND REPAIR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089272\">",
"    <span class=\"h2\">",
"     Indications for primary closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary closure (ie, wound repair at the time of presentation) is the preferred treatment for auricular lacerations, especially if the ear cartilage is exposed or the wound extends through the ear. Failure to cover exposed cartilage increases the risk of infection, erosive chondritis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis which may lead to cartilage loss or significant cosmetic disfigurement (&ldquo;cauliflower ear&rdquo;). (See",
"    <a class=\"local\" href=\"#H28089329\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Delayed primary closure (ie, cleansing and debridement at the time of initial presentation with definitive wound closure performed electively four to five days later) may be appropriate for wounds of the earlobe that present after 24 hours and have increased risk for infection. In general, the decision should be based upon the time from injury, patient factors that increase the risk of infection (eg, vascular insufficiency, diabetes mellitus), and wound factors (bite wound, other contamination, or foreign body potential). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089279\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds with obvious signs of inflammation (redness, warmth, swelling, pus drainage) should not be closed primarily. Auricular laceration closure should also",
"    <strong>",
"     not",
"    </strong>",
"    delay further evaluation and definitive care of more urgent traumatic injuries, including underlying middle ear or intracranial injuries.",
"   </p>",
"   <p>",
"    When closure is delayed, saline-soaked gauze packing (wet-dry dressing) can be provided to enhance secondary healing. Although not required based upon evidence, when prescribing antibiotics, coverage (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or, in penicillin allergic patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ) should be aimed at the flora of the skin and possibly upper respiratory tract and can be initiated in selected patients with wounds other than bite wounds (eg, adult patient with diabetes mellitus, or other risks for poor wound outcome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications and empiric oral antibiotic regiments for patients with animal bites (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"UTD.htm?37/4/37964\">",
"     table 2",
"    </a>",
"    ) and human bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"UTD.htm?6/17/6429\">",
"     table 3",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of animal and human bites\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089286\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation for the care of auricle lacerations includes a discussion of the likely outcomes of repair, the choice of repair, assembly of the appropriate equipment, provision of anesthesia and analgesia,",
"    <strong>",
"    </strong>",
"    and wound debridement and cleansing.",
"   </p>",
"   <p>",
"    General consent forms for treatment are commonly part of the registration process for all patients arriving into the emergency department (ED) and a separate written consent for wound repair in the emergency department is not usually obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    caregiver must be aware of the general risks of laceration repair which include infection, pain and scarring. With respect to scarring, the potential for poor cosmetic outcome after auricular laceration repair and need for further surgery should be explained to patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089301\">",
"    <span class=\"h3\">",
"     Anesthesia and analgesia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3624313\">",
"    <span class=\"h4\">",
"     Local anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local anesthetic infiltration using buffered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    <strong>",
"     without",
"    </strong>",
"    epinephrine or similar agent (",
"    <a class=\"graphic graphic_table graphicRef56799 \" href=\"UTD.htm?25/56/26509\">",
"     table 4",
"    </a>",
"    ) provides adequate analgesia for most simple auricular laceration repairs in adults and cooperative children. The discomfort of infiltration may be further decreased by the use of nonpharmacologic interventions such as biobehavioral and cognitive distraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link&amp;anchor=H2694394#H2694394\">",
"     \"Infiltration of local anesthetics\", section on 'Procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"     \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local anesthetics that contain epinephrine should be",
"    <strong>",
"     avoided",
"    </strong>",
"    to prevent vasoconstriction and disruption of the tenuous vascular supply to the ear cartilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3624359\">",
"    <span class=\"h4\">",
"     Regional auricular block",
"    </span>",
"    &nbsp;&mdash;&nbsp;This field nerve block provides anesthesia to the auricle, with the exception of the concha and meatus, which are innervated by branches of the vagus nerve (",
"    <a class=\"graphic graphic_figure graphicRef57847 \" href=\"UTD.htm?7/57/8081\">",
"     figure 1",
"    </a>",
"    ). A regional auricular block is indicated for repair of extensive auricular lacerations or to avoid local tissue distortion when cosmetic alignment is important. It is performed as follows (",
"    <a class=\"graphic graphic_figure graphicRef77328 \" href=\"UTD.htm?33/36/34373\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cleanse the ear and the surrounding skin with an antiseptic solution (eg, povidone-iodine solution).",
"     </li>",
"     <li>",
"      Inject buffered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      1 percent",
"      <strong>",
"       without",
"      </strong>",
"      epinephrine using a long (1.5 inch), small gauge (25 or 27 gauge) needle. The total dose of lidocaine administered should",
"      <strong>",
"       not exceed",
"      </strong>",
"      4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (0.4",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      of lidocaine 1 percent.",
"     </li>",
"     <li>",
"      Enter the skin at a point just below the ear and advance the needle posteriorly along the back of the ear.",
"     </li>",
"     <li>",
"      Inject up to 5 mL of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (depending upon patient weight) as the needle is withdrawn.",
"     </li>",
"     <li>",
"      Without removing the needle from the skin, redirect it anterior to the ear and inject up to 5 mL of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      again (depending upon patient weight). The tracks should form an upright &ldquo;V&rdquo;.",
"     </li>",
"     <li>",
"      Enter the skin at a point just above the ear and advance the needle posteriorly along the back of the ear",
"     </li>",
"     <li>",
"      Inject up to 5 mL of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (depending upon patient weight) as the needle is withdrawn",
"     </li>",
"     <li>",
"      Without removing the needle from the skin, redirect it anterior to the ear and inject up to 5 mL (depending upon the patient&rsquo;s weight) of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      again. These tracks should form an inverted &ldquo;V&rdquo;.",
"     </li>",
"     <li>",
"      Wait approximately 10 minutes after completion of the injections in order to achieve maximum anesthesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3624306\">",
"    <span class=\"h4\">",
"     Procedural sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Procedural sedation in children and adults is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Procedural sedation is likely to maximize patient comfort and cosmetic outcomes in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple complex auricular lacerations",
"     </li>",
"     <li>",
"      Auricular lacerations in young children",
"     </li>",
"     <li>",
"      Heavily contaminated ear lacerations that require aggressive cleaning",
"     </li>",
"     <li>",
"      Highly anxious or otherwise uncooperative patients, especially when the safety of the clinician or staff may be compromised",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089308\">",
"    <span class=\"h3\">",
"     Wound preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once anesthetized, auricular lacerations should undergo copious irrigation with 100 to 200 mL of sterile normal saline. During irrigation, the clinician should avoid excessive irrigation pressure that might strip the perichondrium from the cartilage. Wound irrigation is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H17#H17\">",
"     \"Minor wound preparation and irrigation\", section on 'Irrigation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Debridement of skin should be avoided or kept to a minimum to ensure that any exposed cartilage can be covered. Cartilage should",
"    <strong>",
"     not",
"    </strong>",
"    be d&eacute;brided so as to avoid notching of the auricular contours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089315\">",
"    <span class=\"h3\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment should be assembled for auricular laceration repair: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sterile gloves",
"     </li>",
"     <li>",
"      Surgical mask",
"     </li>",
"     <li>",
"      Eye protection",
"     </li>",
"     <li>",
"      Buffered 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or similar local anesthetic (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"UTD.htm?25/56/26509\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Moderate volume syringe (eg, 6 or 12 mL)",
"     </li>",
"     <li>",
"      Small gauge needle (eg, 27 or 30 gauge, 1.5 inch if performing an auricular block) for infiltration of local anesthetic",
"     </li>",
"     <li>",
"      Suture material:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For skin, 5-0 or 6.0 nonabsorbable sutures (eg, nylon [Ethilon&reg;], polybutester [Novafil&reg;], polypropylene [Prolene&reg;] (",
"      <a class=\"graphic graphic_table graphicRef63622 \" href=\"UTD.htm?36/14/37099\">",
"       table 5",
"      </a>",
"      )). In children 6.0 absorbable sutures (eg, fast-absorbing gut) avoids the trauma of suture removal and may be preferable.",
"     </li>",
"     <li>",
"      For perichondrium, undyed 5.0 absorbable sutures (eg, poliglecaprone 25 [Monocryl&reg;], polyglactin [Vicryl&reg;], polyglycolic acid [Dexon&reg;] (",
"      <a class=\"graphic graphic_table graphicRef51741 \" href=\"UTD.htm?32/22/33132\">",
"       table 6",
"      </a>",
"      )).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Needle holder",
"     </li>",
"     <li>",
"      Hemostat",
"     </li>",
"     <li>",
"      Scalpel with handle (#15 blade) if debridement or revision are planned",
"     </li>",
"     <li>",
"      Tissue forceps",
"     </li>",
"     <li>",
"      Scissors",
"     </li>",
"     <li>",
"      Surgical probe",
"     </li>",
"     <li>",
"      Sterile 4 x 4 gauze",
"     </li>",
"     <li>",
"      Absorbent towels",
"     </li>",
"     <li>",
"      Sterile field drapes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency departments generally are well equipped with minor surgical or suture trays that contain the instruments, sterile gauze, towels, and drapes listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3627497\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auricular lacerations can be described as simple, complex, or avulsion injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/9\">",
"     9",
"    </a>",
"    ]. The type of injury largely determines the surgical approach. The clinician should also be alert for signs of an auricular hematoma, which must be drained to prevent pressure necrosis of the ear cartilage. (See",
"    <a class=\"local\" href=\"#H5326055\">",
"     'Auricular hematoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Regardless of the nature of the injury, the patient&rsquo;s contralateral ear serves as an excellent model when normal landmarks are obscured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628344\">",
"    <span class=\"h3\">",
"     Simple lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple lacerations that spare cartilage most commonly involve the earlobe but may also involve other parts of the auricle. These wounds can be closed with simple interrupted sutures using 6.0 nonabsorbable sutures (",
"    <a class=\"graphic graphic_table graphicRef63622 \" href=\"UTD.htm?36/14/37099\">",
"     table 5",
"    </a>",
"    ) or, in young children and patients without assure follow-up, 6.0 absorbable suture, such as fast-absorbing gut. When nonabsorbable suture is used, some experts prefer monofilament polybutester (Novafil&reg;) because of its greater elasticity and decreased potential for suture marks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"     \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H14#H14\">",
"     \"Closure of skin wounds with sutures\", section on 'Nonabsorbable sutures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5325511\">",
"    <span class=\"h3\">",
"     Split earlobe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Split earlobes are most commonly caused by pulling through of earrings or allergy to earring metal alloys. Acute wounds require subcutaneous placement of 4.0 or 5.0 absorbable suture (eg, poliglecaprone 25 [Monocryl&reg;] or polyglycolic acid [Dexon&reg;] (",
"    <a class=\"graphic graphic_table graphicRef51741 \" href=\"UTD.htm?32/22/33132\">",
"     table 6",
"    </a>",
"    )) and skin closure of the front and the back of the earlobe with 6.0 nonabsorbable sutures (eg, polybutester [Novafil&reg;]) or, in young children and patients without assured follow-up, 6.0 absorbable sutures (fast-absorbing gut). Careful approximation is important.",
"   </p>",
"   <p>",
"    Clinicians with less experience managing these injuries may wish to refer them to an appropriate surgical specialist, when available, because primary closure of these earlobe lacerations can be complicated by notching and recurrence of the cleft. Thus, multiple cosmetic techniques based upon the classic Z-plasty have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/10\">",
"     10",
"    </a>",
"    ]. Some surgeons will close the laceration around an angiocatheter or other stenting device to preserve a piercing for future earring use; a less complicated approach closes the entire laceration and allows for re-piercing as early as six weeks following repair [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the split earlobe is chronic and epithelialized, the wound management is complicated by the need to excise skin margins of the cleft and to provide repair that avoids loss of earlobe tissue strength [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/11\">",
"     11",
"    </a>",
"    ]. Various techniques, including straight repair, Z-plasty, flap method, or concha cartilage graft have been proposed and are best performed by an appropriate surgical specialist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628394\">",
"    <span class=\"h3\">",
"     Complex lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auricular lacerations that expose or extend through the cartilage require careful closure. The perichondrium must be reapproximated and the cartilage covered with skin in order to prevent notching or a step-deformity. Because the overlying skin is so thin and is so densely adherent to the underlying perichondrium, stitches that incorporate both layers are appropriate; burying perichondrial sutures under such thin auricular skin is technically challenging and can produce unwanted subcutaneous nodularity. Furthermore, any absorbable suture utilized, particularly for buried sutures, should be undyed in order to avoid tattooing. As with simple ear lacerations, nonabsorbable monofilament 6.0 suture (eg, polybutester [Novafil&reg;]) (",
"    <a class=\"graphic graphic_table graphicRef63622 \" href=\"UTD.htm?36/14/37099\">",
"     table 5",
"    </a>",
"    ) should be used and is appropriate if the patient can follow-up for removal in 7 to 10 days. In young children and those patients with uncertain follow-up, 6.0 fast-absorbing gut may be used. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628440\">",
"    <span class=\"h3\">",
"     Avulsion injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avulsion injuries of the ear usually warrant subspecialty consultation for definitive repair. Avulsion injuries are designated as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/9\">",
"     9",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Partial avulsion with a wide pedicle",
"      </strong>",
"      &ndash; As long as capillary refill distal to the avulsion is adequate, these wounds respond well to primary closure as for complex lacerations described above. (See",
"      <a class=\"local\" href=\"#H3628394\">",
"       'Complex lacerations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Wounds that extend into the auditory canal require meticulous approximation and, in some instances, grafting to achieve adequate closure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/9\">",
"       9",
"      </a>",
"      ]. Placement of an ear wick can help prevent the formation of canal stenosis or cicatrix. Repair by a surgical subspecialist, if available, is advised.",
"     </li>",
"     <li>",
"      <strong>",
"       Partial avulsion with a narrow pedicle",
"      </strong>",
"      &ndash; These wounds can have marginal blood supply to the avulsed segment. Surgical methods to preserve the segment such as local advancement flaps may be necessary and are best performed by an experienced surgical subspecialist [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Complete avulsion",
"      </strong>",
"      &ndash; Management of complete avulsion of the auricle depends upon the availability and integrity of the avulsed segment:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the avulsed segment is absent, local wound care should be provided and subspecialty consultation obtained. The missing auricle can be reconstructed in an immediate or delayed fashion, depending upon the judgment of the subspecialty consultant. Exposed cartilage may be best treated with local advancement flaps to preserve remaining structure where possible.",
"     </li>",
"     <li>",
"      Any completely avulsed segment that is available should be wrapped in gauze and placed in a sterile plastic bag, then submerged in a 4",
"      <sup>",
"       &deg;",
"      </sup>",
"      C ice bath until subspecialty consultation is available [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/9\">",
"       9",
"      </a>",
"      ]. Repair ideally occurs immediately (ie, within four hours of the injury); however, reimplantation has been reported to be successful up to 33 hours after the avulsion [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/13\">",
"       13",
"      </a>",
"      ]. Ultimately, the decision to reimplant depends upon whether vessels suitable for microvascular anastomosis are present in the avulsed segment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/9,12,14\">",
"       9,12,14",
"      </a>",
"      ]. Clinicians should exercise caution regarding the use of pressure dressings to the ear. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628633\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628641\">",
"    <span class=\"h2\">",
"     Tetanus prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus prophylaxis should be provided for all wounds as indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 7",
"    </a>",
"    ). Pregnant women should receive immunization based upon their immunization history, as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628648\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ear wounds do",
"    <strong>",
"     not",
"    </strong>",
"    warrant empiric antibiotic treatment. Prophylactic antibiotics may decrease the risk of wound infection in patients with animal or human bites, excessive wound contamination, vascular insufficiency (eg, peripheral artery disease), or immunodeficiency.",
"   </p>",
"   <p>",
"    Recommendations for the use of prophylactic antibiotics after the closure of skin wounds other than bite wounds are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=see_link&amp;anchor=H38#H38\">",
"     \"Closure of skin wounds with sutures\", section on 'Prophylactic antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for antibiotics and empiric oral antibiotic regimens for patients with animal bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"UTD.htm?6/17/6429\">",
"     table 3",
"    </a>",
"    ) and human bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"UTD.htm?6/17/6429\">",
"     table 3",
"    </a>",
"    ) are discussed separately. When the ear cartilage is exposed, some authors recommend 24 to 28 hours of intravenous antibiotics and delayed primary closure of the bite wound [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of animal and human bites\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628655\">",
"    <span class=\"h2\">",
"     Bite wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bites, scratches, abrasions, or contact with animal saliva via mucous membranes or a break in the skin can all transmit rabies. Early wound cleansing is an important prophylactic measure, in addition to timely administration of rabies immune globulin and vaccine (",
"    <a class=\"graphic graphic_table graphicRef70600 \" href=\"UTD.htm?27/43/28347\">",
"     table 8",
"    </a>",
"    ). Indications for rabies prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link&amp;anchor=H19#H19\">",
"     \"Rabies immune globulin and vaccine\", section on 'Dosing schedules and routes of administration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link&amp;anchor=H8#H8\">",
"     \"When to use rabies prophylaxis\", section on 'Types of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any unvaccinated patient or individual negative for anti-HBs antibodies who is bitten by an individual positive for HBsAg should receive both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59736 \" href=\"UTD.htm?20/39/21116\">",
"     table 9",
"    </a>",
"    ). In addition, although the risk for transmitting HIV through saliva is extremely low, infection is of concern if there is blood in the saliva. Counseling regarding post-exposure HIV prophylaxis is appropriate in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial management of animal and human bites\", section on 'Viral prophylaxis after human bites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089322\">",
"    <span class=\"h1\">",
"     AFTERCARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care for ear lacerations closed with nonabsorbable sutures includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily gentle cleansing of the incision followed by topical application of triple antibiotic ointment (eg, Polysporin&reg;) to the wound.",
"     </li>",
"     <li>",
"      Although ear pressure dressings are used by some clinicians to reduce the risk for the development (or recurrence) of an auricular hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/8,16\">",
"       8,16",
"      </a>",
"      ], the authors typically avoid such bandages after simple auricular laceration repair because auricular hematomas are uncommon with such wounds and wound compression may cause vascular compromise and poor healing.",
"     </li>",
"     <li>",
"      Patients should be reevaluated in 24 to 48 hours to assess for signs of infection or auricular hematoma. (See",
"      <a class=\"local\" href=\"#H5325954\">",
"       'Perichondritis or chondritis'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H5326055\">",
"       'Auricular hematoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Nonabsorbable sutures should be removed in 7 to 10 days. The wound should not be submerged in water until the skin edges have completely healed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089329\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications after auricular repair include notching of the auricle, auricular hematoma with the formation of a &ldquo;cauliflower ear&rdquo;, scarring, perichondritis, and chondritis. Patients with split earlobes may experience recurrence of earlobe notching or splitting, especially if they continue to wear heavy earrings. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5326048\">",
"    <span class=\"h2\">",
"     Auricular notching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Notching of the auricle is due to loss of auricular cartilage and may occur even after an optimal repair. Potential causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor skin or cartilage alignment during wound repair.",
"     </li>",
"     <li>",
"      Cartilage damage during wound debridement or repair.",
"     </li>",
"     <li>",
"      Vascular insufficiency after auricular avulsion repair. Necrosis and failure of the reconstruction may occur despite best efforts by the surgical subspecialist.",
"     </li>",
"     <li>",
"      Local wound infection with perichondritis or chondritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5326055\">",
"    <span class=\"h2\">",
"     Auricular hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most commonly occurring after blunt trauma during sports (eg, amateur wrestling, rugby, boxing), auricular hematomas may occur after wound closure. This complication warrants prompt drainage and application of a pressure dressing to prevent reaccumulation of blood. Fibrocartilage overgrowth, or &ldquo;cauliflower ear&rdquo; can occur if drainage is incomplete or if the hematoma recurs. The assessment and management of auricular hematoma and cauliflower ear are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/25/29079?source=see_link\">",
"     \"Assessment and management of auricular hematoma and cauliflower ear\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5325954\">",
"    <span class=\"h2\">",
"     Perichondritis or chondritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perichondritis arises from infection of the perichondrium. Chondritis is inflammation and infection of the cartilage itself. These infections can result in drastic deformity of the ear (",
"    <a class=\"graphic graphic_picture graphicRef82036 \" href=\"UTD.htm?28/40/29314\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/17\">",
"     17",
"    </a>",
"    ]. Signs of perichondritis or chondritis include pain, swelling and erythema of the overlying skin. Fluctuant swelling indicates an abscess that must be drained;",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    is the pathogen in up to 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6137/abstract/18\">",
"     18",
"    </a>",
"    ]. Antibiotic options include oral fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ) in adolescents and adults and parenteral antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ) in children. Even with timely and proper antibiotic treatment, these infections may result in cartilage necrosis and cosmetic disfigurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=see_link\">",
"       \"Patient information: Stitches (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28089344\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The external ear is composed of the auricle, or pinna, and the external auditory canal. Because of the protuberant nature of the ear, most traumatic lacerations involve the auricle. The cartilaginous subunits of the auricle include: the helix, antihelix, concha, tragus, and antitragus (",
"      <a class=\"graphic graphic_figure graphicRef57847 \" href=\"UTD.htm?7/57/8081\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28089220\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with auricular (ear) lacerations require careful evaluation to determine the location and depth of the injury, degree of cartilage involvement, extension of the laceration into the auditory canal, and the presence of tissue avulsion. In addition, patients with major trauma should be assessed for signs of associated middle ear injury and basilar skull fracture. (See",
"      <a class=\"local\" href=\"#H28089227\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with auricular avulsions, external ear lacerations that extend into the external auditory canal, chronically split earlobes or clefts, or have associated middle ear trauma or basilar skull fractures warrant consultation with an appropriate surgical subspecialist. Through and through lacerations of the auricle may also be an indication for subspecialty consultation, depending upon the capability of the clinician. (See",
"      <a class=\"local\" href=\"#H1222218\">",
"       'Indications for subspecialty consultation or referral'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Primary closure (ie, wound repair at the time of presentation) is the preferred treatment for auricular lacerations, especially if the ear cartilage is exposed or the wound extends through the ear. Failure to cover exposed cartilage increases the risk of infection, erosive chondritis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      necrosis with resulting cartilage loss or significant cosmetic disfigurement (&ldquo;cauliflower ear&rdquo;). Wounds with obvious signs of inflammation (redness, warmth, swelling, pus drainage) should not be closed primarily. Auricular laceration closure should also",
"      <strong>",
"       not",
"      </strong>",
"      delay further evaluation and definitive care of more urgent traumatic injuries, including underlying middle ear or intracranial injuries. (See",
"      <a class=\"local\" href=\"#H28089272\">",
"       'Indications for primary closure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28089279\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infiltration of local anesthesia (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      1 percent",
"      <strong>",
"       without",
"      </strong>",
"      epinephrine) or a regional auricular nerve block (",
"      <a class=\"graphic graphic_figure graphicRef77328 \" href=\"UTD.htm?33/36/34373\">",
"       figure 5",
"      </a>",
"      ) typically provides adequate analgesia for closure of auricular lacerations. (See",
"      <a class=\"local\" href=\"#H28089301\">",
"       'Anesthesia and analgesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once anesthetized, auricular lacerations should undergo copious irrigation with 100 to 200 mL of sterile normal saline. During irrigation, the clinician should avoid excessive irrigation pressure that might strip the perichondrium from the cartilage. Debridement of skin should be avoided or kept to a minimum to ensure that any exposed cartilage can be covered. Cartilage should",
"      <strong>",
"       not",
"      </strong>",
"      be d&eacute;brided so as to avoid notching of the auricular contours. (See",
"      <a class=\"local\" href=\"#H28089308\">",
"       'Wound preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The suggested equipment and techniques for closure of auricular lacerations are provided. (See",
"      <a class=\"local\" href=\"#H28089315\">",
"       'Equipment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3627497\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients should receive tetanus prophylaxis, as needed. Most ear wounds do",
"      <strong>",
"       not",
"      </strong>",
"      warrant empiric antibiotic treatment. Prophylactic antibiotics may decrease the risk of wound infection in patients with animal or human bites, excessive wound contamination, vascular insufficiency (eg, peripheral artery disease), or immunodeficiency. (See",
"      <a class=\"local\" href=\"#H3628633\">",
"       'Other considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repaired auricular lacerations warrant close follow-up in 24 hours to assess for signs of infection or auricular hematoma. Nonabsorbable sutures should be removed 7 to 10 days after repair. (See",
"      <a class=\"local\" href=\"#H28089322\">",
"       'Aftercare'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Auricular hematomas, perichondritis, and chondritis are potential complications of auricular lacerations that warrant prompt recognition and treatment during follow-up. (See",
"      <a class=\"local\" href=\"#H5326055\">",
"       'Auricular hematoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5325954\">",
"       'Perichondritis or chondritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Janfaza P, et al. Surgical Anatomy of the Head and Neck, Lippincott Williams &amp; Wilkins, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/2\">",
"      Brown DJ, Jaffe JE, Henson JK. Advanced laceration management. Emerg Med Clin North Am 2007; 25:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/3\">",
"      Erdmann D, Bruno AD, Follmar KE, et al. The helical arcade: anatomic basis for survival in near-total ear avulsion. J Craniofac Surg 2009; 20:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/4\">",
"      Raveendran SS, Amarasinghe L. The mystery of the split earlobe. Plast Reconstr Surg 2004; 114:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/5\">",
"      Moskop JC. Informed consent in the emergency department. Emerg Med Clin North Am 1999; 17:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/6\">",
"      Code of ethics for emergency physicians. American College of Emergency Physicians. Ann Emerg Med 1997; 30:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/7\">",
"      Tsai AK, Schafermeyer RW, Kalifon D, et al. Evaluation and treatment of minors: reference on consent. Ann Emerg Med 1993; 22:1211.",
"     </a>",
"    </li>",
"    <li>",
"     Martinez NJ, friedman MJ. External ear procedures. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, PA 2008. p.593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/9\">",
"      Lavasani L, Leventhal D, Constantinides M, Krein H. Management of acute soft tissue injury to the auricle. Facial Plast Surg 2010; 26:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/10\">",
"      Xu JH, Shen H, Hong XY. The aesthetic repair of complete traumatic cleft earlobe with a three-flap method. Ann Plast Surg 2010; 65:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/11\">",
"      Agarwal R, Chandra R. A new technique for repair of acquired split-ear-lobe deformity: the free conchal cartilage sandwich graft. J Plast Reconstr Aesthet Surg 2010; 63:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/12\">",
"      Steffen A, Katzbach R, Klaiber S. A comparison of ear reattachment methods: a review of 25 years since Pennington. Plast Reconstr Surg 2006; 118:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/13\">",
"      Shelley OP, Villafane O, Watson SB. Successful partial ear replantation after prolonged ischaemia time. Br J Plast Surg 2000; 53:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/14\">",
"      Kind GM. Microvascular ear replantation. Clin Plast Surg 2002; 29:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/15\">",
"      Stierman KL, Lloyd KM, De Luca-Pytell DM, et al. Treatment and outcome of human bites in the head and neck. Otolaryngol Head Neck Surg 2003; 128:795.",
"     </a>",
"    </li>",
"    <li>",
"     Lammers R. Methods of wound closure. In: Clinical Procedures in Emergency Medicine, 5th edition, Roberts JR, Hedges JR.  (Eds), Saunders Elsevier, Philadelphia, PA 2010. p.592.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/17\">",
"      Stewart GM, Thorp A, Brown L. Perichondritis--a complication of high ear piercing. Pediatr Emerg Care 2006; 22:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6137/abstract/18\">",
"      Fisher CG, Kacica MA, Bennett NM. Risk factors for cartilage infections of the ear. Am J Prev Med 2005; 29:204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13874 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6137=[""].join("\n");
var outline_f5_63_6137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28089344\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28089213\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28089220\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28089227\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28089235\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28089250\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19950078\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1222218\">",
"      INDICATIONS FOR SUBSPECIALTY CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28089264\">",
"      WOUND REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28089272\">",
"      Indications for primary closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28089279\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28089286\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28089301\">",
"      - Anesthesia and analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3624313\">",
"      Local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3624359\">",
"      Regional auricular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3624306\">",
"      Procedural sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28089308\">",
"      - Wound preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28089315\">",
"      - Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3627497\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3628344\">",
"      - Simple lacerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5325511\">",
"      - Split earlobe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3628394\">",
"      - Complex lacerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3628440\">",
"      - Avulsion injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3628633\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3628641\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3628648\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3628655\">",
"      Bite wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28089322\">",
"      AFTERCARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28089329\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5326048\">",
"      Auricular notching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5326055\">",
"      Auricular hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5325954\">",
"      Perichondritis or chondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28089344\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13874\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13874|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/57/8081\" title=\"figure 1\">",
"      Auricle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/51/33587\" title=\"figure 2\">",
"      Auricular blood supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 3\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/5/41043\" title=\"figure 4\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/36/34373\" title=\"figure 5\">",
"      Regional auricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13874|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/17/32031\" title=\"picture 1\">",
"      Traumatic hemotympanum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/39/40561\" title=\"picture 2\">",
"      Battles sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/40/29314\" title=\"picture 3\">",
"      Auricular perichondritis with abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13874|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/29/13787\" title=\"table 1\">",
"      Interpreting Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/4/37964\" title=\"table 2\">",
"      Empiric oral antibiotics animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/17/6429\" title=\"table 3\">",
"      Oral antibiotics human bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/56/26509\" title=\"table 4\">",
"      Comparison of commonly infiltrated local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/14/37099\" title=\"table 5\">",
"      Nonabsorbable sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/22/33132\" title=\"table 6\">",
"      Absorbable sutures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 7\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/43/28347\" title=\"table 8\">",
"      Rabies postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/39/21116\" title=\"table 9\">",
"      Postexposure prophylaxis hepatitis B vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/62/34792?source=related_link\">",
"      Allergic reactions to local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/25/29079?source=related_link\">",
"      Assessment and management of auricular hematoma and cauliflower ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/53/12122?source=related_link\">",
"      Assessment and management of facial lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30872?source=related_link\">",
"      Assessment and management of scalp lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=related_link\">",
"      Evaluation and management of middle ear trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/51/6962?source=related_link\">",
"      Patient information: Stitches (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/25/3481?source=related_link\">",
"      Skull fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/24/13704?source=related_link\">",
"      Skull fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_63_6138="Clinical aspects, diagnosis, and treatment of the sideroblastic anemias";
var content_f5_63_6138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6138/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6138/contributors\">",
"     Sylvia S Bottomley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6138/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/63/6138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/63/6138/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/63/6138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sideroblasts are found in the bone marrow of normal, iron-sufficient subjects. They are nucleated red blood cell precursors (erythroblasts) with one or more iron-containing granules in the cytoplasm. In their most abnormal form (ie, ring sideroblasts), in which the granules may completely surround the nucleus (",
"    <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62536 \" href=\"UTD.htm?37/56/38788\">",
"     picture 2",
"    </a>",
"    ), they represent the singular diagnostic feature of the sideroblastic anemias and reflect various aberrations in the processing of iron by the erythroblast [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apart from the congenital syndromic forms, the principal clinical features of all anemias associated with ring sideroblasts (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"UTD.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ) are those of a variably severe anemia. However, mild life-long anemia may go unnoticed, and symptoms and signs of the iron overload associated with some sideroblastic anemias may lead to discovery of the underlying disorder. The history and clinical findings, together with typical laboratory features, usually permit accurate diagnosis of each category of sideroblastic anemia. The molecular defects can be identified in many congenital forms and suggested in patients with clonal sideroblastic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical aspects, diagnosis, and treatment of the sideroblastic anemias will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/2\">",
"     2",
"    </a>",
"    ]. The pathophysiology of these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35750?source=see_link\">",
"     \"Pathophysiology of the sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A constellation of laboratory findings represents the diagnostic features of the sideroblastic disorders, as described in the following sections. The following major criteria should be fulfilled:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microcytic, normocytic, or macrocytic anemia",
"     </li>",
"     <li>",
"      The presence of ring sideroblasts on bone marrow examination",
"     </li>",
"     <li>",
"      Commonly, evidence for systemic iron overload unless iron deficiency is also present (eg, from excessive menstrual blood loss)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common but not constant finding in the sideroblastic anemias is the presence of erythrocyte microcytosis (low mean corpuscular volume, MCV), and hypochromia (low mean corpuscular hemoglobin, MCH), the degree of which roughly parallels the severity of the anemia (",
"    <a class=\"graphic graphic_picture graphicRef66705 \" href=\"UTD.htm?28/4/28742\">",
"     picture 3",
"    </a>",
"    ). Typical variation in RBC size and shape is reflected in an abnormally wide red cell volume distribution width (RDW) (",
"    <a class=\"graphic graphic_figure graphicRef69210 \" href=\"UTD.htm?37/51/38717\">",
"     figure 1",
"    </a>",
"    ). Siderocytes, hypochromic red cells with coarse basophilic granules that stain positive for iron (ie, Pappenheimer bodies) &ndash; representing mature, enucleated erythrocyte counterparts of the ring sideroblasts &ndash; may be seen in the peripheral blood in those with more severe degrees of anemia (",
"    <a class=\"graphic graphic_picture graphicRef51160 \" href=\"UTD.htm?31/27/32178\">",
"     picture 4",
"    </a>",
"    ) and are always numerous if splenectomy has been performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hemoglobin level is highly variable among patients, but is nearly always below 7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      at the time of diagnosis in the autosomal recessive sideroblastic anemia due to SLC25A38 defects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H7#H7\">",
"       \"Causes of congenital and acquired sideroblastic anemias\", section on 'Mitochondrial transporter SLC25A38 defects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leukocyte and platelet values are generally normal, but may be reduced in the presence of splenomegaly (hypersplenism). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H28#H28\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Extravascular nonimmune hemolysis due to hypersplenism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neutropenia is almost a constant finding in the anemia of copper deficiency. Only the Pearson marrow-pancreas syndrome commonly presents with pancytopenia.",
"     </li>",
"     <li>",
"      In females with X-linked sideroblastic anemia, the MCV is most often normal or increased, and a biphasic automated red cell volume histogram is typically present if the anemia is not severe (",
"      <a class=\"graphic graphic_figure graphicRef69210 \" href=\"UTD.htm?37/51/38717\">",
"       figure 1",
"      </a>",
"      ), reflecting the presence of a double population of red cells.",
"     </li>",
"     <li>",
"      In the common acquired clonal sideroblastic anemia the MCV is normal or increased, as it is in most of the congenital syndromic forms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Iron studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stigmata of iron overload are present in many congenital and acquired clonal sideroblastic anemias, but generally not in the acute, reversible forms. These include increased serum iron, reduced transferrin (total iron binding capacity), increased serum transferrin saturation, and increased serum ferritin levels.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging shows iron overload in the liver, heart, endocrine organs, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The degree of iron overload is best assessed by obtaining a liver biopsy or by use of the T2* method by MRI, as serum ferritin values afford only a rough indication of the degree of iron overload. The liver biopsy also provides additional prognostic information through demonstration of the degree of liver damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33748?source=see_link\">",
"     \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the exceptional case with concomitant iron deficiency, most commonly encountered in young females with excess menstrual blood losses, the ring sideroblast abnormality may be masked, such that only occasional ring sideroblasts may be found [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/5\">",
"     5",
"    </a>",
"    ]. In these patients, iron studies show a reduced or normal serum iron, along with a low ferritin concentration, consistent with the presence of an unrelated iron deficiency state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3562573\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow shows normoblastic erythroid hyperplasia with poorly hemoglobinized cytoplasm in the developing red cell precursors. Megaloblastic changes are uncommon, but may be found if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency coexists. The diagnostic hallmark of the sideroblastic anemias is the presence of ring sideroblasts (",
"    <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62536 \" href=\"UTD.htm?37/56/38788\">",
"     picture 2",
"    </a>",
"    ). The amount of iron in bone marrow macrophages is strikingly increased, due to the presence of ineffective erythropoiesis (intramedullary hemolysis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Erythrocyte protoporphyrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and amount of erythrocyte protoporphyrin (PP) found in the various sideroblastic anemias varies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In X-linked sideroblastic anemia and in autosomal recessive sideroblastic anemia due to defects in the SLC25A38 transporter, the erythrocyte PP level is uniformly low because of reduced protoporphyrin production consequent to defective ALAS2 enzyme activity and apparent impaired import of the substrate glycine for ALAS2, respectively.",
"     </li>",
"     <li>",
"      In acquired clonal sideroblastic anemia zinc protoporphyrin is increased.",
"     </li>",
"     <li>",
"      A markedly increased PP level (exclusively as free protoporphyrin) is characteristic of erythropoietic protoporphyria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link&amp;anchor=H8738170#H8738170\">",
"       \"Erythropoietic protoporphyria\", section on 'Erythrocyte protoporphyrin'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Erythrocytic PP is increased in the rare congenital variant with ataxia (mainly as zinc protoporphyrin) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/6\">",
"     6",
"    </a>",
"    ] as well as in some cases without an identified molecular defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15130170\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis in a subject with congenital or acquired sideroblastic anemia includes the three myelodysplastic variants in which ring sideroblasts are present. These consist of refractory anemia with ring sideroblasts (RARS), RARS with thrombocytosis (RARS-T), and refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Acquired clonal sideroblastic anemia / MDS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       RARS",
"      </strong>",
"      in a female subject may be difficult to distinguish from X-linked sideroblastic anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presence of chromosomal abnormalities points to the diagnosis of RARS while the presence of a skewed X chromosome inactivation pattern in blood cells and an ALAS2 gene mutation indicate X-linked sideroblastic anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of congenital and acquired sideroblastic anemias\", section on 'X-linked sideroblastic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In X-linked sideroblastic anemia, ring sideroblasts are typically prominent at the late, non-dividing erythroblast stage, whereas they are evident at all stages of maturation in RARS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       RARS-T",
"      </strong>",
"      is distinguished from other sideroblastic anemias by the presence of thrombocytosis and the JAK2 mutation.",
"     </li>",
"     <li>",
"      <strong>",
"       RCMD-RS",
"      </strong>",
"      is distinguished from other sideroblastic anemias by the presence of dysplastic changes in the myeloid and megakaryocyte lineages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895186\">",
"    <span class=\"h1\">",
"     CONGENITAL SIDEROBLASTIC ANEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sideroblastic anemia uncommonly rarely occurs as a part of several genetic syndromes associated with abnormalities in various non-hematopoietic organ systems (eg, manifested by ataxia, mitochondrial myopathy, diabetes mellitus, pancreatic insufficiency) (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"UTD.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef83838 \" href=\"UTD.htm?40/48/41730\">",
"     algorithm 1",
"    </a>",
"    ). In such syndromic congenital sideroblastic anemias, the anemia may be mild and of secondary importance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'Sideroblastic anemia as a component of genetic syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15571650\">",
"    <span class=\"h2\">",
"     X-linked sideroblastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked sideroblastic anemia is the most common non-syndromic congenital form and is found in females in up to one-third of cases. The anemia is of variable severity from the outset and often remains stable over many years. However, in some individuals it worsens over time. Although unrelated causes need to be ruled out (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency, other systemic disease), disease worsening may be attributable in part to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discontinuation of pyridoxine (which had been part of a multivitamin preparation the patient no longer takes), changes in dietary habits, or alterations in pyridoxine metabolism with age in patients with pyridoxine-responsive X-linked sideroblastic anemia.",
"     </li>",
"     <li>",
"      Skewing of the X inactivation pattern (lyonization) in hematopoietic cells with age in women with X-linked sideroblastic anemia. In such cases, the normal allele becomes progressively inactivated, leading to a greater (",
"      <a class=\"graphic graphic_figure graphicRef69210 \" href=\"UTD.htm?37/51/38717\">",
"       figure 1",
"      </a>",
"      ) relative expression of the mutant allele [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse effects of the associated iron overload or accompanying hypersplenism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35750?source=see_link&amp;anchor=H7#H7\">",
"       \"Pathophysiology of the sideroblastic anemias\", section on 'Iron overload'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with the",
"    <strong>",
"     autosomal recessive form due to defects in the SLC25A38 transporter",
"    </strong>",
"    usually present with severe anemia in infancy or early childhood and nearly always require chronic transfusional support.",
"   </p>",
"   <p>",
"    Apart from symptoms and signs of anemia, all patients without an associated genetic syndrome (with the exception of erythropoietic protoporphyria) eventually exhibit manifestations of iron overload, due to the increased absorption of iron owing to the presence of ineffective erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/9\">",
"     9",
"    </a>",
"    ]. This is invariably accentuated in transfusion-dependent individuals. Clinical diabetes mellitus or abnormal glucose tolerance may be related to the degree of iron overload. The most dangerous complications of the iron overload are cardiac arrhythmias and heart failure, which usually occur late in the course of the disease (",
"    <a class=\"graphic graphic_picture graphicRef81850 \" href=\"UTD.htm?24/37/25177\">",
"     picture 5",
"    </a>",
"    ). In severely affected children, growth and development may also be impaired.",
"   </p>",
"   <p>",
"    Mild to moderate degrees of hepatosplenomegaly are common, but liver function is usually normal or only mildly disturbed at presentation. Liver biopsy reveals a pattern of iron deposition that is indistinguishable from that of hereditary hemochromatosis (",
"    <a class=\"graphic graphic_picture graphicRef60882 \" href=\"UTD.htm?8/60/9162\">",
"     picture 6",
"    </a>",
"    ). Not infrequently, well-established but asymptomatic micronodular cirrhosis is discovered by the third or fourth decade, which does not correlate with severity of the anemia (",
"    <a class=\"graphic graphic_picture graphicRef62989 \" href=\"UTD.htm?14/58/15274\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895436\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic findings are described above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895345\">",
"    <span class=\"h3\">",
"     Molecular studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene define the X-linked form of congenital sideroblastic anemia, while mutations in the SLC25A38 mitochondrial transporter gene specify an autosomal recessive sideroblastic anemia. However, in approximately 40 percent of non-syndromic cases, causative genetic molecular defects have as yet not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations are found in the ABCB7 transporter gene in X-linked sideroblastic anemia with ataxia, in the PUS1 and YARS2 genes in the myopathy, lactic acidosis and sideroblastic anemia syndrome, and in the SLC19A2 gene in thiamine-responsive megaloblastic anemia syndrome. In the Pearson marrow-pancreas syndrome major mitochondrial DNA deletions and rearrangements are typical. These defects are described in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link\">",
"     \"Causes of congenital and acquired sideroblastic anemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;To improve or achieve close to normal survival of patients with the non-syndromic forms of congenital sideroblastic anemia, the treatment program must be aimed at prevention of organ damage from the associated iron overload, as well as control of the symptoms of anemia. Unlike cases of acquired clonal sideroblastic anemia, a predisposition to leukemic evolution has not been observed in patients with the congenital and acquired reversible forms.",
"   </p>",
"   <p>",
"    Definitive cure is not readily available, although allogeneic hematopoietic cell transplantation has been successful in seven reported patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/13-17\">",
"     13-17",
"    </a>",
"    ], including recovery from chronic graft-versus-host disease after orthotopic liver transplantation in one of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/18\">",
"     18",
"    </a>",
"    ]. Gene therapy as yet presents formidable challenges, due to difficulty in transducing hematopoietic stem cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked sideroblastic anemia may respond to pyridoxine supplements in up to two-thirds of cases; hemoglobin concentrations return to normal in about one-third of the responders.",
"   </p>",
"   <p>",
"    The morphologic red cell abnormalities improve variably, but very rarely completely disappear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Vitamin B6 (pyridoxine), in oral doses of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    over and above the estimated adult daily requirement of 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are sufficient for a maximal response; in some cases only 2 to 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    were found to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/20\">",
"     20",
"    </a>",
"    ]. Maintenance treatment with vitamin B6 is necessary, as relapse follows within several months after discontinuing treatment. If a concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency is documented, this vitamin should be replaced at the same time.",
"   </p>",
"   <p>",
"    The hallmark of the thiamine responsive megaloblastic anemia (TRMA) syndrome is clinical response of the anemia, and to a lesser extent the other clinical features, to supraphysiologic oral doses of thiamine (ie, 25 to 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report of a single patient with the syndromic form of congenital sideroblastic anemia and mitochondrial myopathy, treatment with coenzyme Q10 at an oral dose of 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with a dramatic decrease in red cell transfusion requirement and improvement in muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2536?source=see_link&amp;anchor=H6#H6\">",
"     \"Mitochondrial myopathies: Treatment\", section on 'Coenzyme Q10'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For severely anemic individuals otherwise, periodic transfusions are necessary to relieve symptoms, and, for children, to allow normal growth and development. Transfusion of red cells should be kept to a minimum as the iron contained in the transfused red cells accelerates the degree of iron overload already present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron overload associated with the sideroblastic anemias requires treatment for optimal prognosis by averting or minimizing morbidity from parenchymal organ damage in the liver, heart, and endocrine organs. Based on the severity of iron overload (eg, serum ferritin &gt;500",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    best documented by liver biopsy or T2* by MRI, an iron depletion program must be instituted. This is accomplished in one of two ways: therapeutic phlebotomy or iron chelation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Therapeutic phlebotomy",
"      </strong>",
"      &mdash; Graded phlebotomies can be performed in patients who have responded to pyridoxine supplements, and in all others with mild or moderate anemia (ie, hemoglobin &gt;9",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      when there are no contraindications to therapeutic phlebotomy, such as congestive failure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Once the serum ferritin level has been reduced sufficiently, maintenance phlebotomies are continued on a regular basis for life, in order to prevent reaccumulation of iron. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hereditary hemochromatosis\", section on 'Phlebotomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Iron chelation therapy",
"      </strong>",
"      &mdash; In patients who have more severe anemia, and in those who require regular red cell transfusions and thus cannot undergo phlebotomy, chelation of the excess iron is undertaken with an iron chelating agent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"       \"Chelation therapy for iron overload states\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Splenectomy and its risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a temptation to perform splenectomy in patients with severe anemia and a significant degree of splenomegaly with suspected splenic sequestration of red cells. However, this procedure is invariably complicated by postoperative thromboembolic events and often a fatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Factors other than persistent thrombocytosis appear to play a role; control of the platelet count and anticoagulant therapy are not usually effective.",
"   </p>",
"   <p>",
"    For these reasons, splenectomy is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in the congenital sideroblastic anemias. Information on the safety of partial splenectomy in this situation is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ACQUIRED CLONAL SIDEROBLASTIC ANEMIA / MDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder generally occurs in middle-aged and older individuals, although younger persons, including children, may be affected. The anemia develops insidiously and may be discovered during a routine examination or in association with an unrelated complaint. Older individuals more often experience symptoms of fatigue and angina, especially if there is coexisting coronary artery disease. Apart from pallor, hepatosplenomegaly is found in one-third to one-half of patients. With advanced iron overload, often after repeated transfusions, symptoms and signs of liver decompensation, as well as heart failure and arrhythmia, may occur.",
"   </p>",
"   <p>",
"    Since 1982 this disorder has been included in the French-American-British (FAB) classification of hematopoietic disorders (",
"    <a class=\"graphic graphic_table graphicRef51895 \" href=\"UTD.htm?20/33/21020\">",
"     table 2",
"    </a>",
"    ), and is currently included in the WHO classification of the myelodysplastic syndromes (MDS) as refractory anemia with ring sideroblasts (RARS (",
"    <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"     table 3",
"    </a>",
"    )). RARS has the best overall prognosis of all of the recognized MDS variants. It often tends to run an indolent course, but not infrequently patients become transfusion dependent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359854#H359854\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'WHO Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on analyses of large series of patients, three subtypes of the disorder are now distinguished with different prognostic features (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"UTD.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pure sideroblastic anemia (PSA), with dysplasia confined to the erythroid cell lineage, called RARS.",
"     </li>",
"     <li>",
"      The RARS variant associated with thrombocytosis (RARS-T), which frequently has the JAK2V617F mutation, appears to have a better prognosis than RARS [",
"      <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A \"true\" myelodysplastic form with additional dysplastic features involving granulopoiesis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      megakaryopoiesis, called refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall survival at three years differed significantly for PSA and the myelodysplastic form, at 77 and 56 percent, respectively. For patients with PSA, survival was similar to that of age-matched controls, and the incidence of leukemic transformation was nil [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. In contrast, approximately 5 percent of patients with RCMD-RS evolved into acute leukemia (",
"    <a class=\"graphic graphic_table graphicRef50664 \" href=\"UTD.htm?24/36/25163\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women, the hematologic phenotype of RARS is often indistinguishable from X-linked sideroblastic anemia; this latter disorder should therefore be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'X-linked sideroblastic anemia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15130170\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia is usually moderate and normocytic or macrocytic, with a variable population of hypochromic cells on the blood smear. Particularly characteristic are occasional siderocytes: hypochromic red cells with basophilic granules that stain positive for iron (ie, Pappenheimer bodies) (",
"    <a class=\"graphic graphic_picture graphicRef51160 \" href=\"UTD.htm?31/27/32178\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Leukocyte and platelet counts are usually within the normal range in patients with RARS. The presence of moderate leukopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia, the pseudo-Pelger anomaly (",
"    <a class=\"graphic graphic_picture graphicRef71990 \" href=\"UTD.htm?4/45/4816\">",
"     picture 8",
"    </a>",
"    ), or immature leukocytes in the peripheral blood are not features of RARS and suggest the presence of the RCMD-RS subtype. Thrombocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukocytosis are least common and reflect the presence of RARS-T",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a myeloproliferative neoplasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Erythrocyte protoporphyrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The erythrocyte protoporphyrin is characteristically increased, up to about 300",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (normal: 20 to 65). However, in some patients, values have ranged from 1055 to 10,514",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    and some have experienced photosensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/2,31\">",
"     2,31",
"    </a>",
"    ]. Patients with these striking levels likely harbor a ferrochelatase gene defect, and should be evaluated for the presence of late onset erythropoietic protoporphyria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link\">",
"     \"Erythropoietic protoporphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Iron studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum iron and ferritin levels reflect the commonly associated iron overload, as in congenital sideroblastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Iron studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow aspirate shows the presence of erythroid hyperplasia, commonly with mild megaloblastic changes. The marrow macrophage iron content is increased and, in contrast to the congenital forms, ring sideroblasts are evident at all stages of maturation; their presence establishes the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"     picture 1",
"    </a>",
"    ). The cytomorphologic findings as noted above should allow one to subclassify the condition as RARS, RARS-T, or RCMD-RS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Notably, bone marrow cytogenetic abnormalities in patients with RARS are relatively uncommon; in one study chromosomal abnormalities known to be associated with an unfavorable clinical course (eg monosomy 7, 7q- and complex aberrations) were only encountered in the RCMD-RS group [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/28\">",
"     28",
"    </a>",
"    ]. In the RARS-T subtype, the JAK2 V617F mutation is frequent as in myeloproliferative disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available treatment measures for RARS are supportive. The use of agents to stimulate erythropoiesis (eg, erythropoietin), chemotherapy, and hematopoietic cell transplantation in patients with RARS and the other myelodysplastic variants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link\">",
"     \"Overview of the treatment of myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H7193969#H7193969\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;If anemia is symptomatic or progresses to a symptomatic stage, regular red cell transfusions are necessary, especially in the presence of advanced age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other comorbid conditions, such as coronary artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Removal of excess iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phlebotomy or iron chelation (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    ) can be used to control the iron overload. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H2104230#H2104230\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Risk of splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to patients with congenital sideroblastic anemia, splenectomy is contraindicated because of the high risk of complications. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Splenectomy and its risks'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3562827\">",
"    <span class=\"h3\">",
"     Pyridoxine supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyridoxine supplementation is often prescribed but a response is",
"    <strong>",
"     not",
"    </strong>",
"    expected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'Molecular basis for pyridoxine responsiveness'",
"    </a>",
"    .) Associated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency is uncommon and should be documented before folic acid is prescribed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ACQUIRED REVERSIBLE SIDEROBLASTIC ANEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this category of sideroblastic anemias, the clinical setting characterizes the problem and defines the laboratory studies required for the diagnosis. The anemia is invariably corrected upon removal of the precipitating cause. Iron overload is not observed in the acquired reversible sideroblastic anemias with the exception of the sideroblastic anemia associated with alcoholism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Sideroblastic anemia associated with alcoholism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the ring sideroblast abnormality contributes to the severity of anemia in an alcoholic patient, and usually reflects a more advanced stage of a multi-factorial anemia (eg, from associated liver disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency, blood loss, hemolysis, hypersplenism), including the direct effects of alcohol on hematopoiesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=see_link&amp;anchor=H8#H8\">",
"     \"Alcohol abuse and hematologic disorders\", section on 'Bone marrow examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sideroblastic change occurs in approximately one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/34\">",
"     34",
"    </a>",
"    ] and is evident in a dimorphic erythrocyte pattern, as well as the presence of an occasional siderocyte in the peripheral blood. Marrow ring sideroblasts typically represent late erythroblasts. Marrow iron stores are usually increased, as are the serum transferrin saturation and the serum ferritin level, unless concomitant iron deficiency is present.",
"   </p>",
"   <p>",
"    Withdrawal of alcohol is followed by disappearance of ring sideroblasts within a few days to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/35\">",
"     35",
"    </a>",
"    ]. Recovery from the anemia tends to occur over several weeks. The rate of improvement of the anemia depends on the presence of other erythroid defects induced by alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/36\">",
"     36",
"    </a>",
"    ], as well as any associated medical illness affecting erythropoiesis. A more prompt recovery phase may be associated with a brisk reticulocytosis and erythroid hyperplasia of the bone marrow, a picture that might be otherwise mistaken as an episode of hemolytic anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Drug-induced sideroblastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    have served as the prototype drugs that produce a sideroblastic anemia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     Cycloserine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21651?source=see_link\">",
"     fusidic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , and triethylene tetramine dihydrochloride have also been implicated in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Isoniazid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of anemia in relation to the extensive use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH) appears to be quite low. However, the presence of another hematologic disorder may render certain individuals more susceptible to INH-induced anemia. In one study, ring sideroblasts or increased erythroblast iron was found in 58 percent of all patients treated with INH for tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anemia occurs from 1 to 10 months after institution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    therapy. The anemia is moderately severe (hematocrit 20 to 26 percent). The MCV is usually reduced, with dimorphic red cell morphology and prominent hypochromia and microcytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/42\">",
"     42",
"    </a>",
"    ]. Ring sideroblasts are invariably present in the bone marrow. Serum pyridoxal concentrations were subnormal in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Increased transferrin saturation is also consistent with the abnormality.",
"   </p>",
"   <p>",
"    The anemia is promptly and fully reversed on withdrawal of the drug or by administering large doses of pyridoxine (up to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally), while continuing the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Chloramphenicol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    , an antibiotic that has also been associated with sporadic or idiosyncratic and usually fatal aplastic anemia often occurring weeks or months after its use, regularly produces the ring sideroblast abnormality in all individuals, depending on the dose and duration of its administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In addition, this agent suppresses erythropoiesis by producing a hypoproliferative state.",
"   </p>",
"   <p>",
"    The anemia may reach moderately severe levels. Marrow studies reveal variable degrees of hypocellularity and ring sideroblasts as well as prominent vacuolization of early erythroid precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Reticulocytopenia and increased serum iron levels are characteristic. The anemia and associated morphologic abnormalities disappear upon withdrawal of the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Copper deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copper deficiency anemia is associated with the presence of ring sideroblasts and occurs in a number of clinical settings. It has developed after prolonged parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] or forced enteral feeding if copper was not included in the formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], in association with intestinal malabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], following the use of a copper-chelating agent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/55\">",
"     55",
"    </a>",
"    ], and in a case of nephrotic syndrome due to urinary losses of ceruloplasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/56\">",
"     56",
"    </a>",
"    ]. Some patients have had prior gastrointestinal operations (eg, gastrectomy, bariatric surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/54,57\">",
"     54,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The copper deficiency anemia may also occur after prolonged ingestion of zinc supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The use of zinc supplements may explain some of the cases of copper deficiency seen following gastric bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. &nbsp;Similarly, zinc toxicity with resulting copper deficiency has developed from ingestion of zinc-containing coins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. Chronic use of large amounts of denture cream containing zinc has more recently been recognized as another cause of zinc toxicity and clarified the origin of high zinc levels in at least some patients with this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes of congenital and acquired sideroblastic anemias\", section on 'Zinc toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3563010\">",
"    <span class=\"h3\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia is very often, if not invariably, accompanied by a variety of neurologic manifestations, including CNS demyelination, peripheral neuropathy, optic neuropathy, or, most often, myeloneuropathy; this appears to have been overlooked in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/54,68-73\">",
"     54,68-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic manifestations of copper deficiency tend to mimic those seen in subacute combined degeneration of the cord associated with vitamin B12 deficiency; the two conditions may also coexist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/54,74\">",
"     54,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link&amp;anchor=H2126412#H2126412\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Neurologic changes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia due to copper deficiency is progressive in most cases and may be profound, with hemoglobin levels as low as 3.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/58\">",
"     58",
"    </a>",
"    ]. The MCV is normal or slightly increased, but hypochromic and microcytic red cells are detectable on the blood smear. Absolute neutrophil counts are strikingly reduced, often to less than",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    while the platelet count is usually normal. Pancytopenia has been reported in some cases. The bone marrow is variably cellular; vacuolization of early erythroid and granulocytic precursors is a common finding [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/73,75\">",
"     73,75",
"    </a>",
"    ]. Moderate numbers of ring sideroblasts are observed; plasma cells often contain prominent hemosiderin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/54,75\">",
"     54,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum iron levels and transferrin saturation are normal. The serum copper and ceruloplasmin levels are uniformly low. In cases of zinc-induced copper deficiency, serum zinc levels are increased two- to threefold. Serum and urine zinc concentrations were also increased in some patients with copper deficiency and neurologic disease without identifiable excess zinc intake [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/68,73,76\">",
"     68,73,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, normocytic or macrocytic anemia with neutropenia and marrow ring sideroblasts with or without neurologic abnormalities would nearly always indicate a copper deficiency state and not one of the myelodysplastic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/73,75\">",
"     73,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The copper deficit is readily corrected with parenteral or oral copper preparations that provide 2 mg of elemental copper per day, and the hematologic abnormalities return to normal in less than two months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/50,58,68,73,75,76\">",
"     50,58,68,73,75,76",
"    </a>",
"    ]. However, this usual dose of copper may not be sufficient for all patients as relapse has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/77\">",
"     77",
"    </a>",
"    ], and long-term follow-up is advised for all patients.",
"   </p>",
"   <p>",
"    Hematologic recovery may occur following discontinuation of excess zinc intake alone. Neurologic deficits, when present, may improve or only stabilize with continued copper supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/63/6138/abstract/54,68,73,75,76\">",
"     54,68,73,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Lead poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;This condition, which is associated with disordered heme metabolism, is often listed in textbooks as a cause of sideroblastic anemia. It is the author's opinion, however, that lead poisoning is not associated with sideroblastic changes. On the other hand, lead poisoning should be considered in the differential diagnosis of hypochromic microcytic anemia with or without basophilic stippling of circulating red cells, and may therefore be confused with the sideroblastic anemias.",
"   </p>",
"   <p>",
"    The subject of lead poisoning in adults and children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link\">",
"     \"Childhood lead poisoning: Exposure and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=see_link\">",
"     \"Childhood lead poisoning: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3563029\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sideroblastic anemias can be congenital, acquired as a clonal disorder, or associated with alcoholism, adverse drug reactions, or copper deficiency (",
"    <a class=\"graphic graphic_table graphicRef79712 \" href=\"UTD.htm?9/3/9276\">",
"     table 1",
"    </a>",
"    ). A schema for the diagnostic evaluation of a patient with sideroblastic anemia is shown in the accompanying algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef83838 \" href=\"UTD.htm?40/48/41730\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Congenital sideroblastic anemia",
"      </strong>",
"       Hypochromic microcytic red cells and marrow ring sideroblasts, along with stigmata of systemic iron overload, are the cardinal features of a congenital sideroblastic anemia when anemia is the only manifestation. However, several forms of the disease are syndromically associated with other clinical features, particularly neuromuscular and metabolic phenotypes that may cause the most overt symptoms and signs (eg, ataxia, mitochondrial myopathy, diabetes mellitus, pancreatic insufficiency). In these syndromes, hypochromia and microcytosis are mostly not evident and iron overload is not observed in the absence of transfusions. The molecular basis is known in six forms of congenital sideroblastic anemia. Management includes removal of excess iron by phlebotomy in those with minimal anemia or use of iron chelating agents in those with anemia requiring periodic blood transfusion. (See",
"      <a class=\"local\" href=\"#H24895186\">",
"       'Congenital sideroblastic anemias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Acquired clonal sideroblastic anemia",
"      </strong>",
"       Acquired clonal sideroblastic anemia (refractory anemia with ring sideroblasts) is one of the myelodysplastic syndromes and occurs in three variant forms (",
"      <a class=\"graphic graphic_table graphicRef79712 \" href=\"UTD.htm?9/3/9276\">",
"       table 1",
"      </a>",
"      ). The anemia is normocytic or macrocytic. Marrow ring sideroblasts are evident at all stages of maturation; their presence establishes the diagnosis (",
"      <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"       picture 1",
"      </a>",
"      ). Associated body iron excess is not uncommon. Management is supportive and includes blood transfusion for symptomatic anemia and phlebotomy or iron chelation for the iron overload. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Acquired clonal sideroblastic anemia / MDS'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H7193969#H7193969\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acquired reversible sideroblastic anemia",
"      </strong>",
"       In this category, the clinical setting characterizes the problem and defines the laboratory studies required for the diagnosis. Causes include alcoholism, drug toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      ), copper deficiency, and zinc toxicity. The anemia is invariably corrected upon removal of the precipitating cause. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Acquired reversible sideroblastic anemias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/1\">",
"      Fleming MD. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology Am Soc Hematol Educ Program 2011; 2011:525.",
"     </a>",
"    </li>",
"    <li>",
"     Bottomley SS. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 12th ed, Greer JP, Foerster J, Rodgers GM, et al. (Eds), Lippincott, Williams and Wilkins, Philadelphia 2008. p.835.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/3\">",
"      Ben Salem D, Cercueil JP, Ricolfi F, Kraus&eacute; D. Case 75: erythropoietic hemochromatosis. Radiology 2004; 233:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/4\">",
"      Sussman NL, Lee PL, Dries AM, et al. Multi-organ iron overload in an African-American man with ALAS2 R452S and SLC40A1 R561G. Acta Haematol 2008; 120:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/5\">",
"      Bottomley SS. Sideroblastic anaemia. Clin Haematol 1982; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/6\">",
"      Maguire A, Hellier K, Hammans S, May A. X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L. Br J Haematol 2001; 115:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/7\">",
"      Bottomley SS, Wise PD, Wasson EG, et al. X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation. Am J Hum Genet 1998; 63:A352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/8\">",
"      Aivado M, Gattermann N, Bottomley S. X chromosome inactivation ratios in female carriers of X-linked sideroblastic anemia. Blood 2001; 97:4000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/9\">",
"      Marcus RE. Iron overload in mild sideroblastic anaemia. Lancet 1983; 1:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/10\">",
"      Peto TE, Pippard MJ, Weatherall DJ. Iron overload in mild sideroblastic anaemias. Lancet 1983; 1:375.",
"     </a>",
"    </li>",
"    <li>",
"     Bottomley SS. Iron overload in sideroblastic and other non-thalassemic anemias. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment, Barton JC, Edwards CQ (Eds), Cambridge University Press, Cambridge 2000. p.442.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/12\">",
"      Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010; 54:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/13\">",
"      Urban C, Binder B, Hauer C, Lanzer G. Congenital sideroblastic anemia successfully treated by allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/14\">",
"      Gonz&aacute;lez MI, Caballero D, V&aacute;zquez L, et al. Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. Br J Haematol 2000; 109:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/15\">",
"      Ayas M, Al-Jefri A, Mustafa MM, et al. Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation. Br J Haematol 2001; 113:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/16\">",
"      Medeiros BC, Kolhouse JF, Cagnoni PJ, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. Bone Marrow Transplant 2003; 31:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/17\">",
"      Meo A, Ruggeri A, La Rosa MA, et al. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin 2006; 30:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/18\">",
"      Urban CH, Deutschmann A, Kerbl R, et al. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/19\">",
"      Cotter PD, May A, Fitzsimons EJ, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 1995; 96:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/20\">",
"      Cox TC, Bottomley SS, Wiley JS, et al. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med 1994; 330:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/21\">",
"      Bergmann AK, Sahai I, Falcone JF, et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009; 155:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/22\">",
"      Bachmeyer C, Ferroir JP, Eymard B, et al. Coenzyme Q is effective on anemia in a patient with sideroblastic anemia and mitochondrial myopathy. Blood 2010; 116:3681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/23\">",
"      Bottomley SS. The spectrum and role of iron overload in sideroblastic anemia. Ann N Y Acad Sci 1988; 526:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/24\">",
"      Hines JD. Effect of pyridoxine plus chronic phlebotomy on the function and morphology of bone marrow and liver in pyridoxine-responsive sideroblastic anemia. Semin Hematol 1976; 13:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/25\">",
"      BYRD RB, COOPER T. Hereditary iron-loading anemia with secondary hemochromatosis. Ann Intern Med 1961; 55:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/26\">",
"      Aleali SH, Castro O, Spencer RP, Finch SC. Sideroblastic anemia with splenic abscess and fatal thromboemboli after splenectomy. Ann Intern Med 1975; 83:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/27\">",
"      Bottomley SS. Sideroblastic anemia: Death from iron overload. Hosp Pract 1991; 26(suppl 3):55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/28\">",
"      Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 1990; 74:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/29\">",
"      Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008; 93:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/30\">",
"      Germing U, Gattermann N, Aivado M, et al. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 2000; 108:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/31\">",
"      Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 1988; 25:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/32\">",
"      Kushner JP, Lee GR, Wintrobe MM, Cartwright GE. Idiopathic refractory sideroblastic anemia: clinical and laboratory investigation of 17 patients and review of the literature. Medicine (Baltimore) 1971; 50:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/33\">",
"      Cazzola M, Barosi G, Gobbi PG, et al. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988; 71:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/34\">",
"      Savage D, Lindenbaum J. Anemia in alcoholics. Medicine (Baltimore) 1986; 65:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/35\">",
"      Eichner ER, Hillman RS. The evolution of anemia in alcoholic patients. Am J Med 1971; 50:218.",
"     </a>",
"    </li>",
"    <li>",
"     Bottomley SS. Sideroblastic anaemia. In: Iron in Biochemistry and Medicine II, Jacobs A, Worwood M (Eds), Academic Press, London 1980. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/37\">",
"      Vial T, Grignon M, Daumont M, et al. Sideroblastic anaemia during fusidic acid treatment. Eur J Haematol 2004; 72:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/38\">",
"      Montpetit MC, Shammo JL, Loew J, et al. Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device. J Heart Lung Transplant 2004; 23:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/39\">",
"      Condamine L, Hermine O, Alvin P, et al. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride. Br J Haematol 1993; 83:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/40\">",
"      Kandola L, Swannell AJ, Hunter A. Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis. Ann Rheum Dis 1995; 54:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/41\">",
"      Roberts PD, Hoffbrand AV, Mollin DL. Iron and folate metabolism in tuberculosis. Br Med J 1966; 2:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/42\">",
"      Haden HT. Pyridoxine-responsive sideroblastic anemia due to antituberculous drugs. Arch Intern Med 1967; 120:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/43\">",
"      Hines JD, Love DS. Determination of serum and blood pyridoxal phosphate concentrations with purified rabbit skeletal muscle apophosphorylase b. J Lab Clin Med 1969; 73:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/44\">",
"      Standal BR, Kao-Chen SM, Yang GY, Char DF. Early changes in pyridoxine status of patients receiving isoniazid therapy. Am J Clin Nutr 1974; 27:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/45\">",
"      Beck EA, Ziegler G, Schmid R, L&uuml;din H. Reversible sideroblastic anemia caused by chloramphenicol. Acta Haematol 1967; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/46\">",
"      SCOTT JL, FINEGOLD SM, BELKIN GA, LAWRENCE JS. A CONTROLLED DOUBLE-BLIND STUDY OF THE HEMATOLOGIC TOXICITY OF CHLORAMPHENICOL. N Engl J Med 1965; 272:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/47\">",
"      Smith U, Smith DS, Yunis AA. Chloramphenicol-related changes in mitochondrial ultrastructure. J Cell Sci 1970; 7:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/48\">",
"      Skinnider LF, Ghadially FN. Chloramphenicol-induced mitochondrial and ultrastructural changes in hemopoietic cells. Arch Pathol Lab Med 1976; 100:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/49\">",
"      Vilter RW, Bozian RC, Hess EV, et al. Manifestations of copper deficiency in a patient with systemic sclerosis on intravenous hyperalimentation. N Engl J Med 1974; 291:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/50\">",
"      Takeuchi M, Tada A, Yoshimoto S, Takahashi K. [Anemia and neutropenia due to copper deficiency during long-term total parenteral nutrition]. Rinsho Ketsueki 1993; 34:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/51\">",
"      Banno S, Niita M, Kikuchi M, et al. [Anemia and neutropenia in elderly patients caused by copper deficiency for long-term enteral nutrition]. Rinsho Ketsueki 1994; 35:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/52\">",
"      Nagano T, Toyoda T, Tanabe H, et al. Clinical features of hematological disorders caused by copper deficiency during long-term enteral nutrition. Intern Med 2005; 44:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/53\">",
"      Halfdanarson TR, Kumar N, Hogan WJ, Murray JA. Copper deficiency in celiac disease. J Clin Gastroenterol 2009; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/54\">",
"      Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc 2006; 81:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/55\">",
"      Perry AR, Pagliuca A, Fitzsimons EJ, et al. Acquired sideroblastic anaemia induced by a copper-chelating agent. Int J Hematol 1996; 64:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/56\">",
"      Niel O, Thouret MC, B&eacute;rard E. Anemia in congenital nephrotic syndrome: role of urinary copper and ceruloplasmin loss. Blood 2011; 117:6054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/57\">",
"      Prodan CI, Bottomley SS, Vincent AS, et al. Copper deficiency after gastric surgery: a reason for caution. Am J Med Sci 2009; 337:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/58\">",
"      Fiske DN, McCoy HE 3rd, Kitchens CS. Zinc-induced sideroblastic anemia: report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol 1994; 46:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/59\">",
"      Irving JA, Mattman A, Lockitch G, et al. Element of caution: a case of reversible cytopenias associated with excessive zinc supplementation. CMAJ 2003; 169:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/60\">",
"      von Drygalski A, Andris DA. Anemia after bariatric surgery: more than just iron deficiency. Nutr Clin Pract 2009; 24:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/61\">",
"      Choi EH, Strum W. Hypocupremia-related myeloneuropathy following gastrojejunal bypass surgery. Ann Nutr Metab 2010; 57:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/62\">",
"      Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990; 264:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/63\">",
"      Hassan HA, Netchvolodoff C, Raufman JP. Zinc-induced copper deficiency in a coin swallower. Am J Gastroenterol 2000; 95:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/64\">",
"      Kumar A, Jazieh AR. Case report of sideroblastic anemia caused by ingestion of coins. Am J Hematol 2001; 66:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/65\">",
"      Pawa S, Khalifa AJ, Ehrinpreis MN, et al. Zinc toxicity from massive and prolonged coin ingestion in an adult. Am J Med Sci 2008; 336:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/66\">",
"      Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology 2008; 71:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/67\">",
"      Hedera P, Peltier A, Fink JK, et al. Myelopolyneuropathy and pancytopenia due to copper deficiency and high zinc levels of unknown origin II. The denture cream is a primary source of excessive zinc. Neurotoxicology 2009; 30:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/68\">",
"      Prodan CI, Holland NR, Wisdom PJ, et al. CNS demyelination associated with copper deficiency and hyperzincemia. Neurology 2002; 59:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/69\">",
"      Prodan CI, Holland NR, Wisdom PJ, Bottomley SS. Myelopathy due to copper deficiency. Neurology 2004; 62:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/70\">",
"      Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004; 63:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/71\">",
"      Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 2005; 123:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/72\">",
"      Rowin J, Lewis SL. Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation. J Neurol Neurosurg Psychiatry 2005; 76:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/73\">",
"      Kumar N, Elliott MA, Hoyer JD, et al. \"Myelodysplasia,\" myeloneuropathy, and copper deficiency. Mayo Clin Proc 2005; 80:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/74\">",
"      Prodan CI, Bottomley SS, Vincent AS, et al. Hypocupremia associated with prior vitamin B12 deficiency. Am J Hematol 2007; 82:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/75\">",
"      Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood 2002; 100:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/76\">",
"      Greenberg SA, Briemberg HR. A neurological and hematological syndrome associated with zinc excess and copper deficiency. J Neurol 2004; 251:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/63/6138/abstract/77\">",
"      Prodan CI, Bottomley SS, Holland NR, Lind SE. Relapsing hypocupraemic myelopathy requiring high-dose oral copper replacement. J Neurol Neurosurg Psychiatry 2006; 77:1092.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7123 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-F0872C54B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6138=[""].join("\n");
var outline_f5_63_6138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3563029\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Iron studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3562573\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Erythrocyte protoporphyrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15130170\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24895186\">",
"      CONGENITAL SIDEROBLASTIC ANEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15571650\">",
"      X-linked sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24895436\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24895345\">",
"      - Molecular studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Iron overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Splenectomy and its risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ACQUIRED CLONAL SIDEROBLASTIC ANEMIA / MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Erythrocyte protoporphyrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Iron studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Removal of excess iron",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Risk of splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3562827\">",
"      - Pyridoxine supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ACQUIRED REVERSIBLE SIDEROBLASTIC ANEMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Sideroblastic anemia associated with alcoholism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Drug-induced sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Isoniazid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Chloramphenicol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Copper deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3563010\">",
"      - Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3563029\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7123\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7123|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/48/41730\" title=\"algorithm 1\">",
"      Diagnosis of sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7123|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/51/38717\" title=\"figure 1\">",
"      RBC size sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7123|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/705\" title=\"picture 1\">",
"      Ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/56/38788\" title=\"picture 2\">",
"      Bone marrow sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/4/28742\" title=\"picture 3\">",
"      RBC in sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/27/32178\" title=\"picture 4\">",
"      Pappenheimer bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/37/25177\" title=\"picture 5\">",
"      Myocardial siderosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/60/9162\" title=\"picture 6\">",
"      Liver in sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/58/15274\" title=\"picture 7\">",
"      Severe cirrhosis iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/45/4816\" title=\"picture 8\">",
"      Pelger Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7123|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/3/9276\" title=\"table 1\">",
"      Causes of sideroblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/33/21020\" title=\"table 2\">",
"      FAB classification of MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9996\" title=\"table 3\">",
"      MDS classification WHO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/36/25163\" title=\"table 4\">",
"      MDS outcome by FAB subgroup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36441?source=related_link\">",
"      Causes of congenital and acquired sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=related_link\">",
"      Childhood lead poisoning: Exposure and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21594?source=related_link\">",
"      Childhood lead poisoning: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=related_link\">",
"      Erythropoietic protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33748?source=related_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2536?source=related_link\">",
"      Mitochondrial myopathies: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35750?source=related_link\">",
"      Pathophysiology of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_63_6139="Toxicity preparative regimens";
var content_f5_63_6139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment modalities commonly utilized in hematopoietic cell transplantation preparative regimens and their dose limiting organ effects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Modality",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major organ affected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        Lungs, heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        Heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Busulfan",
"       </td>",
"       <td>",
"        Lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        Liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carmustine",
"       </td>",
"       <td>",
"        Lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"       </td>",
"       <td>",
"        CNS, nervous tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melphalan",
"       </td>",
"       <td>",
"        Lungs, gastrointestinal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6139=[""].join("\n");
var outline_f5_63_6139=null;
var title_f5_63_6140="Possible causes for the increase in allergic disease";
var content_f5_63_6140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Changes that may have contributed to the rise in allergic disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       I. Increased exposure to perennial indoor allergens",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased time spent indoors (1955-1995)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Improved conditions for mite and mold growth (1955-1975)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased ventilation*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased reservoirs for allergen (carpets/sofas) (1935-1965)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       II. Changes in hygiene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Clean water",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Separation from sewage (1900)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Chlorination (1920)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Eradication of helminths and malaria in Europe and USA (1920-1940)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decline in Hepatitis A infection (1920-1990)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Introduction of broad spectrum antibiotics (&sim;1960)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased treatment and control of food to prevent bacterial infection (1900-1980)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunization to control infectious diseases (1800-1990)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       III. Lifestyle changes: Secondary to the introduction of sedentary entertainment in homes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increase in the percentage of homes with television and increase in hours spent watching television (1955-1990)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decline in outdoor \"play\" (1955-1995)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rise in obesity (1970-2000)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Changes in diet following changes in traditional family life (1965-2000)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased vitamin D levels secondary to decreased time spent outdoors and decreased intake",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    *Variable by locale",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6140=[""].join("\n");
var outline_f5_63_6140=null;
var title_f5_63_6141="Interventions intracell calcium";
var content_f5_63_6141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interventions that theoretically alter diastolic cytosolic calcium levels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Theoretical effect on diastolic Ca(i)2+",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanisms/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemia or hypoxia",
"       </td>",
"       <td>",
"        Increase",
"       </td>",
"       <td>",
"        Decreased SR uptake and SL extrusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digitalis",
"       </td>",
"       <td>",
"        Increase",
"       </td>",
"       <td>",
"        Increases NA(i)+ by Na+/K+ pump inhibition; Ca(i)2+ increased secondary to increased Na+ -Ca2+ exchange. Combination of ischemia or hypoxia + digitalis cause exaggerated diastolic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ca2+ channel blocker",
"       </td>",
"       <td>",
"        Decrease",
"       </td>",
"       <td>",
"        Decreased Ca2+ entry by way of sarcolemma. Associated bradycardia prolongs diastole, allowing for greater calcium removal via SR and SL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;-adrenergic blocker",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Decreased c-AMP levels decrease Ca2+ entry via Ca2+-channel, but also decrease Ca2+ reuptake by SR. Associated bradycardia prolongs diastole as with Ca2+ channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;-adrenergic agonist",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Increased c-AMP levels increase Ca2+ entry, but also increase SR calcium reuptake by phospholamban regulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphodiesterase inhibitors",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Same mechanisms as &beta;-adrenergic agonist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ca2+ agonist (BAYK8644)",
"       </td>",
"       <td>",
"        Increase",
"       </td>",
"       <td>",
"        Increased Ca2+ influx via L-type channels can produce Ca2+ overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ca2+ ionophore (A23187)",
"       </td>",
"       <td>",
"        Increase",
"       </td>",
"       <td>",
"        Increased transsarcolemmal Ca2+ influx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Na+ agonist (vertridine)",
"       </td>",
"       <td>",
"        Increase",
"       </td>",
"       <td>",
"        [Ca2+]i loading by Na+/Ca2+ exchange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Na+ ionophore (monensin)",
"       </td>",
"       <td>",
"        Increase",
"       </td>",
"       <td>",
"        [Ca2+]i loading by Na+/Ca2+ exchange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antagonist of Na+/Ca2+ exchanger (dichlorobenzamil)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Potential to affect [Na+]i",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Antagonist of Na+/H+ exchanger (amiloride)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Potential to affect [Na+]i",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibitor of SERCA2(caffeine)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Multiple effects but blocks Ca2+ uptake after inducing&nbsp;Ca2+ release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SR Ca2+ ATPase inhibitor (thapsigarin)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Blocks Ca2+ uptake by inhibiting pump",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhibitor of RYR2 (ryanodine)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Blocks Ca2+ release channel of SR leading to Ca2+ overload of vesicles and decreased uptake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phospholamban antibodies",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        May enhance SR Ca2+ uptake by modifying function of phospholamban",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial inhibitors (FCCP)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Decreased Ca2+ storage capacity of mitochondria in overload state",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    SERCA2: sarco(endo)plasmic reticulum Ca2+ ATPase pump; RYR2: ryanodine receptor 2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6141=[""].join("\n");
var outline_f5_63_6141=null;
var title_f5_63_6142="Sclerosing agent for lower extremity venous disease";
var content_f5_63_6142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sclerosing agent for lower extremity venous disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Formulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Composition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vessel size, mm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injection/vein, mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Max dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Hypertonic saline",
"       </td>",
"       <td rowspan=\"5\">",
"        Osmotic",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         14.6%",
"        </p>",
"        <p>",
"         23.4%",
"        </p>",
"       </td>",
"       <td rowspan=\"5\">",
"        Sodium chloride",
"       </td>",
"       <td rowspan=\"5\">",
"        Not required",
"       </td>",
"       <td rowspan=\"5\">",
"        No allergy",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Pain",
"        </p>",
"        <p>",
"         Muscle cramping",
"        </p>",
"        <p>",
"         Ulceration/necrosis",
"        </p>",
"        <p>",
"         Hyperpigmentation",
"        </p>",
"       </td>",
"       <td>",
"        &lt;0.5",
"       </td>",
"       <td>",
"        11.7 to 15",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td rowspan=\"5\">",
"        None*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5 to 1.0",
"       </td>",
"       <td>",
"        11.7 to 15",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        15 to 23.4",
"       </td>",
"       <td>",
"        0.5 to 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Polidocanol(Aethoxysclerol)",
"       </td>",
"       <td rowspan=\"6\">",
"        Detergent",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         1%",
"        </p>",
"        <p>",
"         3%",
"        </p>",
"       </td>",
"       <td rowspan=\"6\">",
"        Hydroxypolyethoxydodecane, distilled, ethyl alcohol",
"       </td>",
"       <td rowspan=\"6\">",
"        .5 mL",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Painless",
"        </p>",
"        <p>",
"         Not toxic to tissue",
"        </p>",
"        <p>",
"         Rare ulceration",
"        </p>",
"        <p>",
"         No skin necrosis",
"        </p>",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Allergy",
"        </p>",
"        <p>",
"         Telangiectatic matting",
"        </p>",
"        <p>",
"         Hyperpigmentation",
"        </p>",
"       </td>",
"       <td>",
"        &lt;0.5",
"       </td>",
"       <td>",
"        0.25 to 0.5",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        3% solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5 to 1.0",
"       </td>",
"       <td>",
"        0.5 to 0.75",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        50 kg: 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        0.75 to 1",
"       </td>",
"       <td>",
"        0.5 to 0.75",
"       </td>",
"       <td>",
"        60 kg: 6 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 5",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        0.75 to 1",
"       </td>",
"       <td>",
"        70 kg: 7 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5",
"       </td>",
"       <td>",
"        3 to 5",
"       </td>",
"       <td>",
"        to max",
"       </td>",
"       <td>",
"        80 kg: 8 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        90 kg: 9 mL",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Sodium tetradecyl sulfate",
"       </td>",
"       <td rowspan=\"4\">",
"        Detergent",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         1%",
"        </p>",
"        <p>",
"         3%",
"        </p>",
"       </td>",
"       <td rowspan=\"4\">",
"        Sodium 1-isobutyl-4thyloctyl sulfate, benzoyl alcohol 2%, phoshate",
"       </td>",
"       <td rowspan=\"4\">",
"        .5 mL",
"       </td>",
"       <td rowspan=\"4\">",
"        Less telangiectatic matting",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Allergy",
"        </p>",
"        <p>",
"         Hyperpigmentation",
"        </p>",
"        <p>",
"         Ulceration/necrosis",
"        </p>",
"       </td>",
"       <td>",
"        0.2 to 1",
"       </td>",
"       <td>",
"        0.1 to 0.3",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td rowspan=\"4\">",
"        10 mL of 3% solution&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        0.25 to 0.5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 5",
"       </td>",
"       <td>",
"        0.5 to 1",
"       </td>",
"       <td>",
"        0.5 to 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5",
"       </td>",
"       <td>",
"        1.5 to 3",
"       </td>",
"       <td>",
"        to max",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Glycerin",
"       </td>",
"       <td>",
"        Osmotic",
"       </td>",
"       <td>",
"        72%",
"       </td>",
"       <td>",
"        Glycerol, 1, 2, 3-propanetrial, glycerine",
"       </td>",
"       <td>",
"        .5 mL",
"       </td>",
"       <td>",
"        <p>",
"         No matting",
"        </p>",
"        <p>",
"         No ulceration",
"        </p>",
"        <p>",
"         No necrosis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Contact sensitivity",
"        </p>",
"        <p>",
"         Rare: hematuria",
"        </p>",
"        <p>",
"         Urethral colic",
"        </p>",
"       </td>",
"       <td>",
"        &lt;1.0",
"       </td>",
"       <td>",
"        25 to 72",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        10 mL of 72% solution",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"     <br>",
"      * None labeled. Limit use as with any product with saline.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       United States and Canada (elsewhere see drug insert).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Tisi, PV, Beverley, C, Rees, A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2006; :CD001732.",
"       </li>",
"       <li>",
"        Goldman, MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg 2002; 28:52.",
"       </li>",
"       <li>",
"        Parsi, K, Exner, T, Connor, DE, et al. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34:731.",
"       </li>",
"       <li>",
"        Weiss, RA, Weiss, MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol 1990; 16:800.",
"       </li>",
"       <li>",
"        Bukhari, RH, Lohr, JM, Paget, DS, et al. Evaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy. J Vasc Surg 1999; 29:479.",
"       </li>",
"       <li>",
"        Davis, LT, Duffy, DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol 1990; 16:327.",
"       </li>",
"       <li>",
"        Norris, MJ, Carlin, MC, Ratz, JL. Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. J Am Acad Dermatol 1989; 20:643.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6142=[""].join("\n");
var outline_f5_63_6142=null;
var title_f5_63_6143="Causes maternal death";
var content_f5_63_6143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Global causes of maternal mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The World Health Report 2005: Make every mother and child count. World Health Organization, Geneva 2005. Copyright &copy;2005 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_63_6143=[""].join("\n");
var outline_f5_63_6143=null;
